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action of organometallic anticancer complexes 
 
 
Abstract 
Since the discovery of cisplatin, numerous attempts have been made to emulate its 
activity while reducing its collateral toxicity. Coordination complexes based on a 
wide number of transition metals have been developed in the search for improved 
bioavailability, selectivity and reduced adverse side-effects. Ruthenium(II) 
complexes have been widely developed in this field as a viable alternative to 
platinum chemotherapeutics.  
This thesis is concerned with the synthesis, characterization and biological 
evaluation of three series of novel half-sandwich complexes of the general 
formula [RuII(arene)(X)(YZ)]n+. These piano-stool RuII complexes have been 
designed as to allow the fine-tuning of their chemical and biological properties. In 
the first two series, the arene unit has been varied between p-cymene, biphenyl 
and terphenyl to investigate the correlation between hydrophobicity and 
antiproliferative activity, while the N,N-imino pyridine chelating ligand, YZ, has 
been modified to include either a higher number of aromatic units that could allow 
better DNA intercalation or substituent groups that could affect the overall charge 
distribution in the complex. Finally, the monodentate ligand, X, is either chloride 
or iodide. These compounds have been fully characterised by NMR, MS and 
elemental analysis. Their aqueous behaviour has been investigated together with 
the extent of 9-EtG binding, as an indication of the possible interaction with 
V 
 
nucleobases. The antiproliferative activity of these novel RuII complexes was 
determined, several of them show promising IC50 values, in the low µM range, 
against ovarian, colon, lung and breast cancer cell lines, in many cases the 
activities observed are better than cisplatin. The pathways for cellular 
accumulation were investigated. Complexes with an I as the monodentate ligand, 
X, exhibit partial energy-independent uptake. Overall results indicate that the 
novel RuII complexes synthesised in this thesis are most likely to be multi-targeted 
and that their mechanism of action depends to a great extent on the nature of the 
monodentate ligand, X. Two particularly active complexes in these series include 
the impy-NMe2 ligand as YZ chelate. These have been compared to their 
isostructural azopyridine analogues and also to their OsII equivalents. In this case, 
experiments were designed to study the activation of landmark events that lead to 
apoptosis, allowing contrasting the effects of different metal centres (Ru vs Os), 
isoelectronic ligands (impy-NMe2 vs azpy-NMe2) and monodentate ligands (Cl vs 
I). Results indicate that the molecular pathway followed by the iodido complexes 
is p53-independent. In comparison, the chlorido analogues activate the intrinsic 
apoptotic pathway and their activity relies on the existence of this tumour 
suppressor. DNA intercalation was also evaluated as a possible mechanism of 
action. 
Finally, the third series includes inactive RuII complexes with tetrahydroquinoline 
derivatives, which were found to enhance the activity of platinum drugs in clinical 
use. These promising preliminary results in the use of RuII complexes in 
combination therapy open a world of possibilities for the dose-reduction of 
platinum-chemotherapeutics. 
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WHO   World Health Organization 
WT1   Wilm’s tumour gene 
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This thesis deals with the synthesis, characterization, chemical, and biological 
studies of the mechanism of action of novel Ru(II)half-sandwich arene complexes 
with antineoplastic activity. Understanding the molecular basis of cancer is crucial 
for the study of the metabolic pathways activated by metal-based anticancer 
agents. For this reason, this Chapter introduces core concepts in cancer biology. It 
also establishes the current approaches for treatment, including the new trend of 
single targeted therapy while recognising the benefits of multi-targeted agents. 
Platinum and ruthenium-based chemotherapeutics and their mechanism of action 
are summarised.  
 
1.1. Cancer 
Cancer, defined by the WHO as ‘the uncontrolled growth and spread of cells’, is 
responsible for at least 13% of world-wide deaths. Cancer, known since the early 
Greeks, was reported by Hippocrates (460-370 BC) as an ulcerous formation and 
by the roman physician Galen (130-200 AC), as a malignant swelling. However, 
current statistics indicate that 1 in every 3 people will develop some form of 
cancer during their life time. It is estimated that by 2030 there will be 21.4 million 
new cases diagnosed every year.1   
Cancerogenesis is a process in which normal cells convert into neoplastic tissue, 
and disturbs cellular events such as proliferation, differentiation and development 
as a consequence of the lack of response to normal control mechanisms in cells.2  
Hanahan and Weinberg described tumour progression process as the result of six 
main events that are known as the hallmarks of cancer. They are: 1) self-
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sufficiency in growth signals, 2) insensitivity to antigrowth signals, 3) evasion of 
apoptosis, 4) limitless replicative potential, 5) sustained angiogenesis and 6) tissue 
invasion and metastasis.3 
 
Figure 1.1. Hallmarks of cancer according to  Hanahan and Weinberg.3 
 
Cancers can be divided according to the tissue involved, for instance, carcinomas 
are cancers affecting the epithelium, while adenocarcinomas involve glandular 
tissue. Sarcoma is the generic name for malignant tumours of the mesenchyme 
(eg. fibrosarcoma, osteosarcoma, angiosarcoma, liposarcoma) and the hemato-
lymphoid system gives origin to leukaemias and lymphomas, respectively. 2,4 
The generation of neoplastic tissue has often been associated to environmental, 
behavioural and genetic issues.4,5 However, it is accepted that cancer is the result 
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of multi-factorial causes. As a leading cause of death, multiple approaches have 
been made to understand its molecular basis in the quest for a cure.  
 
1.1.1 Molecular basis of cancer 
1.1.1.1 Genetic instability 
Genetic instability is a very common event in cancer development, it occurs as a 
result of the loss of DNA integrity and is present in all stages of the disease, from 
pre-cancerous lesions to advanced cancer.6 This instability is critical in the 
process in which pre-cancerous lesions accumulate mutations characteristic of a 
cancerous state.7 It is possible to classify genomic instability into three: firstly, the 
microsatellite instability MSI, which is characterised by expansion and 
contraction of oligonucleotide repeats in microsatellite sequences. Secondly, an 
instability defined by the increased frequency of base-pair mutations and thirdly, 
the most common of them all, chromosomal instability, CIN. This type of 
instability relates to the rate in which the number and structure of chromosomes 
varies over time in cancerous tissue8 as a consequence of errors in chromosome 
segregation.9 Chromosomal instability has been directly linked with colorectal 
cancers, which are ~ 80% aneuploid and with aggressive epithelial tumours in 
pancreatic, ovarian and lung tissue.9  
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1.1.1.2 Oncogene activation 
An oncogene is defined as the altered manifestation of a normal gene that encodes 
a regulatory protein with dominant transforming proteins.4 Molecular alterations 
leading to cancer include the de-regulation of oncogenes and/or the activation of 
proto-oncogenes.10 This activation can occur by point-mutation or over-
expression of the gene, the latter involving one of two distinctive genetic 
mechanisms: amplification (increase of the number of copies) or translocation.2  
The most widely known oncogenes belong to the MYC and RAS families. De-
regulated MYC gene is associated with several malignancies, including cancer.11 
c-myc, a member of this oncogene family, is generally over-expressed in rapidly 
proliferating tissue. Its de-regulation has been linked to Burkitt’s lymphoma, 
invasive ductal breast carcinoma and colon adenocarcinoma amongst others. 10,11 
This oncogene is thought to cause genomic instability, promote angiogenesis 5 and 
therefore represents an attractive target for anticancer agents, since its inhibition 
may be enough to stop tumour growth.10 
RAS proteins are involved in multiple signalling pathways between cell surface 
receptors and intracellular pathways.12 Its mutations are frequently observed in 
human cancers where it modulates the tumour micro-environment and promotes 
pro-angiogenic mechanisms.13 Pancreatic, colon and lung adenocarcinoma have 
been associated with a high incidence of RAS oncogenic mutations which have 
lost the ability of becoming inactive after the external stimulus has ceased.14 Table 
1. 1. below shows the function associated to the principal human oncogenes and 
their mechanism of activation in cancer. 
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Table 1. 1. Principal human oncogenes (adapted from ref 15) 
Oncogene Function Mechanism of  
activation in cancer 
RAS GTPase in mitogenic signaling Mutation block GTPase 
MYC Regulatory factor in mitogenic 
signalling Gene over expression 
RAF Protein kinase mitogenic signaling Mutation inactivates kinase 
BCL2 Protein kinase of multiple functions Gene over expression or 
activation by mutation 
   
 
1.1.1.3 Tumour suppressor gene inactivation 
Tumour suppressor genes encode proteins whose absence, repression, inactivation 
or mutation promotes oncogenesis. These include DNA repair and cell cycle 
control proteins. Some examples of relevant tumour suppressor genes are shown 
in Table 1. 2 below, such as p53, WT1, PTEN, BRCA1 and BRCA22 amongst 
others, together with their familial cancer association. Mutations in the p53 
protein are the most common event in human cancer. These occur in at least 50% 
of all cases. In normal tissue, activation of p53 allows the cell to respond to stress 
triggered by DNA-damaging agents amongst other external stimuli which in turn 
results in apoptosis.5 More detailed explanation of the role of p53 can be found in 
Chapter 5 where the activity of Ru/Os organometallic anticancer complexes are 
evaluated against a colon carcinoma cell line with a p53 mutation. Tumour 
suppressor genes involved in the regulation of cell proliferation are usually 
inactivated during cancer. Their re-activation is the basis of the development of 
new anticancer therapies. 
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Table 1. 2. Principal human tumour suppressors (adapted from ref 16) 
Tumour 
suppressor gene Function 
Familial cancer 
association 
WT1 Transcription factor Wilm’s tumour 
NF1 GTPase activating protein for RAS mitogenic signaling 
Neurofibromatosis, 
sarcomas and gliomas 
PTEN Antagonist of PI3 kinase Cowden syndrome 
RB Inhibitor of G1/S gene 
expression Retinoblastoma 
BRCA1, BRCA2 DNA repair, damage 
response 
Familial breast cancer and 
ovarian cancer 
   
 
1.1.1.4 Cell cycle-related events in neoplastic cells 
Normal cells proliferate freely and only withdraw from the cell cycle after 
growth-factor deprivation or growth inhibitory signals. However, within the cell 
cycle, there are a number of checkpoints to ensure safe progression.17 De-
regulation of the cell cycle is a common event in human cancer.  In this case 
persistent cell cycle progression occurs, losing the controls that limit the transition 
between phases. Check-point controls rely on cyclin-dependent kinases, CDKs. 
De-regulation of CDKs can cause excessive cell proliferation as well as genomic 
and chromosomal instability.18 
 
1.1.1.5 Angiogenesis and metastasis 
The microenvironment of solid tumours is usually associated with poor 
oxygenation19 and low pH as consequences of accelerated metabolism.20 Recent 
studies have demonstrated high correlation between this micro enviroment and 
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aggressive tumour progression. The presence of immune modulatory mediators 
together with the activation of inflammatory tissue surrounding the neoplasia are 
critical in tumour evolution towards metastasis.21 
Tumour growth is closely related to the generation/improvement of vascularity. 
Drugs inhibiting angiogenesis have been used as antitumour agents. This type of 
therapeutic intervention suggests that targeting stromal events can affect tumour 
progression.21 An example of this is bevacizumab  for the treatment of metastatic 
colorectal cancer.22 Neoplasms tend to disseminate, leaving the primary lesion and 
forming secondary tumours.23 This process called metastasis has already occurred 
in two-thirds of cases by the time of diagnosis.4 Critical events in the so called 
“metastatic cascade” include cell detachment from the primary tumour, invasion, 
penetration into the vascular system, extravastation and proliferation.4,24 
 
1.1.1.6 Senescence and apoptosis as mechanisms of cell 
death 
Cellular senescence refers to a cellular proliferation arrest triggered by stress 
stimuli, that can include telomere shortening, chemotherapeutic agent intervention 
or oncogene activation.25 Different to quiescence, which is proliferative arrest 
caused by absence of growth factors, senescence can limit cancer progression in 
early neoplastic lesions.26 and could be induced with therapeutic aims.27  
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Figure 1.2. Angiogenesis and metastasis (adapted from ref 28). (a) generation of a 
primary neoplasia, (b) angiogenesis, (c) invasion of the stroma, (d) detachment of 
cancerous cells from the primary tumour, (e) extravasation, (f) proliferation into a 
new organ. 
 
Normal cell proliferation is restrained by telomere degeneration as telomerase 
activity is usually absent in somatic cells. In early neoplastic lesions, 
dysfunctional telomere shortening can cause chromosomic instability and is 
associated oncogene activation.29,30 At this point the lesions can activate cellular 
senescence. However, in advanced tumours, telomerase is activated, allowing 
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cells to exceed the regular limit of cell division cycles and progress towards 
malignancy and metastasis.15,31 
Another cellular response to stress stimuli is apoptosis or programmed cell death. 
This energy-dependent process is based on morphological and biochemical 
changes that do not include inflammation.32 Apoptosis can be activated by two 
main signalling pathways, however they both conclude in the formation of 
apoptotic bodies that surrounding fagocytic tissue can engulf.   
 
1.2 Cancer Therapy  
1.2.1 Surgery and other therapies 
Surgery is the primary treatment for solid tumours; it involves the total removal of 
neoplastic tissue and the surrounding lymph nodes. This type of radical 
intervention depends to a great extent on the type of cancer, the affected organ and 
the stage of the diagnosed lesion. This treatment has strong limitations, especially 
for aggressive tumours with high rate of metastasis. Alternative therapies include 
the following. 
 
• Photodynamic therapy, PDT: involves the administration of a non-toxic 
pro-drug and its subsequent selective activation at a specific wavelength. 
An example of a red-light activated antineoplastic agent is photofrin, while 
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levulan is activated by blue light. This therapy is widely used for skin 
cancers. 
• Radiotherapy: based on the use of gamma radiation to treat neoplastic 
lesions; this radiation generates DNA damage in the affected tissue. 
• Hormone therapy: the rate of growth and spread of neoplastic lesions that 
are hormone-dependent, such as breast, endometrial and prostate cancer, 
can be diminished by modulating hormonal levels in the patient. An 
example of this is the use of tamoxifen for the treatment of breast cancer. 
• Immunotherapy: includes ligand-targeted therapeutics in which an 
immunotoxin or an immunoconjugate are used to improve drug-
selectivity.33 
• Cryosurgery or cryotherapy: an alternative to surgery for some types of 
cancer, for example liver, prostate and skin neoplastias.  
• Radiofrequency ablation, RFA: Commonly used for liver and lung 
neoplastias, this intervention relies on high temperatures, generated by 
radiofrequencies, to destroy cancerous tissue.  
 
1.2.2 Chemotherapy 
Surgery and radiotherapy dominated cancer treatment during the first half of the 
20th century. Chemotherapy, as a viable alternative, was first considered in the 
1940s when nitrogen mustards were used against lymphomas. Since then, 
extensive research into the use of drugs against the proliferation of malignant 
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tissue has taken place. In time, important discoveries have been made that have 
allowed the cure and/or improvement of life expectancy for cancer patients.34 
Selectivity has always been presented as the downside of chemotherapy, mostly 
because the severity of undesired side-effects which range from nausea and 
vomiting to acute renal failure. Theoretically, reduction of side-effects could be 
achieved by increasing the dose of drug that reaches the diseased tissue while 
reducing the dose that reaches and affects normal surrounding tissue/organs. 
However, in the practice, selectivity is a much more complicated issue, especially 
because of the lack of unique molecular targets in cancer cells. 
Anticancer agents currently in clinical use rely on the high proliferation rate of 
neoplastic tissue as means for selectivity.35 This results in side-toxicity in tissues 
that also exhibit frequent cellular replacement such as bone marrow and 
gastrointestinal tract.33  
 
1.2.2.1 Single-targeted chemotherapeutic agents 
Single-targeted chemotherapy aims to selectively deliver the drug to the 
neoplastic growth, avoiding the surrounding tissue. It also refers to some 
antineoplastic agents that are able to interrupt a particular metabolic pathway only 
present in cancerous cells or to directly interact with a unique molecular target. 
The benefits of such therapy are the increase in selectivity and the possibility of 
reducing adverse side-effects.  
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Molecularly-targeted therapies are in their early stages. However, several 
examples can be found, for instance imatinib targets the BCR-ABL oncogene that 
causes chronic myelogenous leukaemia and trastuzumab targets the ERBB2 
receptor to stop proliferation of breast cancer. In both cases, these antineoplastic 
agents aim to target pathways that are specifically activated in cancers.33 Frequent 
targets for cancer therapies are tyrosine kinase receptors. These receptors for 
growth factors are located in the cell surface and have a crucial role in 
oncogenesis.36 One example of this is the use of cetuximab to target the family of 
epidermal growth factor receptors, EGFR, in metastatic colorectal and head and 
neck cancers or gefitinib in the analogous breast and lung cancers.37  
Cellular metabolism in cancer is altered to allow cells to sustain a high rate of 
proliferation and to avoid cell death-signalling usually caused by increased 
cellular stress levels.35,38 Such alterations in metabolism can be exploited by 
targeted agents,39 such as lonidamine, which inhibits glycolysis and is currently in 
phase III clinical trials. Another example of this type is the use of arginine 
deiminase against metastatic melanoma and hepatocellular carcinomas, as it 
reduces arginine levels in plasma (clinical trials phases I/II).35  
New possible targets are being investigated, such as those of the hypoxia-
inducible factor 1, HIF-1, which is involved in cancer progression. HIF-1 is over 
expressed in solid tumours as result of microenvironment hypoxia and it activates 
the transcription of angiogenesis-promoting genes.40,41  
Finding unique molecular targets in a disease not fully understood at molecular 
levels can prove to be a difficult endeavour42. Although there have been 
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advantages in single-targeted therapies, many workers insist they will not be the 
ultimate answer to increase chemotherapy’s selectivity. Cancer is a very dynamic 
disease, resulting from sporadic mutations and genomic instability, which 
promotes rapid somatic evolution. Single-targeted therapy undoubtedly can be 
able to promote resistance as an evolutive answer.43 This would only allow short-
term use of the therapy with an increased risk of resistant recurrences.32  
 
1.2.2.2 Multi-targeted chemotherapeutic agents 
The efficiency achieved by the complete inhibition of one single molecular target 
can be over-estimated when compared to the partial inhibition of several targets, 
especially when the multi-targeting is the result of a single agent.44  A recent view 
that a multi-targeted drug can prevent cells from developing resistance has 
quickly gained followers. Multiple target screenings are being developed45 to 
tackle multi factorial diseases such as cancer or Alzheimer.46 The aim is to find a 
single agent that would be able to stimulate/inhibit more than one molecular 
activity.32 The best examples of successful multi-targeted antineoplastic agents are 
cisplatin (CDDP) and its derivative drugs carboplatin and oxaliplatin. These 
platinum chemotherapeutics have DNA as their principal target.47 However, in the 
case of CDDP, only 1% of the administered metal reaches the cellular nucleus, 
allowing the rest of the drug to interact with other important biomolecules.48–51  
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1.2.2.3 Combination therapy in cancer treatment 
Multi-targeted therapy can also be achieved by combination of several single-
targeted agents or by co-administration of drugs with synergistic anti-tumour 
activity, which can block simultaneously multiple signalling pathways.52,53 
Several attempts have been made to understand the interaction of two or more 
drugs when they are co-administered. The most-accepted theory, developed by 
Chou and Talalay, indicates that two agents can interact in three different ways. 1) 
synergistically, 2) additively or 3) antagonistically. Synergistic interaction refers 
to the situation when the modulating effect of the combination of both drugs is 
greater than the addition of their single actions, in comparison, in an antagonist 
interaction the modulating result is lower.54–56 
The best outcome of combination therapy in cancer would be a synergistic 
interaction that could allow the reduction of drug doses and subsequently the 
incidence of adverse side-effects. Another possible advantage of this type of 
therapy is the circumvention of drug resistance as is the case on the treatment of 
ovarian cystadenocarcinoma cells treated with tunicamycin and CDDP or 
vincristine.57 
One particular cancer in which multi-targeted agents or the combination of single-
targeted drugs are the best option is non-small cell lung cancer, NSCLC. 
Refractory advanced patients are best treated with EGFR gefitinib in combination 
with erlotinib. Other ongoing clinical trials include the co-administration of 
ZD6474, a kinase inhibitor with gefitinib or docetaxel.52 Other approaches include 
gemcitabine combined with etoposide which also work on ovarian cancer.58 
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Activity of platinum agents such as CDDP can also be enhanced by the co-
administration of secondary chemotherapeutics such as dichloroacetate59 or 
aphidicolin glycinate.60 Combination therapy of anti-angiogenic agents with 
regular chemotherapy increases the survival rate of patients with advanced 
cancers.22  
 
1.2.2.4 Resistance to chemotherapeutics 
One of the major challenges in the use of chemotherapy for cancer treatment is the 
high incidence of resistance.61 Drug resistance is divided into two main 
categories, inherent and acquired resistance. Some of the most important 
molecular mechanisms of resistance include: increased drug efflux, mutations in 
drug targets, activation of downstream or parallel signalling pathways and altered 
drug metabolism.62 The development of drug resistance is not limited to cancer 
treatment, and is a critical factor in the management of diseases such as malaria, 
tuberculosis and HIV.63,64 
Inherent resistance usually has pleiotropic origins and determines the selectivity 
of a neoplastic lesion to chemotherapy. This resistance is the basis of the Goldie-
Coldman hypothesis65 that states that resistance can arise from spontaneous 
mutations that inevitably occur in cell proliferation as part of intrinsic genetic 
instability.66 
In comparison, acquired resistance is developed after initial exposure to 
chemotherapeutics. Multidrug resistance, MDR, can emerge as a cellular response 
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to chemotherapeutic agents.67 The family of proteins know as multidrug 
resistance-associated proteins, MRP are usually organic anion transporters, 
although MRP1, MRP2 and MRP3 can also transport neutral molecules, which 
function as efflux pumps in order to reduce intracellular drug concentrations. The 
most widely known protein of this family is the P-glycoprotein discovered in 
1976.68,69  
Mutations in drug targets as a mechanism of acquired resistance have been 
extensively investigated. Such is the case of chronic myeloid leukaemia. This type 
of cancer is often treated with imatinib, however up to 40% of the cases develop 
some kind of resistance due to a mutation in the kinase domain of BCR.70–72 
Increased drug efflux and therefore impaired cellular accumulation is often related 
to CDDP and other platinum-drug resistance, particularly in the treatment of 
hormone dependent female cancers. For ovarian neoplastias the combination of 
platinum-paclitaxel improves rates of survival, although patients will eventually 
relapse with a median-survival of 18 months.73 After platinum resistance has 
established, patients are often treated with doxorubidicin, topotecan, etoposide or 
other hormonal therapies, but still the relapse is frequent and associated with 
multiple drug resistance.73 
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1.3 Metal-based anticancer agents  
1.3.1 Platinum-based anticancer agents 
Since the serendipitous discovery that cisplatin, CDDP, could arrest cell division 
of E. coli, coordination complexes have been used as anticancer agents.74 CDDP 
had been first reported in 1845 by M. Perone75 and its structure proposed in 1893 
by A. Werner, but it was not until 1965 when the observations of B. 
Rossenberg76,77 started a new field for platinum chemistry and its medical 
applications.78 
CDDP was the first platinum-based drug approved by the FDA with 
antineoplastic activity (1978). Currently, its use is accepted alone or in 
combination with other chemotherapeutic drugs against bladder and advanced 
cervical cancer that cannot be treated with surgery or radiotherapy, also in non-
small cell lung or ovarian cancer that are locally advanced or have metastasised. 
Finally it can be used to treat malignant mesothelioma, squamous cell carcinoma 
of the head and neck and testicular cancer.79  
Since its approval, several attempts have been made to improve the 
pharmacological properties of CDDP. Two important derivatives have gained 
FDA approval, carboplatin in 1989 and oxaliplatin, OXA, in 2002, the latter 
having European approval since 1996. In comparison to CDDP, carboplatin is 
approved to treat non-small cell lung cancer and ovarian cancer, in both cases the 
lesions should be locally advanced or derived from tumour recurrence. Advanced 
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or recurrent colorectal cancers or stage III colon cancers may be treated with 
OXA.79 
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Figure 1.3. Cisplatin, CDDP (a), carboplatin (b) and oxaliplatin, OXA (c) 
 
Despite the wide clinical application of CDDP and its derivatives, these platinum 
chemotherapeutics have strong disadvantages. Their administration causes severe 
side effects which include nephrotoxicity,80,81 neurotoxicity,82,83 ototoxicity,84,85 
nauseas and vomiting amongst others. These side-effects are mostly caused by the 
lack of drug selectivity. Numerous studies have been carried out to improve drug 
delivery including optimised solubility and selective activation of pro-drugs. In 
the latter case, platinum(IV) complexes have lead the research with complexes 
such as tetraplatin, satraplatin. The latter, although it has not yet received full 
FDA approval, is the first platinum antineoplastic agent that can be administered 
orally.86 
  
 
Figure 1.4. Structure of satraplatin
 
1.3.1.1 Mechanism of action of Pt
It is widely accepted that the antineoplastic properties of CDDP rely on the 
interaction with DNA which in turn activates apoptosis. However, this is a 
reductionist view of a process in which several important events are involved 
from drug administration t
events is shown in Figure 1.
CDDP is administered directly in
in blood plasma is 100 mM,
thought that protein binding can deactivate the platinum drug
especially after S-binding 
Cellular accumulation of CDDP occurs by means of diffusion and active transport 
via the copper transporter 
concentration of chloride is reduced to 20 mM a
Aquated forms of CDDP are reactive and bind
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adducts. The formation of inter-strand or intra-strand bifunctional adducts is 
possible.87–90  
 
Figure 1.5. Cellular mechanism of action of CDDP (adapted from ref 87) 
 
Figure 1.6. CDDP-DNA bifunctional adducts (adapted from ref 87) 
 
Once the CDDP-DNA adducts have been formed, the lesions can be repaired by 
three distinct mechanisms: 1) nucleotide excision repair, NER, 2) mismatch 
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repair, MMR or 3) DNA-dependent protein kinase repair mechanisms, DNA-PK. 
NER mechanism is the most common of the three. It involves an ATP-dependent 
protein to recognise the DNA lesion, especially 1,2-intrastrand cross-links, and 
excise the damaged DNA strand-section for the subsequent filling of the gap by 
the DNA polymerase.91 The general scheme for this repair process is shown in 
Figure 1.7. Although the DNA lesions caused by CDDP and their repair processes 
have been extensively investigated, the detailed mechanism  by which they lead to 
apoptosis remains poorly understood.87,92   
Carboplatin and OXA are thought to follow similar mechanisms of action to 
CDDP.47 Although carboplatin shows reduced side-effects and OXA shows 
improved performance on colorectal cancers, CDDP is still the chemotherapeutic 
agent of choice and is more widely available. 
 
Figure 1.7. NER repair mechanism according to Cepeda et al. 91 
 
One major drawback of platinum chemotherapeutics is the high occurrence of 
inherent and acquired resistance. Such resistance against platinum drugs can be 
the result of one of the following mechanisms: a) impaired cellular accumulation 
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as a consequence of reduced cellular uptake or increased cellular efflux, b) 
deactivation by binding to sulfur containing proteins and c) increased repair of 
DNA lesions.93–99  
 
1.3.2 Ruthenium-based anticancer agents 
Since the discovery of CDDP, numerous attempts have been made to emulate its 
activity while reducing its side toxicity. Coordination complexes based on a wide 
number of metals have been developed in the search for improved bioavailability 
and increased selectivity.100–102 Ruthenium (II/III) complexes have been widely 
developed in this field as a viable alternative to platinum chemotherapeutics.  
Two Ru(III) antineoplastic complexes NAMI-A and KP1019, Figure 1.8, have 
reached human clinical trials.103,104 NAMI-A has shown antimetastatic potential, 
while the latter induces apoptosis in primary tumours.  
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Figure 1.8. Structure of NAMI-A (a) and KP1019 (b). 
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Other promising series of Ru(II) complexes have been synthesised, Figure 1.9,  
including organometallic arene diamine complexes prepared in the Sadler Group 
like RM175,105 phosphor-adamantane derivatives such as RAPTA-C106 developed 
by the Dyson Group and polypyridyl complexes synthesised by the Sheldrick 
Group.107 
Ru
Cl
H2N
NH2
+
Ru
Cl
Cl
P
N
N
N
a) b)
+
RuS
N
N
N
NNH2
NH2
c)
2
 
Figure 1.9. Structures of RM175 (a) and RAPTA-C (b) and Ru(II) complex 
synthesised by Sheldrick. 
 
Organometallic Ru(II) ‘piano-stool’ complexes were designed to allow fine tuning 
of the physical and chemical properties which should result in optimised 
biological activity.108–111  These complexes include three basic building units as 
shown in Figure 1.10: an arene ligand, used to stabilise the metal centre oxidation 
state and improve hydrophobicity, a monodentate ligand, X, initially included as 
an activation site, and a bidentate ligand, Y-Z. 100,112 
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Figure 1.10. Basic structure of Ru(II) ‘piano-stool’ complexes. 
 
1.3.2.1 Mechanism of action of Ru-based anticancer agents 
Investigations into the mechanism of action of metal-based chemotherapeutics are 
still in the early stages. Ruthenium organometallic drugs are most likely to be 
multi-targeted. Although the DNA damage caused by most complexes is 
considerable, this mechanism may be only partly responsible for the 
antineoplastic activity observed. Investigations on non-DNA targets are extensive 
but the details of the mechanism of action of these drugs in still poorly 
understood.113 However, significant progress has been made to link their 
biological activity to particular molecular targets that include protein kinases, 
carbonic anhydrases114 and topoisomerases.115–117  
Organometallic Ru(II) piano stool complexes can undergo activation by the 
loss/replacement of the monodentate ligand. This gives rise to a free coordinative 
position that can bind to DNA or other biologically-relevant molecules.100 Some 
cell-free studies show that aquation of the complexes can occur with subsequent 
binding to nucleobases such as 9-EtG and 9-EtA, Figure 1.11. 118,119  
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Figure 1.11. Structures of 9-EtG (a) and 9-EtA (b) ruthenium(II) adducts reported 
by Melchart et al.118  
 
Under the same conditions several studies have shown how these complexes can 
interact with Calf Thymus-DNA.120 Further, in vitro testing has shown the extent 
of the interaction between the Ru(II) complexes and cellular DNA113,121 as well as 
the activation of nucleotide excision repair mechanisms after the formation of Ru-
DNA adducts.122 Metal complexes not only can be activated by aquation but also 
by reduction,100 particularly in the case of Ru(III) complexes.123, 124  
An important advantage of Ru(II) piano stool complexes is their ability to 
circumvent resistance to platinum chemotherapeutics. Such is the case of RM175 
which is active in CDDP-resistant ovarian carcinoma cells A2780cis.125 This 
Ru(II) complex causes G1/G2 arrest in HCT116 cells in a p53 and p21/WAF1- 
dependent manner after short drug-exposure periods.126 
With P-donor ligands, pyridocarbazole half-sandwich Ru(II) complexes, such as 
that shown in Figure 1.12, are able to inhibit protein kinases GSK3α and 
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PAK1.127  The same kinases can be inhibited by octahedral Ru(II) complexes as 
well.128  
Ru
NN
N
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OO
Me3P
 
Figure 1.12. Half-sandwich ruthenium(II) complex inhibitor of GSK3α and 
PAK1.127 
 
Ruthenium polypyridyl complexes can interact with DNA by intercalation,115,129, 
130
 but they can also induce mitochondria-mediated131 and caspase-dependent132 
apoptosis. This mechanism of cell death activation is also observed in ‘piano-
stool’ Ru(II) complexes.133–135   
  
Chapter 1: Introduction 
28 
 
1.3.3. Anticancer agents based on other metals 
 
Research into metal-based anticancer agents, other than Pt and Ru, has seen an 
abrupt increase in the last decades.136 The use of osmium, iridium, gallium, or 
gold as metal centres for novel antineoplastics has achieved important steps 
towards the development of drugs with low side effects.101  
Osmium, has been used to build piano-stool complexes similar to those of Ru(II), 
complexes such as [Os(η6-bip)(en)Cl]+ or [Os(η6-bip)(picolinate)Cl] which have 
shown to have good activity against A2780 ovarian cancer cells. More important, 
they are active in the CDDP resistant derived cell line, A2780cis.120 Os complexes 
are more inert towards aquation and ligand exchange than their Ru analogues. 
They also exhibit lower rates for nucleobase binding than their Ru(II) complexes. 
In addition water molecules bound to the Os metal centre are significantly more 
acidic.137 Attempts have been made to increase the selectivity of such complexes 
based on Os by using targeting peptides.138 
Azopyridine Os(II) complexes such  as [Os(η6-bip)(azpy-OH)I]PF6, [Os(η6-p-
cym) (azpy-OH)I]PF6, [Os(η6-bip)(azpy-NMe2)I]PF6 and [Os(η6-p-cym)(azpy-
NMe2)I]PF6 have shown to be an order of magnitude more active than CDDP in 
the ovarian cancer cell line A2780. In particular, [Os(η6-p-cym)(azpy-NMe2)I]PF6 
exhibited sub-micro molar IC50 values in lung A549, colon HCT116, breast 
MCF7 and prostate cancer PC3. This complex has also shown good in vivo 
tumour reduction for HCT116 xenografs.139   
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Osmium(II) and rhodium(II) analogues of Ru(II) based anticancer agent such as 
RAPTA-C have also been used in order to improve antiproliferative activity. In 
this case, the Rh analogues showed to be twice as active than the original Ru 
complex in A549 lung cancer and T47D breast cancer cells.140 Organometallic 
half-sandwich iridium complexes have also been explored as novel anticancer 
agents. In this case, negatively charged cyclopentadienes are needed in order to 
stabilise Ir(III) as a metal centre. Highly active complexes [Ir(η5-C5Me4 
C6H4C6H5)(phen)Cl]+ and [Ir(η5-C5Me4C6H4C6H5)(bpy)Cl]+ are reported to 
undergo hydrolysis and form nucleobase adducts after reaction with 9-EtG. 
However they do not react with 9-EtA. In both cases their IC50 values in A2780 
ovarian cancer cells is in the sub-micro molar range (0.72 ± 0.01 and 0.57 ± 0.07 
µM respectively).141 
 
Gallium-based compounds have been explored in the clinic as antineoplastic 
agents. Oral administration of Ga salts results in low toxicity which allows for 
chronic treatment. Gallium nitrate has reached phase II clinical trials with 
promising results in the treatment of bladder carcinoma and lymphomas. Gallium 
chloride and maltolate have also been investigated,142 as well as, tris(8-
quinolinolato) gallium(III) (KP46) which is capable of inhibiting tumour growth 
and there is clinical evidence of its activity in renal cell carcinoma.143,144 More 
recently, another gallium based compound, KP2235, which targets the 
functionality of the endoplasmic reticulum has completed pre-clinical trials.145  
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1.4 Aims 
The general aim of this thesis was to synthesise and characterise novel 
ruthenium(II) complexes for subsequent investigation of their biological 
properties as antineoplastic agents,  including their in vitro mechanism of action 
in cancer cells. More specific aims are as follows. 
• Synthesise and characterise novel half-sandwich Ru(II) arene complexes. 
• Investigate the aqueous chemistry of the novel Ru(II) complexes including 
the extent of their aquation and binding to 9-EtG, as a model for nucleobase 
interaction. 
• Determine the antiproliferative activity in vitro and the total cellular 
accumulation of the Ru(II) complexes in cancer cells and investigate the 
molecular pathways involved in the cellular accumulation of the Ru(II) 
complexes. 
• Investigate the mechanism of action of iminopyridine Ru(II) complexes and 
explore DNA as a possible target by means of intercalation. 
• Investigate the differences in the molecular pathways activated by 
organometallic Ru/Os complexes when the monodentate ligand changes from 
chloride to iodide.  
• Investigate the synergistic effect of inactive Ru(II) complexes in combination 
therapy by co-administration with Pt drugs currently in clinical use. 
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This Chapter describes the general experimental techniques and 
instrumentation used in this Thesis. Particular methods for individual 
experiments are described in the appropriate chapters.  
 
2.1 Materials 
RuCl3.xH2O was purchased from Precious Metals Online (PMO pty Ltd).  All 
solvents (acetone, methanol and ether) were obtained from commercial sources 
such as Fisher Scientific and Sigma-Aldrich and were used without further 
purification; ethanol was obtained from the same suppliers but dried over 
Mg/I2 before use. Alpha-phellandrene and cyclopentadiene were purchased 
also from Sigma Aldrich, the latter was obtained in its dimeric form and was 
freshly distilled before use. Octanol (≥ 99%) for Log P determinations was 
purchased from the same provider. Deuterated solvents (CDCl3, MeOD, D2O, 
DMSO-d6) were purchased from Cambridge Isotopes Limited. ICP-MS 
standards (Ru, Pt, Os) were obtained from Inorganic Ventures. 
For the biological experiments, RPMI-1640, DMEM and McCoy 5A media, as 
well as foetal bovine serum, L-glutamine, penicillin/streptomycin mixture, 
trypsin, trypsin/EDTA, phosphate buffered saline (PBS) were purchased from 
PAA Laboratories GmbH. Cisplatin CDDP (≥ 99.9%), oxaliplatin OXA (≥ 
98.9%),  trichloroacetic acid (≥ 99%), 9-EtG, sulforhodamine B (75%), sodium 
phosphate monobasic monohydrate (≥ 99%), sodium phosphate dibasic 
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heptahydrate (≥ 99%), acetic acid (≥ 99%) formaldehyde (36.5–38% in H2O) 
triton X-100 and Tris(hydroxymethyl) aminomethane (TRIS, ≥ 99%)  were 
obtained from Sigma Aldrich. 
 
2.1.1 Synthesis of the starting materials 
Synthesis of the ruthenium p-cymene dimer, [(Ru(η6-p-cymene)Cl2)2].1,2  
Cl
Cl
Ru
Cl Ru
Cl
RuCl3.3H2O +
 
Scheme 2.1. Synthesis of the ruthenium p-cymene dimer [(Ru(η6-p-
cymene)Cl2)2]. 
 
RuCl3.3H2O (150 mg, 0.66 mmol) was dissolved in freshly distilled ethanol (5 
mL), the solution was placed in a round-bottom flask, then alpha-phellandrene 
(105 µL, 0.66 mmol) was added with constant stirring. The reaction mixture 
was heated under reflux for 18 h. The solvent was removed by rotary 
evaporation and the solid precipitate was washed with ethanol and ether, (98 
mg, 48.0%). Elemental analysis calc. for C20H28Cl4Ru2, C: 39.23%, H: 4.58%. 
Found: C: 39.31%, H: 4.56%. NMR-δH (500 MHz; MeOD) 1.29 (6H, d, J = 
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7.10 Hz), 2.15 (3H, s), 2.98 (1H, m), 5.34 (2H, d, J = 5.80 Hz), 5.46 (2H, d, J = 
5.80 Hz). m/z (ESI) found 576.9 (M+ C20H28Cl3Ru2 = 576.93). 
 
2.2 Instrumentation 
2.2.1 Nuclear Magnetic Resonance Spectroscopy (NMR)3,4 
In this thesis, NMR data (1H, 13C and 2D experiments) were acquired using 5 
mm NMR tubes in the NMR Spectroscopy Facility of Warwick University on 
either a 500-MHz spectrometer Bruker DRX-500 or a 600-MHz Bruker AVA 
spectrometer, experiments were carried out at 298 K unless otherwise stated. 
1H-NMR chemical shifts were internally referenced to MeOD (3.49 ppm), 
DMSO-d6 (2.50 ppm) 1,4-dioxane (3.71 ppm, for samples in D2O) or CHCl3 
(7.26 ppm). Typically, 20 ppm were used as spectral width for 1H-NMR and 
200 ppm for 13C-NMR experiments. Spectra were processed using Bruker 
Topspin 2.1. 
 
2.2.2 Elemental Analysis 
Elemental analysis (percentages of C, H and N) was carried out on a CE-440 
Exeter Elemental Analyzer by the Warwick Analytical Service. 
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2.2.3 Absorption  Spectroscopy (UV/Vis) 
Electronic absorption spectroscopy spectra were recorded on a Varian Cary 
300 or Cary 300Bio UV-Vis spectrometers using 1-cm path-length cuvettes 
(600 µL) and processed with Origin Lab 8.1 (Origin, USA). Experiments were 
carried out at 298 K unless otherwise stated; both spectrometers were fitted 
with PTP1 Peltier temperature controllers.  
 
2.2.4 Electrospray Ionisation Mass Spectrometry  
        (ESI-MS)5 
Data were recorded in the Mass Spectrometry Facility of Warwick University 
using methanolic solutions (50% MeOH, 50% H2O) on a Bruker Esquire 2000 
instrument with electrospray as the ionization method. Usually experiments 
were based on scanning a range of up to 1000 m/z for positive ions, the cone 
voltage and source temperature varied depending on the sample.  
 
2.2.5 Inductively Coupled Plasma Mass Spectrometry  
   (ICP-MS)6 
Inductively coupled plasma mass spectrometry was used to determine the metal 
content of cellular samples. Experiments were carried out using an ICP-MS 
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Agilent technologies 7500 series from the Mass Spectrometry Facility of 
Warwick University. The solvent used for all ICP-MS experiments was double 
deionised water (DDW) with 5% HNO3. All metal standards (Ru, Os and Pt) 
were freshly prepared in double deionised water with 5% HNO3 before each 
experiment. The concentrations used for the calibration curve were in all cases 
(0, 5, 10, 50, 200, 500, 1 x 103, 5 x 103, 10 x 103, 50 x 103, 200 x 103 ppt). The 
isotopes detected were 101Ru, 195 Pt and 189Os, and readings were made in 
duplicate (He gas and no gas mode). 
 
2.2.6 Flow Cytometry 7–9 
All flow cytometry experiments were carried out using a Becton Dickinson 
FACScan Flow Cytometer in the School of Life Sciences at Warwick 
University. Typically, A2780 cells were seeded in Pietri dishes using 4 x 106 
cells per plate. Experiments included 24 h of pre-incubation in drug-free media 
at 310 K in CO2 humidified atmosphere (5%), followed by 24 h of drug 
exposure under the same conditions. After this, sample preparation and staining 
depended on the aim of the experiment being carried out; more detailed 
procedures can be found in the appropriate chapters. 
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2.3 Methods 
2.3.1 Aquation studies 
A 2 mM solution of each complex was prepared in D2O water using 5% 
DMSO/MeOD, 1H-NMR spectra were recorded at 298 K within the first 10 
min after mixing and then again under the same conditions after 24 h. Results 
shown were obtained from a 500 MHz spectrometer. All experiments were 
carried out in triplicate and the standard deviations calculated. Aquation of the 
complexes was followed by the observation of a second set of signals after 24 
h, in order to confirm that the process observed was indeed aquation, the 
reaction was inhibited by the addition of NaCl or KI, according to the details in 
the following section. The results presented reflect the extent of aquation after 
a given period of time (24 h); however no attempt was made to determine the 
kinetics of the reactions. In order to verify that after 24 h the reactions had 
reached equilibrium, a further spectrum of each sample was run after 48 h. No 
further changes were detected.  
   
2.3.1.1 Suppression of aquation 
A fresh 2 mM solution of each complex was prepared in a 200 mM solution of 
NaCl / KI in deuterated water (NaCl for chlorido complexes and KI for the 
iodido complexes) with 5% DMSO/MeOD. In order to prepare this solution, 
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the solid complex was dissolved first in DMSO/MeOD to be then diluted in 
deuterated water, already containing NaCl/KI. 1H-NMR spectra were recorded 
at 298 K within the first 10 min of sample preparation and then again after 24 
h. All experiments were carried out in triplicate and the standard deviations 
calculated. The suppression of aquation was monitored, signals generated by 
the complex remained unchanged after the 24 h period.  
 
2.3.2 Determination of partition coefficient (Log P) 
A 2 mM solution of each complex was prepared in octanol-saturated water (5 
mL) and shaken overnight on a IKA Vibrax VXC basic shaker (500 g/min) 
with an equal volume of water-saturated octanol. Layers were separated and 
metal concentration in the aqueous layer was determined via ICP-MS after 
dilution with double distilled water to achieve concentrations within the ICP-
MS standards range mentioned before (5–200 x 103 ppt). For these experiments 
the doubly-distilled water contained 200 mM of NaCl to avoid the aquation of 
the complexes. Partition coefficients were calculated using the formula log P = 
log ([Ru]oct/[Ru]aq).10 Octanol-saturated water and water-saturated octanol were 
prepared before hand by stirring mixtures of octanol and water overnight. The 
value corresponding to the concentration of metal in the octanol layer was 
determined as the difference between the aqueous layer before mixing and the 
corresponding concentration after 24 h. Log P determinations were carried out 
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as duplicates of triplicates in independent experiments and the standard 
deviations were calculated. 
 
 
2.3.3 Nucleobase binding 
A fresh 2 mM solution of each complex was prepared in 50 mM sodium 
phosphate buffer (pH 7.5) with 5% DMSO. In order to prepare this solution, 
the solid complex was dissolved first in DMSO and then diluted with the 
corresponding buffer. The solution also contained 9-ethylguanine for a final 
mol. ratio 1:1.25 where the nucleobase was in excess. As in the case of 
aquation studies, 1H-NMR spectra were recorded at 298 K within the first 10 
min after sample preparation and again after 24 h at 500 MHz. All experiments 
were carried out in triplicate and the standard deviations calculated. 
Nucleobase binding was monitored by the formation of a second set of peaks 
that included bound-9-EtG.11,12 The spectrum of free 9-EtG under the same 
conditions was recorded for comparison purposes.  
 
2.3.4 pH* measurements 
pH* measurements were carried out at ambient temperature in a Corning 240 
pH meter equipped with a microcombination electrode (KNO3, chloride free) 
  
Chapter 2: Experimental 
52 
 
calibrated with Aldrich buffer solutions at pH 4, 7 and 10. pH meter readings 
without correction for effects of deuterium on the glass electrode. 
 
2.3.5 Cancer cell studies 
 2.3.5.1 Cell maintenance 13,14 
Cell lines used in this work, A2780 human ovarian carcinoma, A549 human 
caucasian lung carcinoma, HCT116 human colon carcinoma, MCF7 human 
caucasian breast carcinoma and MRC5 human foetal lung fibroblasts were 
obtained from the European Collection of Cell Cultures (ECACC). Modified 
cell lines HCT116Ox and HCT116p53-/- were kindly provided by R. Sharma 
from Oxford University and J. Cherry from Johns Hopkins International 
Medical Center respectively. A2780 ovarian and MRC5 were grown in 
Roswell Park Memorial Institute medium (RPMI-1640), A549 and MCF7 were 
grown in Dulbecco's Modified Eagle medium (DMEM) and HCT116 and its 
derived cell lines in McCoy′s Modified 5A medium. All media were 
supplemented with 10% of foetal calf serum, 1% of 2 mM glutamine and 1% 
penicillin/streptomycin. 
All cells were grown in 75 cm2 culture flasks as adherent monolayers, and they 
were split two to three times a week when around 80-90% confluence was 
reached, using 0.25% trypsin for A2780 or 0.25% trypsin/EDTA for all other 
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cell lines. Between passages cells are kept in an incubator at 310 K with 5% 
CO2 humidified atmosphere. 
 
 
 2.3.5.2 Antiproliferative activity 
Antiproliferative activity was determined by the sulforhodamine B (SRB) 
colorimetric assay.15,16 This assay was first developed by Skeham in 199017 and 
it is based on the ability of the sulforhodamine B (Figure 2.1) to bind 
electrostatically to basic amino acid residues of proteins from fixed cells.  The 
process is pH-dependent, the binding occurs under mild acidic conditions, but 
under mild basic conditions it is possible to release quantitatively the dye.  
Absorbance measurements of solubilised dye are linear with the amount of 
cellular protein present, allowing for the determination of the amount of viable 
treated cells against an untreated control.  
 
O NN+
SO3H
O3S-
 
Figure 2.1. Structure of sulforhodamine B. 
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Typically, antiproliferative activity experiments involved the following:  
• Cell preparation: human carcinoma cells and fibroblasts were grown as 
indicated above until approximately 80-90% confluence was achieved. 
The medium was removed and cells were washed twice with 
phosphate-buffered saline (PBS. This step allowed the removal of dead 
cells in the supernatant. Then the PBS was removed and 2 mM trypsin 
or trypsin/EDTA (2 mL) was added. The culture flask was left to stand 
for 3 min in the incubator. The trypsin or trypsin/EDTA was diluted 
using the corresponding medium and the solution was mixed to obtain a 
single cell suspension. A hemocytometer was used to determine the 
concentration of cells in the suspension.  
• Plate seeding: the single cell suspension obtained in the previous step 
was diluted with medium in order to seed a 96-well plate with 
approximately 5000 cells per well using 180 µL per well. The plate was 
left in the incubator for two days. 
• Sample preparation: a 2 mM solution of each compound to be tested 
was prepared using a 5% DMSO, 95% (saline: PBS) mixture. This 
stock was then used to prepare six different solutions by dilution with 
PBS. The concentration range of these solutions varied according to the 
screening results for each particular sample, and were adjusted to 
achieve three values above the expected IC50 and three values below. 
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• Positive control preparation: a 2 mM solution of cisplatin was prepared 
using a 5% DMSO, 95% saline. This stock was then used to prepare 
2000, 1000, 500, 200, 50, and 1 µM solutions by dilution in PBS.  
• Negative control preparation: this was obtained by 5 % of DMSO, 95% 
(saline: PBS) mixture. 
• Drug addition: 20 µL of samples, cisplatin, positive and negative 
control solutions were added to the 96-well plate in triplicate. The plate 
was left in the incubator for 24 h. 
• Drug removal: supernatant solutions were removed from each well by 
means of suction. Each well was then washed using 100 µL of PBS, 
finaly 200 µL of fresh medium were added to each well. The plate was 
left to stand for 72 h in the incubator, while the cells were allowed to 
recover.  
• Sulforhodamine B (SRB) colorimetric assay: 50 µL of cold 10% 
trifluoroacetic acid (TCA), 277 K, were added to each well of the plate. 
This was left to incubate for 1 h at 277 K. The TCA was removed and 
the plate was washed with slow-running tap water 10 times. Excess 
moisture was removed and the plate was allowed to air-dry. This step 
fixed the cells to the surface of the wells.  
Aliquots of 50 µL of 0.4% SRB dye (prepared in 1% acetic acid) were 
added to each well. The plate was allowed to stand for 30 min at room 
temperature. This step stained the biomass present in each well. Excess 
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dye was removed by washing the plate 5 times with 1% acetic acid. 
Excess moisture was removed and the plate was allowed to air-dry. 
Aliquots of 10 mM Tris base solution (200 µL, pH 10.5) were added to 
each well and the plate was left to stand at ambient temperature for 1 h. 
This step solubilised the bound dye. The plate was measured in a multi 
reader at 570 nm. Those wells with absorbances over 3.00 units were 
diluted 1:6 and the absorbance was re-read. These dilutions were done 
by removing 150 µL of each of the wells and adding 250 µL of 10 mM 
Tris base solution.  
• Cell viability determination: for each compound screened, survival 
percentages were obtained by dividing the absorbance data by the 
average of the negative-control readings and multiplying by one 
hundred. Then the data were plotted as the survival percentage versus 
the logarithm of the concentration used expressed in mili molar units. A 
sigmoidal curve was fitted using OriginPro 8.1 software, and the IC50 
value was determined, as the half-maximal inhibitory concentration. By 
a way of validation for each plate, the IC50 of cisplatin was determined. 
• Figure 2.2 below shows an example of the dose-response curve 
obtained for cisplatin. 
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Figure 2.2. Dose-response curve for cisplatin. 
 
 
2.3.5.3 Metal accumulation in cancer cells 
• Cell preparation: A2780 human ovarian carcinoma cells were grown in 
a 75 cm2 cell culture flask as indicated in above, until Ca. 80% 
confluence was achieved. The medium was removed and cells were 
washed twice with PBS: this step allowed the removal of supernatant 
dead cells, then the PBS was removed and 2 mL of 2 mM trypsin or 
trypsin/EDTA was added. The culture flask was left to stand for 3 min 
in the incubator. The trypsin was diluted using medium and the solution 
was mixed to obtain a single cell suspension. A hemocytometer was 
used to determine the concentration of cells in the suspension.  
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• Cell seeding: on day one of the experiment, 4 x 106 cells were seeded in 
a 68 mm Petri dish using 9 mL of medium. These cells were incubated 
at 319 K and 5% CO2 levels for 24 h. 
• Sample preparation: 2 mM solution of each compound to be tested for 
cellular uptake was prepared using a 5% DMSO, 95% (saline: PBS) 
mixture. This stock was then used to prepare diluted solutions in PBS.  
• Negative control preparation: this was obtained by using 5% DMSO, 
95% (saline: PBS) mixture. 
• Drug addition: on day-two of the experiment, 1 mL of each compound 
to be tested was added to three pre-incubated Pietri dishes, this resulted 
in a final concentration of the ruthenium(II) complex which is a fifth of 
its IC50 value. On the same day three negative control plates were 
prepared accordingly. Cells were exposed to the drugs for 24 h. 
• Drug removal: on day-three of the experiment, supernatants of the 
Pietri dishes were removed by suction. Cells were washed with PBS 
and treated with trypsin or trypsin/EDTA to obtain a single cell 
suspension as described before in the cell preparation section. Cell 
concentration was determined using a hemocytometer, before 
centrifuging the samples to obtain whole-cell pellets. 
• Sample digestion: cell pellets were transferred into wheaton v-vials and 
digested using 225 µL of freshly distilled concentrated 72% v/v nitric 
acid. For full digestion, the vials were heated to 353 K overnight.  
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• Metal content determination: digested samples were diluted using 
double-distilled deionized water to obtain a final nitric acid 
concentration of Ca. 5% v/v and they were analysed for metal content 
using ICP-MS. 
• The statistical significance of all cellular accumulation values was 
determined using a two-sided t-test with P<0.05. 
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CHAPTER 3 
Ruthenium iminopyridine arene complexes: 
cellular uptake mechanisms. 
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3.1 Introduction 
Ruthenium arene complexes have been widely studied in recent times as a viable 
alternative to platinum chemotherapeutics,1–9 especially because acquired 
resistance to platinum-based drugs represents a major clinical drawback for 
compounds such as cisplatin (CDDP)10,11 or oxaliplatin (OXA).12,13 This type of 
resistance usually develops as a consequence of impaired cellular accumulation 
that can be caused by lower cellular uptake or increased cellular efflux. 10,14,15 
Several attempts have been made to understand platinum uptake and its 
accumulation.16–18 However, there is a lack of knowledge on equivalent 
mechanisms involved in the accumulation of ruthenium anti-cancer drugs. 
Understanding of these pathways could allow rational design and further 
improvement of such complexes. In this Chapter cellular uptake and metal 
accumulation mechanisms for prospective ruthenium anticancer complexes have 
been investigated regarding their time-, concentration- and temperature- 
dependence as well as the extent of metal efflux. Further cellular accumulation 
pathways have been investigated, including the following.  
• Inhibition of P-gp mediated efflux by the use of verapamil: this ATP-
binding protein of the ABC super family19  mediates the efflux of 
xenobiotics and endogenous compounds.  Its substrates include antibiotics, 
steroid hormones and anticancer agents among others. P-gp is responsible 
for the development of multidrug resistance, 20 therefore, its interaction with 
diverse substrates has been widely studied.21–23  P-gp-mediated efflux can be 
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inhibited by the use of verapamil,23 which allows to investigate the role this 
efflux pathway has in the detoxification of chemotherapeutics.24 
• Role of Na+/K+ pump in cellular metal accumulation, as a facilitated 
diffusion endocytotic pathway by ouabain inhibition: Na+/K+ pump is a 
P-type ATPase which pumps three Na+ out of the cells while transporting 
two K+ into it for each hydrolysed unit of ATP.25 This allows the cell to 
keep low intracellular Na+ concentrations,26 a mechanism which has often 
been studied in relation to CDDP uptake. Ouabain is a  cardiac glycoside 
with high bioavailability that inhibits the activity of the Na+/K+ -ATPase as 
it interacts with the extracellular surface of the pump, more specifically, it 
binds to the α subunit.27 Co-incubation of chemotherapeutics with ouabain 
reflects on the role of the pump in drug cellular uptake. 
• Role of CTR1 in cellular accumulation:  CTR1 which is a high affinity 
copper uptake protein,28 encoded in humans by the SLC31A1 gene, is 
responsible to a great extent for CDDP uptake.16,29–34 Also copper exporters 
ATP7A and ATP7B are involved in the efflux of CDDP.35,36 Transporter 
protein, CTR1, can be down-regulated by high levels of intracellular 
copper.37 Cells with a knocked out gene hCTR1 are  resistant to CDDP in 
vitro.38 CTR1 is normally expressed in CDDP resistant cell lines, but the 
transporter is not functional because of a lack of activation by 
glycosylation.39 The details of this mechanism are not yet very clear, 
however it is known that the process is energy independent and highly 
influenced by pH.40 In this study we investigate whether CTR1 is also 
involved in the uptake of ruthenium drugs. 
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• Membrane disruption by amphotericin B as a model for protein 
mediated transport:  amphotericin B is an antifungal agent that has been 
used to potentiate the antiproliferative activity of chemotherapeutic drugs in 
vivo and in vitro, at non-toxic concentrations of up to 15 µM.41  The 
mechanism of action of amphotericin B involves depletion of intracellular 
potassium and therefore modification of membrane permeability. It is 
assumed that amphotericin B binds to sterol molecules and forms pores in 
the membrane of up to 8 Å in diameter which improve cellular uptake of 
exogenous molecules. This antifungal agent has been used in the present 
Chapter to find out wether the uptake of ruthenium(II) from half-sandwich 
arene complexes can be improved by increased facilitated transport. 
• The role of caveolae endocytotic pathway in metal accumulation: 
caveolaes are cholesterol-rich microdomains  in the cell membrane42  and β-
methyl cyclodextrin is known to inhibit caveolae-related uptake by binding 
to cholesterol.31,42,43 Therefore co-incubation with β-methyl cyclodextrin 
could be used to investigate whether this pathway is involved in the cellular 
uptake of a particular drug, in this case, the uptake of ruthenium half-
sandwich complexes. 
In this Chapter the synthesis and characterisation of novel ruthenium arene 
complexes containing imine ligands are described. It also reports on their aquation 
and extent of binding to 9-EtG as a model for nucleobase interaction. The 
antiproliferative activity of all ligands and complexes has been investigated using 
A2780 ovarian, A549 lung, HCT116 colon and MCF7 breast cancer cell lines, 
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these activities were related to their cellular accumulation and hydrophobicity. 
Finally, complex 15 [Ru(η6-p-cym)(p-Impy-NMe2)Cl]PF6 and its iodido analogue 
16 [Ru(η6-p-cym)(p-Impy-NMe2)I]PF6 were used to investigate some of the 
pathways involved in cellular uptake and accumulation of ruthenium in 
comparison to platinum uptake and accumulation from CDDP. These two 
compounds were selected because of their structural similarities (only differ in 
their monodentate ligand Cl vs I) and with the aim to study the effect of the 
monodentate ligand on the cellular uptake behaviour. 
Figure 3.1 summarises the Overview of the cellular accumulation pathways 
investigated in Chapter 3. 
 
Figure 3.1. Overview of the cellular accumulation pathways investigated in 
Chapter 3. 
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3.2 Experimental section 
 
3.2.1 Materials 
Ruthenium half-sandwich arene dimers used in this Chapter include [(η6-p-
cymene)RuCl2]2, reported in Chapter 2, [(η6-p-cymene)RuI2]2, [(η6-m-
terp)RuCl2]2, and [(η6-bip)RuCl2]2, kindly provided by Dr. Abraha Habtemariam. 
2-Pyridine carboxaldehyde (99%), 2-aminophenol (99%), 4-aminophenol (98%) 
were purchased from Sigma-Aldrich. 4-Aminobenzoic acid (≥99.0%) and 
ammonium hexafluorophosphate (≥98.0%) were obtained from Fluka. N,N-
Dimethyl-4-[(E)-(pyridin-2-ylmethylidene) amino]aniline, (p-Impy-NMe2, 6)  was 
kindly provided by Dr. Ying Fu. All deuterated solvents (D2O, MeOD, DMSO-d6, 
acetone-d6, CDCl3) were obtained from Cambridge Isotope Laboratories. For the 
biological assays, verapamil hydrochloride (≥99.0%), ouabain octahydrate 
(≥95%), antimycin A from Streptomyces sp., amphotericin B also from 
Streptomyces sp., methyl β-cyclodextrin and copper(II) chloride dihydrate 
(≥99.0%)   were all purchased form Sigma Aldrich. 
 
3.2.2 Preparation of ligands and complexes 
The synthetic procedure 1, described below was used to generate all the imines 
used as ligands in this Chapter and listed in Figure 3. 2. 
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N
N
OH
 
 
N
N
OH
 
Impy, 1 o-Impy-OH, 2 p-Impy-OH, 3 
N
N
COOH
 
N
N
(CH2)3COOH
 
 
p-Impy-COOH, 4 p-Impy-(CH2)3COOH, 5  
   
Figure 3. 2. Imines synthesised in Chapter 3. 
 
Synthetic Procedure 1. 
N
N
OH
CHO
N
NH2
OH
+
 
Scheme 3.1. Synthesis of 2-{[(E)-pyridin-2-ylmethylidene]amino}phenol [o-Impy-
OH, 2]. 
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2-{[(E)-pyridin-2-ylmethylidene]amino}phenol [o-Impy-OH, 2]. Solid o-
hydroxy aniline (200 mg, 1.832 mmol) was dissolved in acetonitrile (5 mL) at 
ambient temperature with stirring, 1 mol equiv. of the pyridine carboxaldehyde 
was then added (196 mg, 175 µL, 1.83 mmol). The reaction was left to stand with 
stirring for 4 h. The solvent was removed by rotary evaporation. A yellow solid 
was obtained, which was washed with ether (74 mg, 81.5%). Elemental analysis 
calc. for C12H10N2O, C: 72.71%; H: 5.08%; N: 14.13%. Found: C: 72.40%; H: 
5.05%; N: 14.15%. NMR-δH (500 MHz; CDCl3) 7.15 (1H, td, J = 13.9, 7.8, 1.3 
Hz) 7.22 (1H, dd, J = 8.1, 1.3 Hz) 7.46 (1H, td, J = 13.9, 8.1, 1.51 Hz) 7.60 (1H, 
dd, J = 7.8, 1.5 Hz) 7.65 (1H, dd, J = 4.8, 1.6 Hz) 8.07 (1H, td, J = 15.4, 7.9, 1.6 
Hz) 8.38 (1H, d, J =  7.9 Hz) 8.92 (1H, d, J = 4.8 Hz) 9.03 (1H, s). m/z (ESI) 
found 199.0 (calc. M + H+. C12H11N2O = 199.22), found 221.0 (calc. M + Na+ 
C12H10N2NaO = 221.21).  
N-[(1E)-pyridin-2-ylmethylene]aniline [Impy, 1]. As synthetic procedure 1, 
using aniline (100 mg, 98 µL, 1.07 mmol) and pyridine carboxaldehyde (115 mg, 
102 µL, 0.46 mmol). Yield 95.3%. Elemental analysis calc. for C12H10N2, C: 
79.10%; H: 5.53%; N: 15.37%.  Found: C: 78.85%; H: 5.49%; N: 15.69%. NMR-
δH (500 MHz; CDCl3) 7.31 (3H, m) 7.39 (1H, qd, J = 4.7, 7.6, 12.8 Hz) 7.44 (2H, 
t, J = 7.8, 15.4 Hz) 7.83 (1H, td, J = 7.8, 15.3 Hz) 8.32 (1H, d, J = 7.9 Hz) 8.64 
(1H, s) 8.74 (1H, dq, J = 1.4, 4.6 Hz). m/z (ESI) found 184.0 (calc. M + H+ 
C12H11N2 = 184.22). 
4-[(E)-(pyridin-2-ylmethylidene)amino]phenol [p-Impy-OH, 3]. As synthetic 
procedure 1, using p-hydroxy aniline (100 mg, 0.92 mmol) and pyridine 
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carboxaldehyde (98 mg, 87 µL, 0.92 mmol). Yield 92%. Elemental analysis calc. 
for C12H10N2O C: 72.71%; H: 5.08%; N: 14.43%.  Found: C: 72.50%; H: 5.02%; 
N: 14.01%. NMR-δH (500 MHz; DMSO-d6) 6.87 (2H, d, J = 8.6 Hz) 7.30 (2H, d, 
J = 8.6 Hz) 7.50 (1H, cd, J = 1.5, 4.8, 7.6, 15.7 Hz) 7.96 (1H, td, J = 0.5, 7.8, 15.7 
Hz) 8.19 (1H, dt, J = 1.2, 2.2, 8.0 Hz) 8.63 (1H, s) 8.66 (1H, dc, J = 0.9, 1.6, 2.6, 
4.9 Hz). m/z (ESI) found 199.0 (calc. M + H+ C12H10N2O = 199.22). 
 4-[(E)-(pyridin-2-ylmethylidene)amino]benzoic acid [p-Impy-COOH, 4]. As 
synthetic procedure 1, using p-amino benzoic acid (100 mg, 0.73 mmol) and 
pyridine carboxaldehyde (78 mg, 69 µL, 0.73 mmol). Yield 70%. Elemental 
analysis calc. for C13H10N2O2 C: 69.02%; H: 4.46%; N: 12.38%.  Found: C: 
69.15%; H: 4.52%; N: 12.08%.  NMR-δH (500 MHz; DMSO-d6) 5.80 (1H, s) 6.88 
(2H, d, J = 8.8 Hz) 7.44 (1H, cd, J = 1.1, 4.8, 7.6, 12.6 Hz) 7.69 (1H, d, J = 7.8 
Hz) 7.86 (2H, d, J = 8.9 Hz) 7.93 (1H, td, J = 1.9, 7.2, 15.6 Hz). m/z (ESI) found 
227.1 (calc. M + H+ C13H11N2O2 = 227.23). 
4-{4-[(E)-(pyridin-2-ylmethylidene)amino]phenyl}butanoic acid [p-Impy-
(CH2)3COOH, 5]. As synthetic procedure 1, using 4-(4-aminophenyl)butanoic 
acid (100 mg, 0.56 mmol) and pyridine carboxaldehyde (60 mg, 53 µL, 0.56 
mmol). Yield 64%. Elemental analysis calc. for C16H16N2O2, C: 71.62%; H: 
6.01%; N: 10.44%.  Found: C: 71.50%; H: 6.08%; N: 10.52%. NMR-δH (500 
MHz; DMSO-d6) 1.95 (2H, q, J = 7.4, 15.0, 22.7, 30.7 Hz) 2.29 (4H, d, J = 1.4 
Hz) 2.35 (2H, t, J = 6.2, 14.5 Hz)  2.71 (2H, t, J = 7.6, 15.9 Hz) 7.53 (1H, cd, J = 
1.1, 4.9, 7.4, 15.2 Hz) 7.99 (1H, td, J = 2.1, 7.7, 15.2 Hz) 8.22 (1H, td, J = 1.1, 2.0, 
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7.9 Hz) 8.63 (1H, s) 8.69 (1H, dc, J = 0.8, 1.8, 2.8, 4.9 Hz). m/z (ESI) found 291.1 
(calc. M + H+ C16H17N2O2 = 291.33). 
 
Synthetic procedure 2, was used to synthesise all the ruthenium complexes 
described in this Chapter and listed in Table 3.2, on page 84. 
Synthetic procedure 2. 
PF6
Cl
Cl
Ru
Cl Ru
Cl
N
N
Ru
Cl
N
N
+
 
Scheme 3.2. Synthesis of [Ru(η6-p-cym)(Impy)Cl]PF6 [7]. 
 
[Ru(η6-p-cym)(Impy)Cl]PF6, [7]. Ruthenium p-cymene dimer [(η6-p-cymene) 
RuCl2]2 (100 mg, 0.16 mmol) was dissolved in methanol (5 mL). and two mol 
equiv. of the appropriate ligand was added, in this case, N-[(1E)-pyridin-2-
ylmethylene]aniline, (242 mg, 0.33  mmol). The reaction mixture was left at 
ambient temperature with constant stirring for 5 h. After this time, 5 mol. equiv. 
of NH4PF6 were added to the mixture, followed by stirring for a further hour. The 
solid precipitate was filtered off under vacuum and recrystallised. (87 mg, 44%). 
Elemental analysis calc. for C22H24N2ClF6PRu, C: 44.19%, H: 4.05%, N: 4.69%. 
Found: C: 44.25%, H: 4.06%; N: 4.72%. NMR-δH (500 MHz; DMSO-d6) 1.10 
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(6H, d,  J = 9.4 Hz) 2.26 (3H, s) 2.62 (1H, m)  5.49 (1H, dd, J = 6.3, 0.9 Hz) 5.60 
(1H, dd, J = 6.3, 0.9 Hz) 5.67 (1H, q, J = 6.4, 1.1 Hz) 5.97 (1H, dd, J = 6.4, 1.1 
Hz), 7.64  (3H, m) 7.82 (2H, m) 7.85 (1H, m) 8.27 (2H, m) 8.77 (1H, s) 9.51 (1H, 
d, J = 5.6 Hz). m/z (ESI) found 453.1 (calc. M+ C22H24N2ClRu = 452.96).  
[Ru(η6-p-cym)(Impy)I]PF6 [8]. As synthetic procedure 2, using [Ru(η6-p-
cym)2I2]I2 (50 mg, 0.06 mmol) and Impy (65 mg, 0.13 mmol).  Yield 74%. 
Elemental analysis calc. for C22H24N2F6IPRu, C: 38.33%, H: 3.51%, N: 4.06%. 
Found: C: 38.10%, H: 3.68%; N: 4.10%. NRM-δH (500 MHz; DMSO-d6) 0.99 
(6H, dd, J = 8.1, 10.5 Hz) 2.37 (3H, s,) 2.61 (1H, m) 5.63 (1H, d, J = 6.7 Hz) 5.67 
(1H, d, J = 5.5 Hz) 5.82 (1H, d, J = 5.5 Hz) 6.03 (1H, d, J = 6.7 Hz) 7.86 (1H, dd, 
J = 6.0, 13.2 Hz) 8.35 (1H, d, J = 7.0 Hz) 8.93 (1H, s) 9.59 (1H, d, J = 6.7 Hz). 
m/z (ESI) found 544.9 (calc. M+ C22H24N2IRu = 544.41). 
[Ru(η6-p-cym)(o-Impy-OH)Cl]PF6 [9]. As synthetic procedure 2, using [Ru(η6-
p-cym)2Cl2]Cl2 (100 mg, 0.16 mmol) and o-Impy-OH (65 mg, 0.33 mmol).  Yield 
87%. Elemental analysis calc. for C22H24N2ClF6OPRu, C: 43.04%, H: 3.94%, N: 
4.56%. Found: C: 43.28%, H: 3.98%; N: 4.62%. NRM-δH (500 MHz; DMSO-d6) 
1.07 (3H, d, J = 4.2 Hz) 1.09 (3H, d, J = 4.2 Hz) 2.24 (3H, s) 2.64 (1H, q, J = 7.0, 
13.9, 20.9, 27.7 Hz) 5.34 (1H, dd, J = 0.9, 6.2 Hz) 5.56 (1H, dd, J = 1.0, 6.2 Hz) 
5.64 (1H, dd, J = 0.9, 6.2 Hz) 5.96 (1H, dd, J = 0.9, 6.2 Hz) 7.07 (1H, td, J = 1.2, 
7.6, 15.3 Hz) 7.15 (1H, dd, J = 1.2, 8.2 Hz) 7.37 (1H, td, J = 1.5, 8.9, 15.3 Hz) 
7.75 (1H, dd, J = 1.5, 8.1 Hz) 7.85 (1H, td, J = 1.9, 5.6, 12.9 Hz) 8.25 (2H, m) 
8.77 (1H, s) 9.51 (1H, d, J = 5.4 Hz). m/z (ESI) found 469.0 (calc. M+ 
C22H24N2ClORu = 468.96). 
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[Ru(η6-p-cym)(p-Impy-OH)Cl]PF6 [10]. As synthetic procedure 2, using [Ru(η6-
p-cym)2Cl2]Cl2 (100 mg, 0.16 mmol) and p-Impy-OH (65 mg, 0.33 mmol).  Yield 
81%. Elemental analysis calc. for C22H24N2ClF6OPRu, C: 43.04%, H: 3.94%, N: 
4.56%. Found: C: 43.01%, H: 3.90%; N: 4.75%. NMR-δH (500 MHz; DMSO-d6) 
1.10 (6H, d, J = 7.2 Hz) 2.25 (3H, s) 2.60 (1H, q, J = 6.7, 14.0, 20.5, 28.0 Hz) 5.52 
(1H, d, J = 6.0), 5.59 (1H, d, J = 6.5 Hz) 5.65 (1H, d, J = 6.0 Hz) 5.96 (1H, d, J = 
6.5 Hz) 7.00 (2H, d, J = 8.2 Hz) 7.71 (2H, d, J = 8.2 Hz) 7.80 (1H, m) 8.19 (1H, 
dd, J = 1.2, 7.7 Hz) 8.24 (1H, td, J = 1.8, 7.3, 15.7 Hz) 9.45 (1H, d J = 6.0 Hz). 
m/z (ESI) found 469.0 (calc. M+ C22H24N2ClORu = 468.96). 
[Ru(η6-p-cym)(p-Impy-OH)I]PF6 [11]. As synthetic procedure 2, using [Ru(η6-
p-cym)2I2]I2 (150 mg, 0.19 mmol) and p-Impy-OH (76 mg, 0.38 mmol).  Yield 
64%. Elemental analysis calc. for C22H24N2F6IPORu, C: 37.46%, H: 3.43%, N: 
3.97%. Found: C: 37.30%, H: 3.38%; N: 4.01%. NRM-δH (500 MHz; DMSO-d6) 
0.98 (6H, dd, J = 6.0, 13.4 Hz) 2.40 (3H, s,) 2.60 (1H, m) 5.61 (1H, d, J = 6.8 Hz) 
5.66 (1H, d, J = 6.4 Hz) 5.77 (1H, d, J = 6.4 Hz) 6.07 (1H, d, J = 6.8 Hz) 6.97 
(2H, d, J = 8.8 Hz) 7.74 (2H, d, J = 9.6 Hz) 8.25 (2H, d, J = 4.8 Hz) 8.52 (1H, d, J 
= 5.6 Hz) 10.24 (1H, s). m/z (ESI) found 560.0 (calc. M+ C22H24N2IORu = 
560.41). 
[Ru(η6-p-cym)(p-Impy-COOH)Cl]PF6 [12]. As synthetic procedure 2, using 
[Ru(η6-p-cym)2Cl2]Cl2 (100 mg, 0.16 mmol) and p-Impy-COOH (37 mg, 0.33 
mmol). Yield 65%.  Elemental analysis calc. for C23H24N2ClF6O2PRu, C: 43.03%, 
H: 3.77%, N: 4.36%. Found: C: 42.98%, H: 3.61%; N: 4.54%. NMR-δH (500 
MHz; DMSO-d6) 0.98 (3H, d, J = 2.4 Hz) 0.99 (3H, d, J = 2.4 Hz) 2.16 (3H, s) 
  
Chapter 3: Cellular uptake mechanisms 
74 
 
2.84 (1H, m) 5.61 (1H, d, J = 6.8 Hz) 5.69 (1H, d, J = 6.1 Hz) 5.79 (1H, d, J = 6.1 
Hz) 6.10 (1H, d, J = 6.8 Hz) 7.90 (3H, m) 8.18 (2H, d, J = 8.4 Hz) 8.32 (2H, m) 
8.99 (1H, s) 9.60 (1H, d, J = 5.4 Hz). m/z (ESI) found 498.0 (calc. M+ 
C23H24N2ClO2Ru = 497.93). 
[Ru(η6-p-cym)(p-Impy-COOH)I]PF6 [13]. As synthetic procedure 2, using 
[Ru(η6-p-cym)2I2]I2 (50 mg, 0.05 mmol) and p-Impy-COOH (24 mg, 0.10 mmol).  
Yield 52%. Elemental analysis calc. for C23H24N2F6IO2PRu, C: 37.67%, H: 
3.30%, N: 3.82%. Found: C: 37.54%, H: 3.18%; N: 3.69%. NRM-δH (500 MHz; 
DMSO-d6) 1.00 (6H, d, J = 7.9 Hz) 2.18 (3H, s,) 2.62 (1H, m) 5.62 (1H, d, J = 6.0 
Hz) 5.71 (1H, d, J = 6.0 Hz) 5.81 (1H, d, J = 5.7 Hz) 6.13 (1H, d, J = 5.7 Hz) 7.91 
(2H, d, J = 8.7 Hz) 7.98 (1H, d, J = 8.4 Hz) 8.16 (1H, t, J = 7.84 15.4 Hz) 8.19 
(2H, d, J = 8.7 Hz) 8.34 (2H, m) 9.03 (1H, s) 9.62 (1H, d, J = 5.1 Hz). m/z (ESI) 
found 588.4 (calc. M+ C23H24N2IO2Ru = 588.42). 
[Ru(η6-p-cym)(p-Impy-(CH2)3COOH)Cl]PF6 [14]. As synthetic procedure 2, 
using [Ru(η6-p-cym)2Cl2]Cl2 (100 mg, 0.16 mmol) and p-Impy-(CH2)3COOH (44 
mg, 0.33 mmol). Yield 72%. Elemental analysis calc. for C26H30N2ClF6PO2Ru, C: 
57.93%, H: 5.61%, N: 5.20%. Found: C: 57.50%, H: 5.75%; N: 5.18%. NMR-δH 
(500 MHz; DMSO-d6) 1.09 (3H, d, J = 4.4 Hz) 1.33 (3H, d, J = 4.4 Hz) 2.02 (2H, 
q, J = 7.0, 14.5, 21.5, 29.1 Hz) 2.24 (3H, s) 2.40 (2H, t, J = 6.6,  14.1 Hz) 2.61 
(1H, q, J = 6.1, 12.3, 16.5,  20.3 Hz) 2.84 (2H, t, J = 7.0, 15.02 Hz) 5.48 (1H, d, J 
= 6.3 Hz) 5.57 (1H, d, J = 6.3 Hz) 5.64 (1H, d, J = 7.0 Hz) 5.96 (1H, d, J = 6.8 
Hz) 7.49 (2H, d, J = 8.4 Hz) 7.76 (2H, d, J = 8.5 Hz) 7.83 (1H, td, J = 2.7, 6.7, 
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12.2 Hz) 8.24 (2H, m) 8.71 (1H, s) 9.48 (1H, d, J = 5.1 Hz). m/z (ESI) found 
539.2 (calc. M+ C26H30N2ClO2Ru = 539.05). 
[Ru(η6-p-cym)(p-Impy-NMe2)Cl]PF6 [15]. As synthetic procedure 2, using 
[Ru(η6-p-cym)2Cl2]Cl2 (100 mg, 0.16 mmol) and p-Impy-NMe2 (74 mg, 0.33 
mmol). Yield 84%.  Elemental analysis calc. for C22H29N3ClF6PRu, C: 42.83%, 
H: 4.74%, N: 6.81%. Found: C: 42.68%, H: 4.81%; N: 6.74%. NMR-δH (500 
MHz; DMSO-d6) 0.99 (6H, dd, J = 1.1, 2.3, 6.9, 9.3 Hz) 2.20 (3H, s) 2.46 (1H, m) 
3.12 (6H, s) 5.62 (2H) 5.78 (1H, d, J = 7.3  Hz) 6.11 (1H, d, J = 6.7 Hz) 6.89 (2H, 
d, J = 8.4 Hz) 7.70 (2H, d, J = 9.0 Hz) 7.81 (1H, t, J = 7.9, 14.1 Hz) 8.18 (1H, d, J 
= 6.7 Hz) 8.26 (1H, t, J = 7.3, 14.7 Hz) 8.78 (1H, s) 9.51(1H, d, J = 4.0 Hz). m/z 
(ESI) found 472.0 (calc. M+ C22H29N3ClRu = 472.01). 
[Ru(η6-p-cym)(p-Impy-NMe2)I]PF6 [16]. As synthetic procedure 2, using 
[Ru(η6-p-cym)2I2]I2 (150 mg, 0.19 mmol) and p-Impy-NMe2 (89 mg, 0.38 mmol).  
Yield 64%. Elemental analysis calc. for C24H29N3F6IPRu, C: 39.36%, H: 3.99%, 
N: 5.74%. Found: C: 39.24%, H: 3.98%; N: 5.81%. NMR-δH (500 MHz; DMSO-
d6) 1.00 (6H, dd, J = 7.3, 12.2, 18.1 Hz) 2.45 (3H, s) 2.56 (1H, m) 3.07 (6H, s) 
5.59 (1H, d, J = 8.8 Hz) 5.65 (1H, d, J = 8.1  Hz) 5.77 (1H, d, J = 8.8  Hz) 6.08 
(1H, d, J = 8.1 Hz) 7.73 (1H, d, J = 3.8, 6.6 Hz) 7.77 (1H, d, J = 10.8 Hz) 8.19 
(1H, t, J = 7.9, 14.1 Hz) 8.21 (1H, d, J = 7.5 Hz) 8.72 (1H, s) 9.48(1H, d, J = 4.8 
Hz). m/z (ESI) found 587.4 (calc. M+ C24H29N3IRu = 587.48). 
[Ru(η6-bip)(p-Impy-NMe2)Cl]PF6 [17]. As synthetic procedure 2, using [Ru(η6-
bip)2Cl2]Cl2 (50 mg, 0.07 mmol) and p-Impy-NMe2 (35 mg, 0.15 mmol). Yield 
76%. Elemental analysis calc. for C26H25N3ClF6PRu, C: 47.24%, H: 3.81%, N: 
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6.36%. Found: C: 47.12%, H: 3.74%; N: 6.30%. NMR-δH (500 MHz; DMSO-d6) 
3.05 (6H, s) 6.16 (3H, m) 6.34 (1H, d, J = 6.1 Hz) 6.45 (1H, d, J = 7.2 Hz) 6.71 
(2H, d, J = 7.2 Hz) 7.43 (2H, m) 7.51 (3H, m) 7.59 (2H, t, J = 6.2 Hz) 7.69 (1H, t, 
J = 7.1, 13.1 Hz) 8.15 (1H, d, J = 6.8 Hz) 8.21 (1H, t, J = 6.8, 14.3 Hz) 8.72 (1H, 
s) 9.37 (1H, d, J = 5.9 Hz). m/z (ESI) found 515.9 (calc. M+ C26H25N3ClRu = 
516.02). 
[Ru(η6-m-terp)(p-Impy-NMe2)Cl]PF6 [18]. As synthetic procedure 2, using 
[Ru(η6-m-terp)2Cl2]Cl2 (80 mg, 0.01 mmol) and p-Impy-NMe2 (45 mg, 0.20 
mmol). Yield 83%. Elemental analysis calc. for C32H29N3ClF6PRu, C: 52.14%, H: 
3.97%, N: 5.70%. Found: C: 52.28%, H: 3.85%; N: 5.78%. NMR-δH (500 MHz; 
DMSO-d6) 3.02 (6H, s) 6.26 (3H,t, J = 6.5, 12.4 Hz) 6.55 (3H, t, J = 9.5, 16.86 
Hz) 7.29 (2H, d, J = 9.5 Hz) 7.51 (7H, m) 7.78 (2H, d, J = 7.6 Hz) 7.83 (2H, d, J = 
7.6 Hz) 8.15 (2H, m) 8.68 (1H, s) 9.10 (1H, d, J = 5.4 Hz). m/z (ESI) found 592.0 
(calc. M+ C32H29N3ClRu = 592.12). 
  
3.2.3 Methods 
3.2.3.1 Aquation studies 
Aquation of complexes 7 - 18 was studied using 1H-NMR (500 and 600 MHz) as 
described in Chapter 2, using 2 mM solutions of each complex in D2O with 5% 
DMSO/MeOD at 298 K. To suppress the aquation observed in all the chlorido 
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complexes, 200 mM NaCl was added to the deuterated solvent, and, 200 mM KI 
was used to suppress the aquation of iodido complexes.  
 
3.2.3.2 Nucleobase binding 
The extent of binding over 24 h at 298 K for complexes 7 - 18 to 9-ethylguanine, 
as a nucleobase model, was followed by 1H-NMR (500 MHz). The details of these 
experiments can be found in Chapter 2. Briefly, a fresh 2 mM solution of each 
complex was prepared in 50 mM sodium phosphate buffer (pH 7.5) with 5% 
DMSO. The solution also contained 9-EtG for a final mol. ratio 1:1.25 where the 
nucleobase was in excess. As in the case of aquation studies, 1H-NMR spectra 
were recorded at 298 K within the first 10 min after sample preparation and again 
after 24 h at 500 MHz. All experiments were carried out in triplicate and the 
standard deviations calculated. Nucleobase binding was monitored by the 
formation of a second set of peaks that included bound-9-EtG.  
 
3.2.3.3 Antiproliferative activity 
The antiproliferative activity of ligands 1-6 and complexes 7-18 was determined 
in A2780 ovarian, A549 lung, HCT116 colon and MCF7 breast carcinoma cell 
lines.  The experiments to determine IC50 values were carried out as described in 
Chapter 2. Briefly, 96 well plates were used to seed 5000 cells per well, they were 
left to pre-incubate in drug-free media at 310 K for 48 h before adding various 
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concentrations of the compounds to be tested. A drug exposure period of 24 h was 
allowed. After this, supernatants were removed by suction and each well was 
washed with PBS (100 µL). A further 48 h was allowed for the cells to recover in 
drug-free medium (200 µL per well) at 310 K.  The SRB assay was used to 
determine cell viability, as described in Chapter 2.  IC50 values, as the 
concentration which caused 50% of inhibition of cell growth, were determined as 
duplicates of triplicates in two independent sets of experiments, and their standard 
deviations were calculated. 
 
 3.2.3.4 Metal accumulation in cancer cells 
Metal accumulation studies for complexes 7-18 were conducted on the A2780 
ovarian carcinoma cell line. Briefly, 4 x 106 cells were seeded on a Petri dish, 
after 24 h of pre-incubation time in drug-free medium, the test complexes were 
added to give final concentrations equal to IC50/3 and then allowed a further 24 h 
of drug exposure. After this time, cells were counted, treated with trypsin and cell 
pellets were collected. Each pellet was digested overnight in concentrated nitric 
acid (73%) at 353 K; the resulting solutions were diluted (HNO3 5%) and the 
amount of ruthenium taken up by the cells was determined by ICP-MS. These 
experiments did not included any cell recovery time in drug-free media. They 
were all carried out in triplicate and the standard deviations were calculated. 
Results are compared to the corresponding data for CDDP. More experimental 
details can be found in Chapter 2.  
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For following cellular uptake studies, only complexes 15 [Ru(η6-p-cym)(p-Impy-
NMe2)Cl]PF6 and its iodido analogue 16 [Ru(η6-p-cym)(p-Impy-NMe2)I]PF6 were 
used and compared to the corresponding data for CDDP. These two compounds 
were selected because their structural similarities (same arene unit, p-cym, and 
N,N-ligand p-Impy-NMe2)  and with the aim of studying the effect of the 
monodentate ligand on cellular accumulation behaviour. The procedure was 
carried out as described above including the following experimental variations. In 
all cases, 4 per 106 A2780 cells were seeded in Petri dishes, the pre-incubation 
time in drug-free medium was 24 h, and the drug concentrations used  were 
equipotent and equal to  IC50/3 (CDDP= 0.4 µM, 15 = 5 µM and 16 = 1 µM), 
unless otherwise stated. 
 
• Time dependence: these experiments involved variable drug exposure 
time but no recovery time in drug-free medium.  The chosen time points 
for drug exposure were: 1 h, 4 h, 8 h, 24 h, 48 h, 72 h and 96 h.  
• Temperature dependence:  experiments were carried out using 8 h of 
drug exposure and no recovery time in drug-free medium. The chosen 
temperature points for incubation with the drugs were: 277 K, 293 K, 310 
K and 323 K. 
• Concentration dependence: these experiments used 24 h of drug 
exposure and no recovery time in drug-free medium. The chosen drug 
concentrations were:  0.16, 0.33, 1.6, 3.2, 6.4 and 9.6 x IC50 
• Extent of efflux: In these experiments drugs were removed after 24 h and 
fresh drug-free medium was added to the Petri dishes. Cells were 
  
Chapter 3: Cellular uptake mechanisms 
80 
 
incubated again in drug-free medium for 24 h, 48 h and 72 h to allow them 
to recover before being treated with trypsin to collect the cell pellets.  
• Inhibition of efflux: Experiments were done using 24 h of drug exposure 
and 24 h of recovery time using drug-free fresh medium with 5 µM, 10 
µM or 20 µM of verapamil. 
• Role of Na+/K+ pump in cellular metal accumulation, as a facilitated 
diffusion endocytotic pathway: these experiments involved 24 h of drug 
exposure, co-administration of the drug with 5 µM, 10 µM, 20 µM, 0.1 
mM or 0.2 mM of ouabain. No recovery time in drug-free medium was 
allowed. 
• Role of of CTR1 in cellular metal accumulation: experiments were 
carried out using 24 h of drug exposure time and co-administration of the 
drug with 10 µM, 20 µM, 40 µM, 0.1 mM or 0.2 mM of copper(II) 
chloride. No recovery time in drug-free medium was allowed. 
• Effect of ATP depletion in cellular metal accumulation: experiments 
were performed using 24 h of drug exposure time and co-administration of 
the drug with 5 µM and 20 µM of antimycin A. No recovery time in drug-
free medium was allowed. 
• Membrane disruption by amphotericin B as a model for protein-
mediated uptake: these experiments were done using 24 h of drug 
exposure and co-administration of the drug with 1 µM, 5 µM, 10 µM or 20 
µM of amphotericin B. No recovery time in drug-free medium was 
allowed. 
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• The role of caveolae endocytotic pathway in metal accumulation: these 
experiments involved 24 h of drug exposure and co-administration of the 
drug with 10 µM, 20 µM, 0.5 mM or 1 mM of methyl β-cyclodextrin. No 
recovery time in drug-free medium was allowed. 
 
3.2.3.5 Determination of partition coefficient (Log P) 
The partition coefficients of the chlorido complexes 15 [Ru(η6-p-cym)(p-Impy-
NMe2)Cl]PF6, 17 [Ru(η6-bip)(p-Impy-NMe2)Cl]PF6 and 18 [Ru(η6-m-terp)(p-
Impy-NMe2)Cl]PF6 were determined using the shaking flask method. These three 
complexes were selected with the aim of studying the effect of the changes in the 
arene on the lipophilicity of the complexes. They all have the same N,N-chelating 
ligand (p-Impy-NMe2, 6), and the same monodentate ligand (Cl). 
This method used 3 mL of 2 mM octanol-saturated aqueous solutions of the 
complexes which were shaken with equal volumes of water-saturated octanol for 
24 h. The amount of ruthenium in the aqueous layer was determined by ICP-MS 
and the Log P values calculated. Aqueous solutions included 150 mM of NaCl to 
avoid aquation of the complexes. More details of this procedure can be found in 
Chapter 2. 
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 3.2.3.6 HPLC analysis for I to Cl conversion 
6 mM stock solutions of complexes 15 and 16 were prepared in 5% MeOH and 
water; separately 30 mM solutions of NaCl and KI were prepared in the same 
solvent. Aquation of each complex was studied using 40 µL of the stock solution 
and diluting it to 1 mL, chromatograms were recorded after 10 min of sample 
preparation and again after 24 h. Inhibition of aquation was studied by mixing 40 
µL of the stock solutions of 1 or 2 and 40 µL of NaCl/KI (NaCl for complex 1 and 
KI for complex 2) and diluting to 1 mL. Chromatograms were recorded after 10 
min of sample preparation and again after 24 h. Finally for the I to Cl conversion, 
a fresh 1 mL solution was prepared containing together 40 µL of the stock of each 
complex and 40 and µL of NaCl. Chromatograms were recorded after 10 min of 
sample preparation and again after 24 h.  
All chromatograms were obtained using an Agilent 1100 system with a DAD and 
a 100 µL loop with a mobile phase H2O 0.1%TFA/ACN 0.1% TFA and a Agilent 
ZORBAX Eclipse Plus C18, 250 x 4.6 mm column with 5 µm pore size. 
Detection wavelength: 254 nm.  
 
3.3 Results 
3.3.1 Synthesis and characterization  
In all cases the synthesis of the imines involved a nucleophilic attack by the lone 
pair of electrons from the aniline nitrogen on the carbonyl group of the aldehyde, 
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followed by dehydration. Imines 1-6 shown in Table 3.1 below were synthesised 
and characterised using 1H and 13C-NMR (1D, 2D experiments), ESI-MS, and 
elemental analysis.  
 
Table 3.1. Imine ligands studied in Chapter 3. 
N
N
R2
R1
 
   
Ligands R1 R2 
1 Impy H H 
2 o-Impy-OH OH H 
3 p-Impy-OH H OH 
4 p-Impy-COOH H COOH 
5 p-Impy-(CH2)3COOH H (CH2)3COOH 
6 p-Impy-NMe2 H N(CH3)2 
 
   
 
Once the proposed ligands were fully characterised, complexes 7-18 in Table 3.2 
were synthesised. They were characterised using the same techniques as for the 
ligands, 1H and 13C-NMR (1D, 2D experiments), ESI-MS, and elemental analysis,  
as well as, ICP-MS for metal quantification. All the experiments were consistent 
with the proposed formulation for all the complexes. In all cases the chirality of 
the metal centre is inferred by the 1H-NMR spectra which show four sets of peaks 
for the aromatic p-cymene protons. In the case of ligands/complexes containing –
COOH residues the deprotonation of the carboxylic acid is shown as dependent on 
the particular experiments set up (working pH value). No pKa determinations 
were carried out.  
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Table 3.2. Ruthenium(II) arene complexes studied in Chapter 3. 
 
N
N
Ru
X
Arene
R1
R2
PF6
 
 
Complexes Arene Ligand R1 R2 X 
7 
η
6
-p-cym 
Impy H H Cl 8 I 
9 
o-Impy-OH OH H Cl 
10 
p-Impy-OH H OH 
Cl 
11 I 
12 
p-Impy-COOH H COOH 
Cl 
13 I 
14 p-Impy-(CH2)3COOH H (CH2)3COOH Cl 
15 
p-Impy-NMe2 
H N(CH3)2 Cl 16 I 
17 η6-bip H N(CH3)2 Cl 
18 η6-m-terp H N(CH3)2 Cl 
 
     
     
 3.3.2 Aqueous solution chemistry 
Aquation of complexes 7-16  was followed using 1H -NMR of 2 mM solutions of 
each complex in deuterated water.  Each value for the percentage of aquation 
reported represents the mean ± SD for three independent NMR experiments at 298 
K. In the case of chlorido complex 7  [Ru(η6-p-cym)(Impy)Cl]PF6, Figure 3.3 
shows the 1H -NMR spectrum (A) taken within 10 min of sample preparation. 
This spectrum has only one set of four p-cymene signals between 5.4 and 6.2 ppm 
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which is evidence of only one chiral species being present. The asymmetric ligand 
generates chirality on the metal centre, which causes these four protons to be 
magnetically inequivalent. Also there is only one signal that corresponds to the 
iminic proton.  Spectrum (B) was recorded after 24 h of sample preparation, in 
which two set of peaks are observed. Particularly, a new set of signals for the p-
cymene and the presence of two different imine protons indicate the formation of 
a second product. In order to confirm that this second set of peaks corresponded to 
the aqua adduct, another sample was run in the presence of 200 mM NaCl (as 
described in Chapter 2). This time, spectrum (C) only shows one set of p-cymene 
signals with the same chemical shifts as the original spectrum, confirming that the 
process observed was indeed aquation and that it can be suppressed by addition of 
an excess chloride in the media. The addition of AgNO3 to a solution of the 
chloride complex also resulted in the generation of the aqua adduct observed in 
spectrum (B). A similar set of results was obtained when the experiments were 
carried out using 100 mM phosphate buffer pH 7.4 as solvent, instead of 
deuterated water. This indicated that there is no formation of phosphate adducts.  
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Figure 3.3. 1H-NMR studies of the aquation of  a 2 mM solution of complex 15 in  
95% D2O, 5% MeOD at 298 K.  (A) After 8 min of sample preparation (B) After 
24 h (highlighted: proton 5 in complex 15 and its analogous in the aqua complex).  
(C) A fresh solution with 200 mM of NaCl to suppress aquation taken after 24 h 
of sample preparation.  
 
Table 3.3 shows the extent of the aquation after 24 h for all complexes. No 
aquation was observed for complexes 8 and 10, while complexes 9, 11, 12 and 14 
only hydrolysed partially (< 20%). The highest extent of aquation is exhibited by 
PF6
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N
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complexes 15 and 16, (66% and 63% respectively)  which have in common the 
same ligand, 6 p-Impy-NMe2.  
 
Table 3.3. Extent of aquation and extent 9-ethylguanine binding for complexes 7 - 
16 after 24 h, using 2 mM solutions of each complex in phosphate buffer (pH 7.4) 
and a final ratio 1 : 1.25 for 9-EtG binding where the nucleobase was in excess.  
Compound a 
%  
Aquation b 
% 9-EtG 
binding b 
7 [Ru(η6-p-cym)(Impy)Cl]PF6 37 ± 4 30 ± 3 
8 [Ru(η6-p-cym)(Impy)I]PF6 0 ± 2 49 ± 4 
9 [Ru(η6-p-cym)(o-Impy-OH)Cl]PF6 15 ± 5 22 ± 4 
10 [Ru(η6-p-cym)(p-Impy-OH)Cl]PF6 0 ± 3 0 ± 4 
11 [Ru(η6-p-cym)(p-Impy-OH)I]PF6 5 ± 2 4 ± 2 
12 [Ru(η6-p-cym)(p-Impy-COOH)Cl]PF6 9 ± 3 9 ± 5 
13 [Ru(η6-p-cym)(p-Impy-COOH)I]PF6 32 ± 4 47 ± 3 
14 [Ru(η6-p-cym)(p-Impy-(CH2)3COOH)Cl]PF6 8 ± 3 16 ± 4 
15 [Ru(η6-p-cym)(p-Impy-NMe2)Cl]PF6 66 ± 6 68 ± 5 
16 [Ru(η6-p-cym)(p-Impy-NMe2)I]PF6 63 ± 3 75 ± 2 
a
 Complexes 12, 13 and 14 contain carboxyl groups that are likely to be deprotonated 
at pH 7.4.  
b
 Each value represents the mean ± SD for three independent NMR experiments at 
310 K. 
 
Independent NMR experiments were also used to follow the complexes binding to 
9-ethylguanine (9-EtG) as a model for nucleobase interaction. In the case of 
complex 15 Figure 3.4 shows spectrum (C) which corresponds to the proton NMR 
taken within 10 min of sample preparation, followed by spectrum (B) that shows 
the formation of a 9-EtG adduct after 24 h of sample preparation (ratio 1: 1.25 
where the nucleobase is in excess). As in the case of aquation, there are two sets 
of p-cymene signals, as well as two signals for the imine proton. A new peak for 
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bound 9-EtG is observed. Finally spectrum (A) corresponds to free 9-EtG for 
comparison purposes. 
 
Figure 3.4. 1H-NMR studies to determine the extent of binding of 9-EtG (1.25 
mol. equiv.) to 2 mM complex 15 using in 100 mM phosphate buffer pH 7.4 at 
298 K. (A) Free 9-EtG. (B) A fresh solution of complex 15 with adding excess of 
9-EtG after 24 h of sample preparation (highlighted: proton 5 in complex 15 and 
its analogous in the 9-EtG complex). (C) Complex 15. 
 
Table 3.3, on page 87, also includes the extent of nucleobase adduct formation 
after 24 h for all complexes. Binding of complexes 10 [Ru(η6-p-cym)(p-Impy-
OH)Cl]PF6,  11 [Ru(η6-p-cym)(p-Impy-OH)I]PF6 and 12 [Ru(η6-p-cym)(p-Impy-
COO)Cl]PF6  to 9-EtG was found to be negligible (< 10%).   
Complexes 15 and 16, the ones with the greater extent of aquation, are also the 
ones that bind to a greater extent to the nucleobase model. These results do not 
reflect the kinetics involved in the process. 
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3.3.3 Antiproliferative activity 
3.3.3.1 IC50 determination in A2780, A549, HCT116, MCF7 
cells  
Antiproliferative activity for ligands 1-6 and complexes 7-18 was determined 
using the SRB assay (Table 3.4), for which the protocol is described in detail in 
Chapter 2. For these assays, IC50 values above 100 µM are considered inactive, 
while compounds with IC50 values between 50 and 100 µM as moderately active. 
Values within the 15 - 50 µM range define a compound as active while below this 
range, compounds are considered to be highly active. All ligands tested were 
inactive against the chosen cell lines under the conditions described, as their IC50 
values were above 200 µM. Complexes 7, 10, 12, 13 and 14 are also inactive as 
their IC50 value are > 100 µM, while 8, 9  and 11  are moderately active. 
Complexes 15 - 18 exhibited promising antiproliferative activity in all cell lines. 
A sample dose-response curve for IC50 determinations can be found in Chapter 2. 
 
Table 3.4. Part A. Antiproliferative activity of ligands 1-6 in A780, A549, 
HCT116 and MCF7 cell lines. IC50 is expressed as the concentration in which 
each ligand/complex causes 50% cancer cell growth inhibition.  
   IC50 (µM) 
 Compound A2780 A549 HCT116 MCF7 
Ligands 
1 >200 >200 >200 >200 
2 >200 >200 >200 >200 
3 >200 >200 >200 >200 
4 >200 >200 >200 >200 
5 >200 >200 >200 >200 
6 >200 >200 >200 >200 
 
  
Chapter 3: Cellular uptake mechanisms 
90 
 
 
Table 3.4 Part B. Antiproliferative activity of complexes 7-18 in A780, A549, 
HCT116 and MCF7 cell lines.  
   IC50 (µM) 
 Compound A2780 A549 HCT116 MCF7 
RuII 
 complexes 
7 160 ± 3 145 ± 1 158 ± 2 154 ± 3 
8 73 ± 3 54 ± 1 48 ± 4 46 ± 3 
9 84 ± 2 17 ± 3 85 ± 3 88 ± 2 
10 >200 >200 >200 >200 
11 48 ± 2 36 ± 2 51 ± 3 12.9 ± 0.6 
12 >200 >200 >200 >200 
13 135 ± 6 110 ± 3 122 ± 2 118 ± 3 
14 >200 >200 >200 >200 
15 16.2 ± 0.9 10.5 ± 0.8 3.4 ± 0.4 12.1 ± 0.3 
16 3.0 ± 0.2 15.3 ± 0.9 8.6 ± 0.8 4.4 ± 0.4 
17 38 ± 2 18.4 ± 0.3 5.1 ± 0.2 8.8 ± 0.2 
18 2.1 ± 0.2 8.8 ± 0.1 6.9 ± 0.5 5.9 ± 0.3 
 
 
    
 
3.3.3.2  IC50 Time Dependence 
The variation of IC50 values of complexes 15 [Ru(η6-p-cym)(p-Impy-
NMe2)Cl]PF6 and  16 [Ru(η6-p-cym)(p-Impy-NMe2)I]PF6 in the A2780 cell line, 
after different exposure times (8-72 h) was evaluated using the protocol  described 
in Chapter 2. These data were compared to that of CDDP. Results in Figure 3.5 
indicate that there is no significant difference in the antiproliferative activity of 
the ruthenium(II) complexes after 24 h of drug exposure when the maximum 
potency was recorded. 
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IC50 (µM) 
Exposure time (h) 
8 24 48 72 
CDDP 1.42 ± 0.09 1.22 ± 0.08 1.16 ± 0.07 1.1 ± 0.09 
15 37.6 ± 0.9 16.2 ± 0.9 14 ± 1 12.7 ± 0.6 
16 8.1 ± 0.8 3 ± 0.2 2.1 ± 0.8 1.65 ± 0.09 
 
    
Figure 3.5. Dependence of IC50 value in A2780 cell line on time of exposure for 
complexes 15 (−−), 16 (−−) and CDDP (−−). In all cases the pre-
incubation time was 48 h before adding the drugs, and the cell recovery time was 
72 h in drug-free medium. 
 
 3.3.3.3 Metal accumulation in cancer cells. 
One time point, one concentration.  Total cellular accumulation of ruthenium 
for complexes 7-18  was determined in A2780 ovarian cells line in order to relate 
the amount of Ru accumulated to cytotoxicity and to relate it to their 
hydrophobicity (Log P) in the case of complexes 15 [Ru(η6-p-cym)(p-Impy-
NMe2)Cl]PF6, 17 [Ru(η6-bip)(p-Impy-NMe2)Cl]PF6 and 18 [Ru(η6-m-terp)(p-
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Impy-NMe2)Cl]PF6. For these experiments drug exposure time was 24 h and cells 
were not allowed to recover. Values are expressed as ng of Ru per million cells 
and were determined as independent duplicates of triplicates. The statistical 
significance of all cellular accumulation values was determined using a two-sided 
t-test with P<0.05. Results are shown in Table 3.5. 
Table 3.5. Total accumulation of Ru in A2780 cells for complexes 7 - 18 after 24 
h of drug exposure at 310 K with no recovery time, compared to their IC50 values.  
Compound ng Ru x10
6
 
cellsa IC50 (µM) 
7  [Ru(η6-p-cym)(Impy)Cl]PF6 5.3 ± 0.2 160 ± 3 
8  [Ru(η6-p-cym)(Impy)I]PF6 0.88 ± 0.06 73 ± 3 
9  [Ru(η6-p-cym)(o-Impy-OH)Cl]PF6 0.97 ± 0.09 84 ± 2 
10 [Ru(η6-p-cym)(p-Impy-OH)Cl]PF6 6.9 ± 0.3 > 200 
11 [Ru(η6-p-cym)(p-Impy-OH)I]PF6 28 ± 2 48 ± 2 
12 [Ru(η6-p-cym)(p-Impy-COOH)Cl]PF6 7.2 ± 0.3 > 200 
13 [Ru(η6-p-cym)(p-Impy-COOH)I]PF6 0.88 ± 0.06 135 ± 6 
14 [Ru(η6-p-cym)(p-Impy-(CH2)3COOH)Cl]PF6 3.8 ± 0.3 > 200 
15 [Ru(η6-p-cym)(p-Impy-NMe2)Cl]PF6 7.5 ± 0.5 15.8 ± 0.6 
16 [Ru(η6-p-cym)(p-Impy-NMe2)I]PF6 11.9 ± 0.8 3.1 ± 0.3 
17 [Ru(η6-bip)(p-Impy-NMe2)Cl]PF6 10.2 ± 0.3 38 ± 2 
18 [Ru(η6-m-terp)(p-Impy-NMe2)Cl]PF6 4.6 ± 0.2 2.1 ± 0.2 
 
a In all cases concentrations used were IC50/3.   
 
No clear trend was observed that correlates the total cellular accumulation of 
ruthenium with the antiproliferative activity. The highest cellular accumulation is 
for complex 11 [Ru(η6-p-cym)(p-Impy-OH)I]PF6 (28 ± 2 ng of Ru per 106 cells) 
which is only moderately active in the A2780 cell line (IC50 value 48 ± 2 µM). 
The most active complexes 15 - 18 (IC50 values 2-16 µM) have cellular 
accumulation  in the range of 4.5 - 12 ng of metal per 106 cells, in this same range 
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as the cellular uptake of complex 10  [Ru(η6-p-cym)(p-Impy-OH)Cl]PF6 (6.9 ± 
0.3 ng of Ru per 106 cells) which is completely inactive.  
For following cellular accumulation studies, only complexes 15 and its iodido 
analogue 16 [Ru(η6-p-cym)(p-Impy-NMe2)I]PF6 were used and compared to 
CDDP.  
Time dependence. Cellular accumulation of ruthenium from complexes 15 and 
16 was determined at different time points to find out the time of maximum 
uptake. It was also investigated whether the uptake is linear or if there is a 
saturation point, which would indicate the period in which the influx/efflux 
equilibrium is reached. These data, in Figure 3.6, were compared to CDDP. The 
general trend shows that the maximum cellular accumulation is reached at 48 h, 
after which an infflux/efflux equilibrium is reached.  
Temperature dependence. Cellular accumulation studies of ruthenium from 
complexes 15, 16 and platinum from CDDP shown in Figure 3.7, was determined 
at four different temperatures (277, 293, 310 and 323 K), At 277 K there is no 
observable cellular accumulation of platinum from CDDP which indicates the 
active nature of its uptake. Both ruthenium complexes were taken up even at this 
temperature, which suggests that their uptake is partially passive and not energy-
dependent, especially for iodido complex 16.  
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ng Ru/Pt x106 cells 
Drug exposure time (h) 
1 4 8 24 48 72 96 
CDDP 0.0011 
± 0.0001 
0.014 
± 0.004 
0.11 
± 0.08 
0.25 
± 0.03 
0.29 
± 0.02 
0.26 
± 0.01 
0.25 
± 0.02 
15 1.32 
± 0.09 
3.5 
± 0.4 
4.2 
± 0.1 
7.6 
± 0.8 
8.9 
± 0.6 
5.8 
± 0.4 
4.0 
± 0.2 
16 6.5 
± 0.4 
8.2 
± 0.4 
9 
± 2 
11 
± 1 
13.0 
± 0.7 
10.7 
± 0.3 
7.4 
± 0.1 
 
       
Figure 3.6. Time dependence of Ru/Pt accumulation in A2780 cells for 
complexes 15 (−−), 16 (−−) and CDDP (−−) at 310 K. In all cases pre-
incubation time before adding the drug was 48 h and cell recovery time was 72 h 
in drug-free medium. Concentrations used were CDDP = 0.4 µM, 15 = 5 µM and 
16 = 1 µM. 
 
 
 
 
0 20 40 60 80 100
0.0
0.1
0.2
0.3
2
4
6
8
10
12
14
96h
72h
48h
24h
8h
4h
1h
96h
1h
4h
96h
72h
C
e
ll
 a
cc
u
m
u
la
ti
o
n
 o
f 
m
e
ta
l 
(n
g
 /
 1
0
6
 c
e
ll
s)
Exposure time (h)
 CDDP
 Complex 15 X = Cl
 Complex 16 X = I
24h
8h
48h
1h
4h
8h
24h
48h
72h
N
N
Ru
X
N
PF6
72h
 CDDP
 Complex 15 X = Cl
 Complex 16 X = I
  
Chapter 3: Cellular uptake mechanisms 
95 
 
 
 
 
 
ng Ru/Pt x106 cells 
Temperature (K) 
277 293 310 
CDDP N/D 0.005 ± 0.002 0.12 ± 0.03 
15     0.14 ± 0.04 0.61 ± 0.06 4.6 ± 0.6 
16  0.8 ± 0.1 4.1 ± 0.9 10.7 ± 0.6 
 
   
Figure 3.7. Temperature dependence of Ru/Pt accumulation in A2780 cells for 
complexes 15 (−−), 16 (−−) and CDDP (−−) expressed as ng of metal per 
106 cells. Experiments were carried out using 8 h drug exposure time at 277 K, 
293 K and 310 K. The experiments were also carried out at 323 K, but at this 
temperature no cell viability was observed. Concentrations used were CDDP = 
0.4 µM, 15 = 5 µM and 16 = 1 µM. N/D = not detected. 
 
Concentration dependence. The dose dependence of cellular accumulation of 
ruthenium for complexes 15 and 16 was determined in order to investigate 
whether saturation of the system was reached. These experiments were carried out 
using equipotent concentrations of each complex so the data are comparable. As 
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shown in Figure 3.8, chlorido complex 15 [Ru(η6-p-cym)(p-Impy-NMe2)Cl]PF6 
does not seem to saturate the uptake pathway up to more than three times its IC50 
(50 µM).
.
 At higher concentrations both ruthenium(II) complexes cause  total cell 
death. CDDP does not saturate the system up to almost 10 times its IC50 value 
(11.5 µM). 
 
 
 
ng Ru/Pt x106 cells 
Concentration (µM) 
0.16 x IC50 0.33 x IC50 1.6 x IC50 3.2 x IC50 6.4 x IC50 9.6 x IC50 
CDDP 0.16 ± 0.02 0.28 ± 0.05 2.1 ± 0.3 4.8 ± 0.5 10 ± 1 11 ± 3 
15 4.1 ± 0.8 8.0 ± 0.3  40 ± 7 95 ± 3 N/V N/V 
16 5 ± 1 11.4 ± 0.4 42 ± 5 57 ± 6 N/V N/V 
 
      
Figure 3.8. Concentration dependence of Ru/Pt accumulation in A2780 cells for 
complexes 15 (−−), 16 (−−) and CDDP (−−) at 310 K expressed as ng of 
metal per 106 cells. Experiments were carried out using 24 h drug exposure time, 
no recovery time and equipotent concentrations. N/V = no cell viability. 
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Extent of efflux.  Total cellular accumulation of metal depends on cellular uptake 
and on the extent of efflux. Complexes 15 [Ru(η6-p-cym)(p-Impy-NMe2)Cl]PF6 
and 16 [Ru(η6-p-cym)(p-Impy-NMe2)I]PF6 were used to investigate the extent of 
drug efflux during variable recovery times. These data are compared to the 
maximum cellular accumulation after 24 h exposure time studied earlier (see one-
time-point one-concentration section). Results shown in Figure 3.9 indicate that 
even after 72 h in drug-free media, none of the ruthenium(II) complexes was 
completely excreted from the cell, being retained in both cases to more than 25% 
of the original uptake. Moreover, the extent of the efflux seems to reach a plateau 
after 48 h.  
Inhibition of efflux. In this study complexes 15 and 16 were co-incubated with 
verapamil and their cellular accumulation as the amount of Ru was determined. In 
both cases ruthenium accumulation increased with verapamil concentration, as 
seen in Figure 3.10. Under normal conditions iodido complex 16 undergoes a high 
extent of efflux during the first 24 h of recovery, and ruthenium accumulation 
decreases by two thirds (from 11.5 ± 0.8 to 3.7 ± 0.2 ng of Ru per 106 cells). At 
the highest concentration of verapamil used (20 µM), Ru accumulation is reduced 
to only 7.2 ± 0.2 ng of Ru per 106 cells. 
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ng Ru/Pt x106 cells 
Recovery Time (h) 
0 24 48 72 
15 7.8 ± 0.1 3.0 ± 0.3 1.7 ± 0.1 1.7 ± 0.4 
16 11.8 ± 0.8 3.7 ± 0.2 2.8 ± 0.3 2.79 ± 0.07 
 
    
Figure 3.9. Accumulation of Ru/Pt in A2780 cells after variable recovery time for 
complexes 15 (−−) and 16 (−−). Extent of efflux was determined at 310 K 
after 0 h, 24 h, 48 h and 72 h recovery time in drug-free medium and results are 
expressed as ng of metal per 106 cells. Concentrations used were CDDP = 0.4 
µM, 15 = 5 µM and 16 = 1 µM. 
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ng Ru/Pt x106 cells 
Cellular  
AccumulationA Verapamil (µM) 
 0B 5C 10D 20E 
15 7.5 ± 0.5 3.0 ± 0.3 4.1 ± 0.5 4.9 ± 0.2 5.3 ± 0.4 
16 11.9 ± 0.8 3.7 ± 0.2 4.8 ± 0.3 6.1 ± 0.4 7.2 ± 0.2 
 
     
Figure 3.10. Accumulation of Ru/Pt in A2780 cells for complexes 15 () and 16 
() at 310 K after co-incubation with variable concentration of verapamil. Results 
are expressed as ng of metal  per 106 cells. Concentrations used were CDDP = 0.4 
µM, 15 = 5 µM and 16 = 1 µM.  In both complexes (A) metal accumulation with 
no recovery time, (B) metal accumulation with 24h recovery time and 0 µM 
verapamil, (C) 5 µM, (D) 10 µM and (E) 20 µM of verapamil. 
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concentration increases. In the case of CDDP, Pt accumulation decreases to one 
half of its original value (to 0.12 ± 0.03 from 0.24 ± 0.05 ng of Pt per 106 cells). 
The same is true for the accumulation of ruthenium from chlorido complex 15, 
which decreases from 7.5 ± 0.2 to 3.8 ± 0.3 ng of Ru per 106 cells, and complex 
16 that decreases from 11.9 ± 0.8 to 7.5 ± 0.2 ng of Ru per 106 cells. 
Role of CTR1 in cellular metal accumulation. Complexes 15 and 16  were co-
incubated with variable amounts of copper(II) chloride to study the role on 
ruthenium accumulation, and therefore the involvement of the copper transporter 
CTR1 in the cellular uptake.  Results shown in Figure 3.12 indicate that with 200 
µM of Cu(II), Pt accumulation from CDDP is reduced by approximately 40%. At 
a concentration of 200 µM of Cu(II), ruthenium  from chlorido complex 15 is 26% 
less taken up by A2780 cells, while for iodido complex 16, uptake is reduced to a 
third of its original value.  
Role of ATP depletion in cellular metal accumulation. Antimycin A1, which 
can deplete ATP levels,44 was used as co-incubating agent with complexes 15, 16 
and CDDP in order to investigate whether cellular accumulation is influenced by 
changes in the levels of ATP in the cell. Results shown in Figure 3.13 suggest that 
accumulation of platinum from CDDP and Ru from iodido complex 16 are 
unaffected after changes in ATP levels. However cellular accumulation of 
ruthenium from chlorido complex 15 increases markedly from 7.5 ± 0.2 to 32 ± 2 
ng of Ru per 106 cells when co-incubated with 5µM of Antimycin.  
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ng Ru/Pt x106 cells 
Ouabain (µM) 
0 5 10 20 100 200 
CDDP 0.24  
± 0.05 
0.22  
± 0.02 
0.21  
± 0.04 
0.27  
± 0.06 
0.18  
± 0.0.5 
0.12  
± 0.03 
15 7.5  
± 0.2 
5.7  
± 0.4 
5.5  
± 0.2 
5.1  
± 0.6 
4.9  
± 0.6 
3.8  
± 0.3 
16 11.9  
± 0.3 
9.7  
± 0.4 
9.2  
± 0.3 
8.9  
± 0.5 
8.5  
± 0.4 
7.5  
± 0.2 
 
      
Figure 3.11. Accumulation of Ru/Pt in A2780 cells for CDDP () complex 15 
() and 16 () at 310 K after co-incubation with variable concentrations of 
ouabain. Results are expressed in ng of metal per 106 cells. Concentrations used 
were CDDP = 0.4 µM, 15 = 5 µM and 16 = 1 µM. For all complexes the 
concentrations of ouabain used were (A) 20 µM, (B) 5 µM, (C) 10 µM, (D) 20 
µM, (E) 0.1 mM and (F) 0.2 mM. 
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ng Ru/Pt x106 cells 
Copper(II) chloride (µM) 
0 10 20 40 100 200 
CDDP 0.24  
± 0.05 
0.22  
± 0.02 
0.19  
± 0.03 
0.15  
± 0.04 
0.10  
± 0.2 
0.08  
± 0.01 
15 7.5  
± 0.2 
7.0  
± 0.3  
6.8  
± 0.5 
6.7  
± 0.3 
5.2  
± 0.5 
4.6  
± 0.3 
16 11.9  
± 0.3 
11.0  
± 0.5 
10.8  
± 0.2 
10.1  
± 0.6 
9.5  
± 0.3 
8.8  
± 0.4 
 
      
Figure 3.12. Accumulation of Ru / Pt in A2780 cell line for CDDP (), complex 
15 () and 16 () at 310 K after co-incubation with various concentrations of 
Cu(II) . Results are expressed as ng of metal per 106 cells. Concentrations used 
were CDDP = 0.4 µM, 15 = 5 µM and 16 = 1 µM. For all complexes Cu(II) 
concentrations were (A) 0 µM, (B) 5 µM, (C) 10 µM, (D) 20 µM, (E) 0.1 mM and 
(F) 0.2 mM. 
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ng Ru/Pt x106 cells 
Antimycin A1 (µM) 
0 5 
CDDP  0.24 ± 0.05 0.22 ± 0.02 
15 7.5 ± 0.2 32 ± 2  
16 11.9 ± 0.3 13.6 ± 0.4 
 
  
Figure 3.13. Accumulation of Ru / Pt in A2780 cells for CDDP (), complex 15 
() and 16 () at 310 K after co-incubation with antimycin. Results are 
expressed as ng of metal per 106 cells. Concentrations used were CDDP = 0.4 
µM, 15 = 5 µM and 16 = 1 µM.  For all complexes the antimycin concentrations 
were (A) 0 µM, (B) 5 µM.  
 
Membrane disruption by amphotericin B as a model for protein-mediated 
uptake. Complexes 15 [Ru(η6-p-cym)(p-Impy-NMe2)Cl]PF6, 16 [Ru(η6-p-
cym)(p-Impy-NMe2)I]PF6 and CDDP  were co-incubated with variable amounts 
of amphotericin B to observe the changes in their cellular accumulation caused by 
the formation of pores caused by this antifungal drug. Figure 3.14 shows that 
platinum accumulation from CDDP is doubled with 10 µM amphotericin, A 
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similar behaviour was observed for ruthenium accumulation from the iodido 
complex 16. 
 
 
 
ng Ru/Pt x106 cells 
Amphotericin B (µM) 
0  1  5  10  
CDDP 0.24 ± 0.05 0.28 ± 0.03 0.35 ± 0.05 0.49 ± 0.05 
15 7.5 ± 0.2 7.7 ± 0.2  9.8 ± 0.3 10.2 ± 0.5 
16 11.9 ± 0.3 13.0 ± 0.4 18.5 ± 0.7 25.4 ± 0.6 
 
    
Figure 3.14.  Accumulation of Ru/Pt in A2780 cells for CDDP (), complex 15 
() and 16 () at 310 K after co-incubation with various concentration of 
amphotericin B. Results are expressed as ng of metal per 106 cells. Concentrations 
used were CDDP = 0.4 µM, 15 = 5 µM and 16 = 1 µM. For all complexes 
amphotericin concentrations were (A) 0 µM, (B) 1 µM, (C) 5 µM and (D) 10 µM. 
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cyclodextrin and the changes in metal accumulation determined. These 
experiments were carried out in order to investigate the role of the caveolae 
pathway in Ru / Pt cellular accumulation. The results are shown in Figure 3.15 In 
all cases there is no significant change in platinum or ruthenium accumulation in 
cells. 
 
 
ng Ru/Pt x106 cells 
β-methyl cyclodextrin (µM) 
0 10  20  500 1000 
CDDP 0.24 ± 0.05 0.20 ± 0.06 0.26 ± 0.03 0.23 ± 0.05 0.27 ± 0.02 
15 7.5 ± 0.2 7.8 ± 0.4 7.5 ± 0.2 7.6 ± 0.4 7.3 ± 0.3 
16 11.9 ± 0.3 11.2 ± 0.5 11.9 ± 0.5 12.2 ± 0.4 12.1± 0.6 
 
     
Figure 3.15.  Accumulation of Ru/Pt in A2780 cells for CDDP (), complex 15 
() and 16 () at 310 K after co-incubation with various concentratiosn of β-
methyl cyclodextrin. Results are expressed as ng of metal  per 106 cells. 
Concentrations used were CDDP = 0.4 µM, 15 = 5 µM and 16 = 1 µM. For all 
complexes β-methyl cyclodextrin concentrations were (A) 0 µM, (B) 10 µM (C) 
20 µM, (D) 0.5 mM and (E) 1 mM. 
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
8
10
12
14
C
e
ll
 a
cc
u
m
u
la
ti
o
n
 (
n
g
 o
f 
m
e
ta
l 
p
e
r 
m
il
li
o
n
 c
e
ll
s)
A
B C
D E
A
B
C D E
A
B C
D E
Complex 16Complex 15CDDP
N
N
Ru
X
N
PF6
Complex 15 X = Cl
Complex 16 X = I
CDDP
  
Chapter 3: Cellular uptake mechanisms 
106 
 
3.3.4 Determination of partition coefficient (Log P) 
The partition coefficients of chlorido complexes 15, 17 and 18 were determined 
using the shaking-flask method. These three complexes were selected with the 
aim of studying the effect of changes in the arene group on the lipophilicity of the 
complexes. They all include the same N,N-chelating ligand (p-Impy-NMe2) and 
the same monodentate ligand (Cl).To ensure that the complexes would not exist in 
the aquated form during the experiments 150 mM NaCl was added to the octanol-
saturated water. Results are presented in Table 3.6. It is notable that all values 
obtained are negative. 
Table 3.6. Log P values for ruthenium complexes 15, 17 and 18 determined using 
the shaking-flask method. 
Compound Log P 
15 [Ru(η6-p-cym)(p-Impy-NMe2)Cl]PF6 -0.98 ± 0.03 
17 [Ru(η6-bip)(p-Impy-NMe2)Cl]PF6 -0.34 ± 0.02 
18 [Ru(η6-m-terp)(p-Impy-NMe2)Cl]PF6 -0.08 ± 0.01 
 
3.4 Discussion 
3.4.1 Aqueous solution chemistry 
The aquation of complexes 7 - 16 was investigated, as this step is believed to be 
crucial in the activation of metal pro-drugs that contain a  halido ligand.45  The 
aqua adducts formed after the release of the monodentate ligand, chloride and 
iodide in this case, are believed to be responsible for the antiproliferative activity 
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of piano-stool metal arene complexes, as they bind covalently to DNA causing 
irreparable lesions. 46    
Figure 3.16 shows that in the case of the chlorido complexes, aquation follows a 
clear trend that is also found for nucleobase adduct formation. The chlorido 
complexes exhibit extent of aquation following the order: 15 > 7 > 9 > 14 > 12 > 
10. The same order is also found in the extent of their binding to the nucleobase 
9-EtG. This trend was not observed for the iodido analogues. When comparing the 
extent of 9-EtG binding between the chlorido and their corresponding iodido 
complexes (see Table 3.3), it is evident that the iodido analogues bind to a greater 
extent to 9-EtG regardless of the complexes’ aquation. This observation can be 
explained as a consequence of direct substitution of the iodide by the nucleobase. 
 
Complex 15 7 9 12 14 10 
N,N- Ligand p-Impy 
-NMe2 
Impy o-Impy 
-OH 
p-Impy 
-COOH 
p-Impy-
(CH2)3COOH 
p-Impy 
-OH 
Figure 3.16. Comparison of the extent of aquation and 9-EtG binding of chlorido 
complexes followed by 1H-NMR at 310 K. 
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Chlorido complexes 9 [Ru(η6-p-cym)(o-Impy-OH)Cl]PF6 and 10 [Ru(η6-p-
cym)(p-Impy-OH)Cl]PF6 contain the same electron donating hydroxyl group on 
the Impy chelating ligand, although it is placed in different positions (o-
substitution for complex 9, R1  and p-subtitution for complex 10, R2). 
Interestingly, there are major differences in the extent of aquation and 9-EtG 
binding for these complexes, which suggests that the position of the electron-
donating group is highly relevant. Previous reports indicate that similar ruthenium 
arene complexes with chelating ligands can decompose in aqueous solution, in 
those cases, loss of the arene unit has been observed after the aquation has 
occurred.47,48 To investigate this possibility, aqueous solutions of complexes  7-16 
were kept after aquation studies and they were re-analysed after 96 h. No arene 
loss was detected by NMR in any of the cases. 
Aquation of iodido complexes in the presence of high chloride concentration 
could result in the conversion to their chlorido analogues, this conversion could 
also be the result of direct substitution of the iodide by the chloride. However, 
HPLC studies show that after 24 h of incubation at 310 K, a 1:1 mixture of 
complexes 15 and 16 in the presence of NaCl (ca. 10X) remained unchanged as 
the iodido to chlorido conversion is less than 5%. This is consistent with our 
NMR results that indicate that complex 16 is stable after 48 h in cell culture 
media.  A similar complex [Ru(η6-bip)(p-Azpy-NMe2)I]PF6 has been previously 
reported not to undergo conversion to its chlorido analogue after 24h. 49 
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Figure 3.17. HPLC studies of complexes 15 and 16. 
 
3.4.2 Antiproliferative activity 
Ligands 1 - 6 were tested in four cancer cell lines, A2780, A549, HCT116 and 
MCF7 of ovarian, lung, colon and breast tissue origin, respectively. In all cases 
the chelating imine ligands were found to be inactive (IC50 values > 200 µM). 
Chlorido complexes 12  [Ru(η6-p-cym)(p-Impy-COO)Cl]PF6 and 14 [Ru(η6-p-
cym)(p-Impy-(CH2)3COO)Cl]PF6 were also inactive in all cell lines. These 
compounds include in their structure ligands 4 p-Impy-COOH and 5 p-Impy-
(CH2)3COOH which have electron withdrawing groups (-COOH) in position R2. 
The activity of complex 12 seems to be enhanced when the monodentate ligand in 
the complex is changed from chloride to iodide. This observation is also true 
when comparing the analogous complexes 7 [Ru(η6-p-cym)(Impy)Cl]PF6 and 8 
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[Ru(η6-p-cym)(Impy)I]PF6 which have Impy as their chelating ligand. The 
antiproliferative activity increases from 160 µM in A2780 ovarian cancer cells for 
the chlorido complex 7 to 73 µM for the corresponding iodido analogue 8, the 
same effect is observed in all cell lines (see Table 3.4). 
The active complexes in these series, contain electron-donating groups such as -
OH and -NMe2, as substituents on the phenyl ring of the imine ligand (in position 
R2). The effect of the moderately activating hydroxyl group differs according to 
the position in the phenyl ring of the imine ligand. Comparing chlorido complexes 
9  [Ru(η6-p-cym)(o-Impy-OH)Cl]PF6 and 10 [Ru(η6-p-cym)(p-Impy-OH)Cl]PF6, 
the ortho- substituent, R1, generates a more active complex than the para- 
substituent, R2. The most active complexes include ligand 6 which has the 
strongest electron donating group -NMe2 in position R2. These compounds have 
antiproliferative activities comparable to CDDP in A2780 ovarian, HCT116 colon 
and MCF7 breast cancer cells.  
The above trend relating the nature of the substituents to the biological activity of 
the complexes is consistent as well with the extent of nucleobase binding as 
shown in Figure 3.18. Results in A2780 ovarian and MCF7 breast cell lines show 
that iodido complexes 8, 10, 13 and 16 exhibit a higher extent of binding to 9-EtG 
and are always more active than their respective chlorido analogues 7, 11, 12 and 
15, respectively. Complexes 10, 12 and 14 particularly, are inactive in all cell 
lines and bind only weakly to 9-EtG (extent 0 - 16%). Complex 13 [Ru(η6-p-
cym)(p-Impy-COO)I]PF6, which include an electron-withdrawing substituent and 
iodide as monodentate ligand is more active than  its chlorido analogue 12  
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[Ru(η6-p-cym)(p-Impy-COO)Cl]PF6 and it binds to a greater extent to 9-EtG.  
Once again, ortho- substitution, R1 with an electron-donating group improves 
interaction with the nucleobase, thereby increasing its activity. Finally the most 
active complexes 15 and 16, that include the group NMe2 in position R2 bind to 9-
EtG to a greater extent in this series. 
Protocols published in the literature to determine the antiproliferative activity vary 
considerably regarding the length of the drug exposure time, ranging between 24 
to 96 h.50–52 However, the protocol used to determine the IC50 values reported here 
(see Chapter 2), includes a drug exposure period of 24 h. Complexes 15 [Ru(η6-p-
cym)(p-Impy-NMe2)Cl]PF6, 16  [Ru(η6-p-cym)(p-Impy-NMe2)I]PF6 and CDDP 
were used to investigate the dependence of biological activity on the length of 
drug exposure time and to confirm that 24 h was the optimum period. For this, 
A2780 ovarian cells were exposed to the ruthenium complexes for a variable 
number of hours. Figure 3.5 in page 91, showed that there is a difference in the 
antiproliferative activity between 8 and 24 h of drug exposure, however longer 
exposure times have no significant effect after 24 h. A stability plateau is reached 
at 72 h of exposure.  This confirms that the protocol used to determine IC50 values 
is optimised.  
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Complex 15 7 9 12 10 
N,N- Ligand p-Impy-
NMe2 
Impy o-Impy-OH 
p-Impy-
COOH 
p-Impy-
OH 
Figure 3.18. Relation between aquation, 9-EtG binding and antiproliferative 
activity in A2780 cells for chlorido complexes 
 
3.4.2.1 Metal accumulation in cancer cells 
The extent of the ruthenium accumulation in A2780 ovarian cancer cells was 
determined using equipotent concentrations (IC50/3) of complexes 7-16. Results in 
Table 3.5 on page 88 indicate that there is no correlation between the amount of 
ruthenium that is found in the cells after a 24 h drug exposure period and the 
potency of the complexes as anticancer agents (Figure 3.19). For example iodido 
complex 11 [Ru(η6-p-cym)(p-Impy-OH)I]PF6 exhibited high accumulation, 
reaching intracellular concentrations of 28 ± 2 ng Ru per 106 cells, however it is 
only moderately active, with an IC50 value of 48 ± 2 µM. Meanwhile chlorido 
complex 15 [Ru(η6-p-cym)(p-Impy-NMe2)Cl]PF6 only reaches concentrations of 
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7.8 ± 0.5 ng Ru per 106 cells, but is considerably more active towards A2780 cells 
(IC50 16.2 ± 0.9 µM). This indicates that the cytotoxic effects caused by complex 
15 inside A2780 cells are more efficient than those caused by complex 11. Such 
observations have been previously reported for other related ruthenium arene 
complexes.53  
 
 
Figure 3.19. Comparison between cellular accumulation (left axis) and 
antiproliferative activity (right axis) of ruthenium complexes 7-16. 
 
Ruthenium accumulation from chlorido complexes cannot be related to the 
complexes ability to form aqua adducts as it is known that extracellular 
concentrations of chloride (100 mM in blood plasma) would not allow this 
process to occur. In fact, it is accepted that CDDP only hydrolyses after it has 
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22.7 mM.56 Also, in the previous section it has been shown that complex 7 does 
not undergo aquation in cell culture medium after 24h. 
Hydrophobicity is often associated with cellular uptake and therefore with metal 
accumulation. In the case of complexes 7-16 there are no differences in the 
number of aromatic rings present, nor in the arene unit, nor in the N,N-chelating 
ligand. As a consequence, it is expected that their log P values should not vary 
significantly as to determine different patterns in metal accumulation. Calculation 
of the partition coefficient of ligands 1-6 using XLOGP357 software confirms that 
there is no significant variations amongst the ligands (value range 3.84 to 4.81) as 
shown in Table 3. 7. This is consistent with the idea of no significant changes in 
the log P values of complexes 7-16. 
Table 3. 7. Calculated Log P values for ligands 1-6.  
Ligand Calculated Log P 
1 Impy 4.81 
2 o-Impy-OH 3.84 
3 p-Impy-OH 4.09 
4 p-Impy-COOH 4.39 
5 p-Impy-(CH2)3COOH 4.69 
6 p-Impy-NMe2 4.57 
   
 
 3.4.2.2 Pathways involved in cellular uptake and 
accumulation 
For following cellular uptake studies, only complexes 15 [Ru(η6-p-cym)(p-Impy-
NMe2)Cl]PF6 and its iodido analogue 16 [Ru(η6-p-cym)(p-Impy-NMe2)I]PF6 were 
used and compared to the corresponding data for CDDP. These two compounds 
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were selected because of their structural similarities and with the aim to study the 
effect of the monodentate ligand on the cellular uptake behavior. 
Mechanisms of cellular Pt uptake from cisplatin and cellular accumulation of Pt 
have been widely investigated,11,14 however little is known about analogous 
pathways involved in the uptake of half-sandwich ruthenium anticancer 
complexes.58 One of the aims of the research presented in this Chapter was to gain 
a more in-depth understanding of this crucial step.  It has been reported that 
CDDP uptake is linear with respect to time in the first 60 min of drug exposure,37  
however the present investigation involves a longer time frame. A2780 ovarian 
cells were exposed to complex 15, its iodido analogue complex 16
 
and CDDP at 
seven different time points ranging from 1 h to 96 h. In all cases, maximum metal 
cellular accumulation occurs between 24 - 48 h of drug exposure, after this time, 
the amount of Pt / Ru decreases slightly, indicating that influx/efflux equilibrium 
may have been reached. The CDDP accumulation seems to reach a concentration 
plateau at 96 h as shown in Figure 3.6 on page 95.  
The temperature dependence of the cellular uptake and accumulation of Ru was 
also investigated. Experiments were carried out at three different temperatures, 
277 K, 295 K and 310 K. As shown in Figure 3.7, on page 95, CDDP influx is 
nonexistent at the lowest temperature (277 K), this is consistent with previous 
reports which indicate that CDDP uptake is energy dependent.59 As expected for 
an energy dependent process, CDDP influx begins at 295 K and increases as the 
temperature is raised to 310 K (from 0.005 ± 0.002 ng of Pt to 0.12 ± 0.03 ng of Pt 
per 106 cells). Ru accumulation curves for complexes 15 and 16 are very different. 
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Although an increased uptake is accompanied by an increase in temperature, 
ruthenium complex 16 exhibits significant energy independent uptake at 277 K 
(0.8 ± 0.1 ng of Ru per 106 cells)
. 
Another important factor investigated was the saturation of the cellular uptake 
with increasing drug concentration. Experiments were carried out at equipotent 
concentrations of complex 15, 16 and CDDP. Figure 3.8, on page 96 shows that 
CDDP uptake is slowed down after reaching 6.4 x IC50 concentration values (7.6 
mM) as the gradient of the graph decreases, but does not reach a plateau. This is 
consistent with previous reports that indicate that CDDP accumulation does not 
saturate up to 100 µM.17 Meanwhile, ruthenium complexes exhibit a much sharper 
gradient, indicating that concentrations of up to 3.2 x IC50 values do no cause 
saturation of the uptake pathways. It is also relevant that at concentrations equal to 
6.4 x IC50 and 9.6 x IC50 total cell death was observed. Therefore the exact 
saturation of Ru concentration could not be established.  
Cellular accumulation of metal (Ru/Pt) arises as the result of the equilibrium of 
two important processes: cellular uptake and cellular efflux. The latter is 
especially important in antiproliferative activity measurements that involve a cell 
recovery period in drug-free media.  The extent of the efflux of Ru for complexes 
15 [Ru(η6-p-cym)(p-Impy-NMe2)Cl]PF6  and its iodido analogue 16 was 
investigated over time. For this, A2780 ovarian cells were exposed to the 
ruthenium complexes for 24 h and then left to recover at various periods of time. 
Figure 3.9 on page 98, shows that although there is a significant efflux during the 
first 24 h of recovery, the concentration of metal retained in the cells reaches a 
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plateau after 48 h with no marked difference between 24 and 48 h.  Most 
important of all, at the lowest metal concentration point, at least 25% of the 
original ruthenium is retained.  
One of the most important mechanisms of resistance of anticancer 
pharmaceuticals involves impaired cellular accumulation as a result of an 
increased extent of efflux.60 Therefore investigating the mechanism of efflux of a 
drug can provide insights into the mechanism of resistance. Verapamil, an L-type 
calcium channel blocker shown in Figure 3.20 effectively abrogates P-gp 
mediated active efflux of anticancer drugs in ovarian cancer cells by competitive 
inhibition of drug transport and is capable of reversing multi-drug resistance.61,62  
Although it is not fully understood how verapamil interacts with P-gp to decrease 
cellular efflux, it has been reported that 50 µM of verapamil is capable of 
restoring doxorubicin sensitivity in MDR cell lines61 by blocking active efflux.63 
Accordingly, complexes 15 and 16 were used to investigate the extent of Ru 
efflux when cells are allowed to recover in drug-free media that contains 
verapamil. 
N
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Figure 3.20. Structure of verapamil. 
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Results shown in Figure 3.10 on page 99, indicate that by increasing the 
concentration of verapamil it is possible to impair the efflux process of ruthenium 
complexes 15 and 16. This result is especially important for chlorido complex 15 
which is retained by more than 70% in the presence of 20 µM of this calcium 
channel blocker. This result is consistent with P-gp taking part in the efflux of 
complex 15. However, it is remarkable that preliminary molecular docking 
calculations21 carried out for ligands 1-6 seem to indicate that they are not P-gp 
substrates.   
The involvement of P-gp in ruthenium complexes resistance has been 
demonstrated previously, as it is possible to achieve restoration of the sensitivity 
to this type of metal complexes by use of verapamil.6 Particularly, sensitivity to 
RM175, (Figure 3.21)  is restored by verapamil in adriamycin resistant A2780AD 
cells.61 Verapamil does not restore CDDP sensitivity, as it is not recognized by P-
gp.64 
 
Figure 3.21. Structure of RM175. 
 
Polar molecules cannot diffuse freely through the cell membrane; instead, they 
need to rely on membrane proteins or membrane channels to reach the interior of 
Ru
Cl
H2N
NH2
+
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cell compartments. One of these proteins in the plasma membrane is the sodium-
potassium adenosine triphosphatase enzyme or Na+/K+ pump which is responsible 
for maintaining cellular volume and most important of all for maintaining the 
resting potential of the cell.14,17,65,66 The function of this pump can be altered by 
the use of ouabain (Figure 3.22) which  reduces the sodium gradient across the 
cell membrane causing the membrane potential to change.67 There are no previous 
reports that investigate the effect of co-administering ouabain and ruthenium 
drugs. To analyse cellular accumulation of Ru under these conditions, complexes 
15 [Ru(η6-p-cym)(p-Impy-NMe2)Cl]PF6 and 16 [Ru(η6-p-cym)(p-Impy-
NMe2)I]PF6  were co-incubated with 5 µM, 10 µM, 20 µM, 0.1 mM or 0.2 mM of 
ouabain.  Corresponding data for CDDP was also obtained.  
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Figure 3.22. Structure of ouabain 
 
Results in Figure 3.11 on page 101, show that in the case of complexes 15 and 16 
co-incubation with the cardiac glycoside, ouabain, impaired metal cellular 
accumulation. Ru accumulation from complex 15 decreases from 7.5 ± 0.2 ng of 
Ru to 3.8  ± 0.3 ng of Ru per 106 cells when co-incubated with 200 µM of 
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ouabain. In the case of complex 16, its metal accumulation decreases from 11.9 ± 
0.3 ng of Ru to 7.2  ± 0.2 ng of Ru per 106 cells when co-incubated with the same 
concentration of ouabain. These results suggest that there may be a percentage of 
the cellular uptake pathway of these ruthenium complexes that relies on facilitated 
diffusion and in particular that is dependent on the membrane potential.  
Figure 3.11 on page 101, also shows the corresponding results for CDDP co-
incubation with ouabain. As expected from previous reports,17,37cisplatin uptake is 
also reduced with increasing concentrations of ouabain, changing from 0.24 ± 
0.05 ng of Pt to 0.12 ± 0.05 ng of Pt per 106 cells when co-incubated with 200 µM 
of the glycoside. Although this mechanism is still not very clear, previous reports 
propose that the sodium gradient in the membrane determines the facilitated 
transport of CDDP  into the cells.14,68 This suggests that CDDP transport is 
dependent on the membrane potential, therefore any agent that affects the 
electrochemical gradient in the cell could potentially modify the CDDP uptake.59 
The use of ouabain to modify the action of the Na+/K+ -ATPase pump impairs 
CDDP cellular accumulation.11 This effect is indeed caused by changes in the 
electrochemical gradient and not because the pump itself transports the drug into 
the cell.59 
Cellular accumulation of CDDP has been linked to copper transport pathways in 
mammalian cells.36,69 Hence, complexes 15 and 16 were co-incubated with 
various concentration of a copper(II) salt with the aim of investigating whether 
CTR1 is also involved in the transport of these complexes across the cellular 
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membrane. Corresponding data for CDDP was also obtained for comparison 
purposes. 
Results suggest that the CTR1 pathway may also be involved in the uptake of 
ruthenium complexes 15 and 16. Figure 3.12 on page 101 shows that chlorido 
complex 15 exhibits a 26% decrease in its accumulation in the presence of the 
highest concentration of copper used (0.2 mM). The results for complex 16 are 
still more striking as Ru accumulation is lowered by 33% of its original value 
(from 11.9 ± 0.3 ng of Ru per 106 cells to 8.8 ± 0.4 ng of Ru per 106 cells when 
coincubated with 200 µM of Cu(II)). 
A2780 ovarian cancer cells were also co-incubated with CDDP together with 
various concentrations of a copper(II) salt that ranged between 10 µM, and 0.2 
mM. Under these conditions Pt accumulation from CDDP was reduced from 0.24 
± 0.05 ng of Pt to 0.08 ± 0.01 ng of Pt per 106 cells, a reduction in accumulation 
of 40%. Previous reports indicate that CTR1 regulates CDDP toxicity by 
regulating CDDP uptake70 and that the expression of CTR1 alters sensitivity to 
CDDP and other platinum- containing anticancer drugs. 
Although the full extent of this transport remains poorly understood, recent 
developments in NMR analysis show that CDDP binds to the methionine sulfur 
atoms on extracellular CTR1, which might involve the formation of monosulfur 
adducts (cis-[PtCl(Met)(NH3)2]+) that facilitate the transport and activation of the 
drug.71 This could also be an activation step involved in the antiproliferative 
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mechanism of other metal based- chemotherapeutic drugs such as ruthenium arene 
complexes. 
Some energy dependent pathways can be inhibited by lowering the levels of ATP. 
Such reduction of ATP concentrations can be achieved by co-administering 
antimycin A, shown in Figure 3.23, which is a mitochondrial ATP synthesis 
inhibitor that interferes with oxidative phosphorylation.44 In order to investigate 
the role of ATP depletion on cellular accumulation of Ru, complexes 15 and 16 
were co-incubated with 5 µM of antimycin A. These experiments were also 
carried out using CDDP. 
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Figure 3.23. Structure of antimycin A. 
 
It is expected that if the cellular uptake process of complexes 15 and 16 was ATP 
dependent, its depletion should cause a decrease in Ru cellular accumulation. 
However, only a small, non significant variation is observed in the cellular 
accumulation of Ru from complex 16 [Ru(η6-p-cym)(p-Impy-NMe2)I]PF6 (Figure 
3.13, on page 103). These results suggest a significant extent of ATP- independent 
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uptake. This is consistent with cellular accumulation results when the uptake 
process takes place at low temperatures (277 K) (see temperature- dependence 
above). The figure also shows a major increase in cellular accumulation of 
ruthenium for complex 15 [Ru(η6-p-cym)(p-Impy-NMe2)Cl]PF6, this behaviour 
suggests that an ATP-dependent efflux pump is involved in the detoxification of 
this complex. This is consistent with the possibility of an ABC transporter, such 
as the MRP2 pump being involved in complex 15 efflux. MRP2 pump is inhibited 
by antimicyn caused- ATP depletion, therefore its inhibition could allow 
intracellular Ru concentrations to increase. The ATP-dependent pump has been 
reported to be involved in the efflux of CDDP conjugated to glutathione  and to 
several multidrug resistance mechanisms.73 
Figure 3.13, on page 103 also shows that co-incubation of A2780 cells with 
CDDP and 5 µM of antimycin A does not reduce Pt uptake significantly (from 
0.24 ± 0.05 ng of Pt per 106 cells to 0.22 ± 0.02 ng of Pt per 106 cells).  Such 
observation could be interpreted as inconsistent with the results shown above, 
regarding the temperature-dependence of CDDP uptake. Although it is reported 
that antimycin (1.5 µM) can achieve 90% of ATP depletion in LLC-PK cells (Pig 
kidney cells) when exposed for 5h,72 the present work did not include the 
determination of ATP levels in A2780 ovarian cells. It is possible that the 
depletion in this case was not effective enough to cause an observable decrease in 
the CDDP uptake.  The use of antimycin causes striking results when used with 
carboplatin, as it is possible to inhibit 90% of its uptake in the BEL-7404 cell line 
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by using 50 µg/mL of antimycin A.44 However it is important to recognise that the 
concentrations needed for efficient ATP depletion are cell-dependent. 
Enhanced protein-mediated transport across cell membranes has been reported as 
a means of increasing cellular accumulation.74 Consequently, the role of protein- 
mediated transport in the cellular accumulation of Pt and Ru drugs was 
investigated. Complexes 15,
 
16 and CDDP were co-incubated with variable 
concentrations of amphotericin B (Figure 3.24) which forms pores in the cellular 
membrane.41,75–77  
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Figure 3.24. Structure of amphotericin B. 
 
These pores, permeable to water and non-electrolytes, may allow increased influx 
and therefore higher cellular accumulation of the chemotherapeutic drugs. 
Experimental results of co-incubation with amphotericin B (Figure 3.14 on page 
104) show that there is no significant variation in the cellular accumulation of Ru 
from complex 15 [Ru(η6-p-cym)(p-Impy-NMe2)Cl]PF6, suggesting that facilitated 
diffusion may not be involved in the uptake pathway of this complex. In contrast, 
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cellular accumulation of Ru from complex 16 [Ru(η6-p-cym)(p-Impy-NMe2)I]PF6 
is enhanced from 11.9 ± 0.3 ng of Ru per 106 cells to 25.4 ± 0.6 ng of Ru per 106 
cells by the use of 10 µM of amphotericin B, supporting results that involve 
passive diffusion of this complex through the cell membrane (See temperature- 
dependence of cellular uptake above). 
Results in Figure 3.14 on page 104 also show that CDDP accumulation increases 
from 0.24 ± 0.05 ng to 0.49 ± 0.05 ng of Pt per 106 cells. This is consistent with 
previous reports that indicate that amphotericin B increases CDDP cellular 
accumulation 41,14 This effect of amphotericin B on CDDP accumulation  has 
been used to  reverse resistance in non-small cell lung cancer.17 Although when  
CDDP resistance develops, cells may also develop resistance to amphotericin B, 
5-fluorouracil and aphidicolin.78 
Finally, the role of caveolae endocytotic pathway in cellular metal accumulation 
was explored. Complexes 15, 16 and CDDP were co-incubated with increasing 
concentrations of β-methyl cyclodextrin. Results shown in Figure 3.15 on page 
105, indicate that this endocytotic pathway is not involved either in the uptake of 
Pt from CDDP nor in the uptake of Ru for complexes 15, 16  as there are no 
significant changes in metal cellular concentration when increasing concentrations 
of β-methyl cyclodextrin are used. 
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3.4.2.3 Effects of changing the arene.  
Relationship between log P values and cellular 
 accumulation 
Hydrophobicity is also thought to play an important role in the antiproliferative 
activity of a given drug.79 Increments in this factor have been related to enhanced 
cellular uptake and therefore enhanced cellular accumulation.80 Negative Log P 
values indicate higher solubility of a given compound in water than in octanol. 
This can affect its transport through cellular membranes. Complex 15 [Ru(η6-p-
cym)(p-Impy-NMe2)Cl]PF6, has been studied in comparison to  complexes 17 
[Ru(η6-bip)(p-Impy-NMe2)Cl]PF6 and 18 [Ru(η6-m-terp)(p-Impy-NMe2)Cl]PF6. 
All three compounds bear the same imine 6, p-Impy-NMe2 as ligand and they all 
have chloride as their monodentate ligand. However, in this series, the number of 
phenyl rings in the arene unit varies. As expected, the increase in aromatic rings in 
the structure results in higher hydrophobicity, although they all have negative Log 
P values.  
Figure 3.25, compares Log P values and the corresponding cellular accumulation 
data. Although hydrophobicity decreases in the series 18 > 17 > 15 it is observed 
that there is a significant drop in Ru concentration for complex 18, which 
indicates that the shape of the arene unit might play a significant role in cellular 
uptake. However, it is interesting that complex 18 with the lowest cellular 
accumulation of the series (4.6 ± 0.2 ng of Ru per 106 cells) has the greater 
potency against A2780 ovarian cells (IC50 = 2.1 ± 0.2 µM) while complex 17 
which is highly taken up (10.2 ± 0.3 ng of Ru per 106 cells) is only moderately 
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active in the same cell line (IC50 = 38 ± 2 µM). This shows that the 
antiproliferative mechanism of complex 18 is more efficient than that of 17.  
 
 
Figure 3.25. Comparison of total cellular accumulation for complexes 15, 17 and 
18 in A2780 ovarian cell line expressed in ng of metal per million cells against the 
corresponding Log P values.  
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 3.5 Conclusions 
This study shows that ruthenium(II) Impy complexes that include in their 
structure (as R2 substituents) electron-donating groups such as NMe2 are more 
active towards cancer cell lines (A2780, A549, HCT116 and MCF7) than those 
which include electron withdrawing groups (COOH, C3H6COOH). Also, is has 
been demonstrated that there is a correlation between the presence of these groups 
and the extent of aquation exhibited by the complexes after 24 h. The same 
correlation can be drawn to include the ability of the complexes to bind to 9-EtG 
as a nucleobase model. Further analysis on the interaction of Ru(II) half-sandwich 
complexes with DNA is included in Chapter 4.  Potency of the complexes towards 
A2780 cell lines does not correlate with their cellular accumulation, showing that, 
the different ruthenium arene complexes may use different antiproliferative 
pathways (See Chapter 5). 
Complexes 15 [Ru(η6-p-cym)(p-Impy-NMe2)Cl]PF6 and 16 [Ru(η6-p-cym)(p-
Impy-NMe2)I]PF6 were used to investigate the possible pathways for cellular 
accumulation in comparison with CDDP in A2780 ovarian cancer cells. These 
two complexes were chosen as they have in common the arene unit (p-cym) an the 
N,N-chelating ligand (p-Impy-NMe2) with the aim to investigate the role of the 
halide ligand in determining the cellular uptake mechanism involved. It was 
demonstrated that maximum Ru accumulation from both complexes occurs 
between 24 h and 48 h of exposure. Also, they exhibit partial energy-independent 
uptake in comparison to CDDP which is not taken up at low temperatures (277K). 
This is especially true for iodido complex 16, for which uptake is greatly 
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enhanced by amphotericin B, a facilitative diffusion agent. Cellular accumulation 
of ruthenium in A2780 cells was enhanced by inhibition of efflux pathways by 
verapamil, indicating that a MDR protein, such as P-gp, could be involved in 
ruthenium efflux and detoxification. This is also supported by results of co-
incubation with antimycin A, these show that the enhanced accumulation of 
chlorido complex 15 is consistent with the inhibition of MRP2 pump which is 
ATP-dependent. Changes in the resting membrane potential induced by ouabain 
have been shown to reduce Ru accumulation in A2780 ovarian cancer cells, which 
suggests that electrochemical gradient can modulate uptake. CTR1 copper 
transporter, which is involved in the cellular uptake of CDDP, is likely to be 
involved as well in the uptake of complex 16. Finally it was shown that that the 
caveolae endocytotic pathway is not involved in the uptake of either of the 
ruthenium complexes 15 or 16. 
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4.1 Introduction 
DNA is generally accepted to be the main target of cisplatin, which has been 
demonstrated to bind most frequently to guanine residues through their N7 
position, thereby generating a kink in the DNA structure.1 The most abundant 
adducts formed by cisplatin in linear DNA are 1,2-d(GpG) (∼65%) or 1,2- 
d(ApG) (25%) intrastrand and 1,2-d(GG) (∼6%) interstrand cross-links2 
Piano-stool metal complexes were originally designed to have a similar 
behaviour. These complexes could be activated by the loss of the monodentate 
ligand, usually a halogen that undergoes aquation. The result of this reaction is the 
generation of a coordinative vacancy that can be used to target biomolecules such 
as DNA. Some ruthenium compounds have shown a direct correlation between 
their antiproliferative activity and DNA binding.2 It is also known that Ru(II) 
complexes such as [(η6-arene)Ru(en)Cl]+ bind strongly to nucleobase models like 
9-EtG and 9-EtA, showing preference for the guanine base.3 However, it remains 
unclear if nuclear DNA is the principal target of such compounds.4,5 
Interactions with DNA can also include non-covalent binding, in the form of 
DNA-intercalation, in such interaction a planar aromatic unit of the metal 
complex gets inserted between the base pairs of the DNA double helix.6 
Stabilization of the double helix caused by intercalation allows the DNA to be 
unwinded, leading to functional changes that may include inhibition of repair 
processes.7 This in turn can lead to cell death. Ruthenium complexes with 
polypyridyl ligands have been widely used to study DNA intercalation.8–15 
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The present Chapter explores DNA-intercalation as a possible mechanism of 
action for Ru(II) piano-stool complexes that include in their structures N,N-
ligands with an increasing number of aromatic units.  
 
4.2 Experimental section 
 4.2.1 Materials 
Ruthenium arene dimers used in this Chapter include [(η6-p-cymene)RuCl2]2, 
reported in Chapter 2. [(η6-bip)RuCl2]2, and [(η6-terp)RuCl2]2, were kindly 
provided by Dr. Abraha Habtemariam. Quinoline-2-carbaldehyde, aniline (ACS 
Reagent ≥99.5%), 2-aminoanthracene (96%), pyridine-2-carbaldehyde 2-
aminoquinoline (97%), 1H-indol-5-amine (96%) were purchased from Sigma 
Aldrich.  All deuterated solvents (D2O, MeOD, DMSO-d6, acetone-d6, CDCl3) 
were obtained from Cambridge Isotope Laboratories. For the biological assays: 
CT-DNA was also obtained from Sigma Aldrich. 
 
 4.2.2 Preparation of ligands and complexes 
The synthetic procedure 1, described below was used to obtain all the imines used 
as ligands in this Chapter and listed in Figure 4.1.  
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Figure 4.1 Ligands investigated in this Chapter. 
 
Synthetic Procedure 1. 
N
N
CHO
N
NH2
+
 
Scheme 4.1. Synthesis of (E)-N-phenyl-1-(quinolin-2-yl)methanimine  [Phimqn, 
19]. 
 
 (E)-N-phenyl-1-(quinolin-2-yl)methanimine  [19]. Quinoline-2-carbaldehyde 
(50 mg, 0.32 mmol) was dissolved in acetonitrile (5 mL) at ambient temperature 
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with stirring. Then 1 mol. equiv. of aniline was added (30 mg, 29 µL, 0.32 mmol). 
The reaction was left to stand with stirring for 4 h. The solvent was removed by 
rotary evaporation. A pale solid was obtained, which was washed with ether 
(Yield 70%). Elemental analysis calc. for C16H12N2, C: 82.73%; H: 5.21%; N: 
12.06%. Found: C: 82.85%; H: 5.18%; N: 12.32%. NMR-δH (500 MHz; CDCl3) 
7.33 (1H, t, J = 7.4, 14.2 Hz) 7.43 (2H, dd, J = 1.3, 7.5 Hz) 7.48 (2H, m) 7.70 (1H, 
t, J = 8.4, 15.5 Hz) 7.85 (1H, t, J = 7.4, 15.3 Hz) 8.07 (1H, d, J = 9.0 Hz) 8.14 
(1H, d, J = 9.0 Hz) 8.30 (1H, d, J = 9.5 Hz) 8.50 (1H, d, J = 9.5 Hz) 8.78 (1H, s). 
m/z (ESI) found 234.0 (calc. M + H+. C16H13N2 = 234.27). 
(E)-N-(anthracen-2-yl)-1-(quinolin-2-yl)methanimine [Anthimqn, 20]  As 
synthetic procedure 1, using quinoline-2-carbaldehyde  (50 mg, 0.32 mmol) and  
2-aminoanthracene (62 mg, 0.32 mmol). Yield 86%. Elemental analysis calc. for 
C24H16N2  C: 86.72%; H: 4.85%; N: 8.42%.  Found: C: 86.64%; H: 4.81%; N: 
8.36%. NMR-δH (500 MHz; CDCl3) 7.51 (2H, m) 7.66 (2H, m) 7.82 (1H, m) 7.93 
(1H, d, J = 8.0 Hz) 7.98 (1H, d, J = 1.8 Hz) 8.05 (2H, m) 8.11 (1H, d, J = 8.1 Hz) 
8.23 (1H, d, J = 8.2 Hz) 8.33 (1H, d, J = 8.6 Hz) 8.48 (1H, d, J = 2.2 Hz) 8.50 
(2H, m) 9.04 (1H, s). m/z (ESI) found 332.4 (calc. M + H+ C24H17N2 = 332.39). 
(E)-N-(anthracen-2-yl)-1-(pyridin-2-yl)methanimine [Anthimpy, 21] As 
synthetic procedure 1, using pyridine-2-carbaldehyde  (28 mg, 25 µL, 0.26 mmol) 
and  2-aminoanthracene (50 mg, 0.26 mmol). Yield 65%. Elemental analysis calc. 
for C20H14N2  C: 85.08%; H: 5.00%; N: 9.92%.  Found: C: 85.95%; H: 4.92%; N: 
9.78%. NMR-δH (500 MHz; CDCl3) 7.54 (2H, m) 7.58 (1H, qd, J = 1.0, 4.5, 6.0, 
7.5 Hz) 7.67 (1H, dd, J = 2.0, 9.1 Hz) 8.01 (2H, m) 8.10 (2H, c, J = 5.4, 9.0, 15.3 
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Hz) 8.19 (1H, d, J = 9.1 Hz) 8.26 (1H, d, J = 8.3 Hz) 8.63 (2H, d, J = 3.5 Hz) 8.77 
(1H, dc, J = 0.8, 1.7, 2.6, 4.7 Hz) 8.84 (1H, s). m/z (ESI) found 282.0 (calc. M + 
H+ C20H15N2 = 283.33). 
(E)-1-(pyridin-2-yl)-N-(quinolin-3-yl)methanimine [Qnimpy, 22] As synthetic 
procedure 1, using pyridine-2-carbaldehyde  (37 mg, 34 µL, 0.35 mmol) and  2-
aminoquinoline (50 mg, 0.35 mmol). Yield 86%. Elemental analysis calc. for 
C15H11N3  C: 77.23%; H: 4.75%; N: 18.01%.  Found: C: 77.50%; H: 4.89%; N: 
18.22%. NMR-δH (500 MHz; CDCl3) 7.58 (1H, qd, J = 5.0, 6.2, 7.6, 12.1 Hz) 7.64 
(1H, t, J = 7.7, 14.9 Hz) 7.75 (1H, td, J = 1.4, 6.1, 15.4 Hz) 8.03 (3H, m) 8.25 (1H, 
d, J = 7.9 Hz) 8.30 (1H, d, J = 2.6 Hz) 8.77 (1H, d, J = 4.6 Hz) 8.85 (1H, s) 8.97 
(1H, d, J = 2.5 Hz). m/z (ESI) found 234.3 (calc. M + H+ C15H12N3 = 234.26). 
(E)-N-(1H-indol-5-yl)-1-(pyridin-2-yl)methanimine [Indoimpy, 23] As 
synthetic procedure 1, using pyridine-2-carbaldehyde  (40 mg, 38 µL, 0.38 mmol) 
and  1H-indol-5-amine (50 mg, 0.38 mmol). Yield 86%. Elemental analysis calc. 
for C14H11N3  C: 76.00%; H: 5.01%; N: 18.99%.  Found: C: 76.15%; H: 5.19%; N: 
19.09%. NMR-δH (500 MHz; CDCl3) 7.33 (1H, m) 7.36 (1H, s) 7.48 (1H, d, J = 
9.5 Hz) 7.58 (1H, t, J = 1.6 Hz) 7.79 (1H, td, J = 1.9, 7.8, 15.2 Hz) 7.84 (1H, s) 
7.94 (1H, s) 8.10 (1H, d, J = 8.0 Hz) 8.61 (1H, s) 8.68 (1H, d, J = 3.5 Hz). m/z 
(ESI) found 222.3 (calc. M + H+ C14H12N3 = 222.25). 
Synthetic procedure 2, was used to synthesise all the ruthenium complexes 
described in this Chapter and listed in Figure 4.2. 
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Figure 4.2 Complexes investigated in this Chapter. 
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Synthetic procedure 2. 
 
Scheme 4.2. Synthesis of the ruthenium complex  [Ru(η6-p-cym)(Phimqn)Cl]PF6, 
[24]. 
[Ru(η6-p-cym)(Phimqn)Cl]PF6, [24]. Ruthenium p-cymene dimer [(η6-p-
cym)RuCl2]2 (100 mg, 0.16 mmol) was dissolved in methanol (5 mL). This 
mixture was placed in a round bottom flask, then two mol equiv of the appropriate 
ligand was added, in this case, Phimqn (76 mg, 0.32  mmol). The reaction was left 
at ambient temperature with constant stirring for 5 h. After this time 5 equiv of 
NH4PF6 were added to the mixture, and left stirring for a further hour. The solid 
residue was filtered off under vacuum and recrystallised. (Yield 52%). Elemental 
analysis calc. for C26H26N2ClF6PRu, C: 48.19%, H: 4.04%, N: 4.32%. Found: C: 
48.28%, H: 4.07%; N: 4.29%. NMR -δH (500 MHz; DMSO-d6) 0.76 (3H, d,  J = 
6.7 Hz) 0.92 (3H, d,  J = 6.7 Hz) 2.22 (3H, s) 2.36 (1H, m)  5.36 (1H, d, J = 6.7 
Hz) 5.78 (1H, d, J = 6.1 Hz) 5.88 (1H, d, J = 6.1 Hz) 6.12 (1H, d, J = 6.7 Hz), 7.65  
(1H, m) 7.70 (2H, t, J = 7.1, 14.7 Hz) 7.98 (2H, d, J = 7.4 Hz) 8.04 (1H, t, J = 6.7, 
14.5 Hz) 8.19 (1H, t, J = 8.3, 15.6 Hz) 8.34 (2H, t, J = 8.9, 18.4) 8.79 (1H, d, J = 
10.4 Hz) 8.94 (1H, d, J = 8.3 Hz) 9.20 (1H, s). m/z (ESI) found 503.0 (calc. M+ 
C26H26N2ClRu = 503.02).  
PF6
Cl
Cl
Ru
Cl Ru
Cl N
N
Ru
Cl
N
N
+
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[Ru(η6-p-cym)(Anthimqn)Cl]PF6 [25]. As synthetic procedure 2, using [Ru(η6-p-
cym)2Cl2]Cl2 (54 mg, 0.09 mmol) and Anthimqn (50 mg, 0.18 mmol).  Yield 
68%. Elemental analysis calc. for C30H28N2ClF6PRu C: 51.62%, H: 4.04%, N: 
4.01%. Found: C: 51.72%, H: 4.12 %; N: 4.09%. NMR -δH (500 MHz; DMSO-d6) 
0.95 (6H, d, J = 4.8 Hz) 2.10 (3H, s) 2.35 (1H, m) 5.54 (1H, d, J = 7.0 Hz) 5.80 
(1H, d, J = 6.4 Hz) 6.02 (1H, d, J = 7.0 Hz) 6.35 (1H, d, J = 6.5 Hz) 7.45 (2H, m) 
7.58 (2H, m) 7.90 (1H, m) 8.02 (1H, d, J = 7.6 Hz) 8.10 (1H, d, J = 2.3 Hz) 8.15 
(2H, m) 8.32 (1H, d, J = 9.0 Hz) 8.45 (1H, d, J = 7.4 Hz) 8.54 (1H, d, J = 9.1 Hz) 
8.72 (1H, d, J = 3.0 Hz) 8.85 (2H, m) 9.24 (1H, s). m/z (ESI) found 553.0 (calc. 
M+ C30H28N2ClRu = 553.08). 
[Ru(η6-p-cym)(Anthimqn)I]PF6 [26]. As synthetic procedure 2, using [Ru(η6-p-
cym)2I2]I2 (50 mg, 0.08 mmol) and anthimqn (54 mg, 0.16 mmol).  Yield 71%. 
Elemental analysis calc. for C34H30N2IF6PRu C: 48.64%, H: 3.60%, N: 3.34%. 
Found: C: 48.60%, H: 3.58%; N: 3.30%. NMR-δH (500 MHz; DMSO-d6) 0.79 
(3H, d, J = 6.8 Hz) 0.94 (3H, d, J = 6.8 Hz) 2.10 (3H, s,) 2.42 (1H, m) 5.45 (1H, d, 
J = 6.0 Hz) 5.87 (1H, d, J = 6.3 Hz) 5.95 (1H, d, J = 6.3 Hz) 6.18 (1H, d, J = 6.0 
Hz) 7.62 (2H, m) 8.06 (1H, t, J = 8.4, 13.0 Hz) 8.13 (1H, d, J = 8.1 Hz) 8.23 (3H, 
m) 8.36 (1H, d, J = 8.3 Hz) 8.41 (2H, dd, J = 5.0, 8.4 Hz) 8.67 (1H, s) 8.81 (2H, d, 
J = 9.0 Hz) 8.86 (1H, s) 8.98 (1H, d, J = 9.6 Hz) 9.40 (1H, s). m/z (ESI) found 
694.6 (calc. M+ C34H30N2IRu = 694.59). 
[Ru(η6-p-cym)(Anthimpy)Cl]PF6 [27]. As synthetic procedure 2, using [Ru(η6-p-
cym)2Cl2]Cl2 (50 mg, 0.08 mmol) and Anthimpy (38 mg, 0.16 mmol).  Yield 
54%. Elemental analysis calc. for C30H28N2ClF6PRu, C: 51.62%, H: 4.04%, N: 
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4.01%. Found: C: 51.80%, H: 4.11%; N: 4.09%. NMR -δH (500 MHz; DMSO-d6) 
1.01 (6H, t, J = 7.3, 15.2 Hz) 2.23 (3H, s) 2.56 (1H, m) 5.63 (1H, d, J = 5.6 Hz) 
5.72 (1H, d, J = 5.6 Hz) 5.83 (1H, d, J = 6.3 Hz) 6.16 (1H, d, J = 6.3 Hz) 7.63 
(2H, m) 7.93 (1H, c, J = 5.7, 9.0, 14.2 Hz) 7.98 (1H, d, J = 9.7 Hz) 8.20 (1H, q, J 
= 5.7, 9.5, 15.1 Hz) 8.35 (3H, m) 8.47 (1H, s) 8.77 (1H, s) 8.83 (1H, s) 9.14 (1H, 
s) 9.64 (1H, d, J = 5.5Hz). m/z (ESI) found 553.1 (calc. M+ C30H28N2ClRu = 
553.08). 
[Ru(η6-p-cym)(Anthimpy)I]PF6 [28]. As synthetic procedure 2, using [Ru(η6-p-
cym)2I2]I2 (50 mg, 0.08 mmol) and Anthimpy (30 mg, 0.16 mmol).  Yield 70%. 
Elemental analysis calc. for C30H28N2F6IPRu C: 45.64%, H: 3.57%, N: 3.55%. 
Found: C: 45.58%, H: 3.60 %; N: 3.47%. NMR -δH (500 MHz; DMSO-d6) 0.99 
(3H, d, J = 7.2 Hz) 1.05 (3H, d, J = 7. 2 Hz) 2.46 (3H, s) 2.67 (1H, m) 5.70 (1H, d, 
J = 6.2 Hz) 5.75 (1H, d, J = 6.4 Hz) 5.90 (1H, d, J = 6.2 Hz) 6.11 (1H, d, J = 6.4 
Hz) 7.65 (2H, m) 7.88 (1H, t, J = 6.6, 13.2 Hz) 8.09 (1H, d, J = 9.2 Hz) 8.23 (2H, 
m) 8.34 (1H, t, J = 8.4, 16.1 Hz) 8.40 (1H, d, J = 8.7 Hz) 8.55 (1H, s) 8.80 (1H, s) 
8.85 (1H, s) 9.11 (1H, s) 9.63 (1H, d, J = 4.8 Hz).). m/z (ESI) found 644.6 (calc. 
M+ C30H28N2IRu = 644.53). 
[Ru(η6-p-cym)(Qnimpy)Cl]PF6 [29]. As synthetic procedure 2, using [Ru(η6-p-
cym)2Cl2]Cl2 (100 mg, 0.16 mmol) and Qnimpy (76 mg, 0.32 mmol).  Yield 75%. 
Elemental analysis calc. for C25H25N3ClF6PRu C: 46.27%, H: 3.88%, N: 6.47%. 
Found: C: 46.40%, H: 3.95%; N: 6.61%. NMR-δH (500 MHz; DMSO-d6) 0.98 
(3H, d, J = 4.4 Hz) 1.03 (3H, d, J = 4.4 Hz) 2.18 (3H, s) 2.56 (1H, m) 5.68 (1H, d, 
J = 6.1 Hz) 5.80 (1H, d, J = 6.4 Hz) 5.85 (1H, d, J = 6.1 Hz) 6.13 (1H, d, J = 6.4 
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Hz) 7.80 (1H, t, J = 7.7, 15.3 Hz) 7.93 (2H, m) 8.20 (2H, t, J = 8.01, 16.5 Hz) 8.34 
(2H, d, J = 4.0 Hz) 8.34 (2H, d, J = 4.0 Hz) 8.75 (1H, d, J = 2.6 Hz) 9.14 (1H, s) 
9.35 (1H, d, J = 2.3 Hz) 9.64 (1H, d, J = 5.8Hz). m/z (ESI) found 504.0 (calc. M+ 
C22H24N2IRu = 504.01). 
[Ru(η6-p-cym)(Qnimpy)I]PF6 [30]. As synthetic procedure 2, using [Ru(η6-p-
cym)2I2]I2 (50 mg, 0.08 mmol) and Qnimpy (24 mg, 0.16 mmol).  Yield 70%. 
Elemental analysis calc. for C25H25N3F6IPRu, C: 40.55%, H: 3.40%, N: 5.68%. 
Found: C: 40.75%, H: 3.54%; N: 5.74%. NMR-δH (500 MHz; DMSO-d6) 0.97 
(3H, d, J = 6.8 Hz) 1.02 (3H, d, J = 6.8 Hz) 2.41 (3H, s,) 2.68 (1H, m) 5.72 (1H, d, 
J = 6.3 Hz) 5.85 (1H, d, J = 6.9 Hz) 5.92 (1H, d, J = 6.3 Hz) 6.08 (1H, d, J = 6.9 
Hz) 7.82 (1H, t, J = 7.7, 14.8 Hz) 7.89 (1H, td, J = 1.7, 5.9, 13.0 Hz) 7.95 (1H, t, J 
= 7.4, 15.0 Hz) 8.21 (2H, t) 8.33 (1H, t, J = 8.2, 15.1 Hz) 8.37 (1H, d, J = 7.3 Hz) 
8.81 (1H, d, J = 2.3 Hz) 9.09 (1H, s) 9.45 (1H, d, J = 2.3 Hz) 9.63 (1H, d, J = 5.7 
Hz). m/z (ESI) found 595.5 (calc. M+ C25H25N3IRu = 595.46). 
[Ru(η6-p-cym)(Indoimpy)Cl]PF6 [31]. As synthetic procedure 2, using [Ru(η6-p-
cym)2Cl2]Cl2 (69 mg, 0.11 mmol) and Indoimpy (50 mg, 0.23 mmol).  Yield 66%. 
Elemental analysis calc. for C24H25N3ClF6RuP C: 45.26%, H: 3.96%, N: 6.60%. 
Found: C: 45.50%, H: 3.82%; N: 6.54%. NRM-δH (500 MHz; DMSO-d6) 0.95 
(6H, d, J = 7.1 Hz) 2.14 (3h, s) 2.35 (1H, m) 5.85 (1H, d, J = 6.2 Hz) 5.96 (1H, d, 
J = 7.1 Hz) 6.12 (1H, d, J = 6.1 Hz) 6.54 (1H, d, H = 7.1 Hz) 7.42 (1H, m) 7.54 
(1H, s) 7.62 (1H, d, J = 8.0 Hz) 7.74 (1H, t, J = 2.1 Hz) 7.86 (1H, td, J = 2.1, 8.0, 
14.6 Hz) 7.93 (1H, s) 8.08 (1H, s) 8.17 (1H, d, J = 8.6 Hz) 8.47 (1H, s) 8.82 (1H, 
d, J = 4.3 Hz). m/z (ESI) found 492.0 (calc. M+ C24H25N3ClRu = 492.06). 
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[Ru(η6-bip)(Anthimpy)Cl]PF6 [32]. As synthetic procedure 2, using [Ru(η6-
bip)2Cl2]Cl2 (50 mg, 0.08 mmol) and Anthimpy (44 mg, 0.16 mmol).  Yield 73%. 
Elemental analysis calc. for C32H24N2ClF6PRu C: 53.52%, H: 3.36%, N: 3.90%. 
Found: C: 53.48%, H: 3.28%; N: 3.99%. NRM-δH (500 MHz; DMSO-d6) 6.08 
(1H, d, J = 5.5 Hz) 6.23 (2H, m) 6.26 (1H, m) 6.44 (2H, m) 7.37 (2H, t, J = 7.5, 
15.0 Hz) 7.49 (2H, m) 7.62 (3H, m) 7.83 (2H, m) 8.18 (3H, m) 8.32 (1H, d, J = 
4.9 Hz) 8.50 (1H, s) 8.71 (1H, s) 9.09 (1H, s) 9.54 (1H, d, J = 5.5 Hz). m/z (ESI) 
found 572.9 (calc. M+ C32H24N2ClRu = 573.0). 
[Ru(η6-m-terp)(Anthimpy)Cl]PF6 [33]. As synthetic procedure 2, using [Ru(η6-
p-terp)2Cl2]Cl2 (80 mg, 0.09 mmol) and Anthimpy (56 mg, 0.18 mmol).  Yield 
54%. Elemental analysis calc. for C38H28N2ClF6PRu C: 57.47%, H: 3.55%, N: 
3.52%. Found: C: 57.60%, H: 3.48%; N: 4.11%. NRM-δH (500 MHz; DMSO-d6) 
6.41 (1H, t, J = 6.1, 12.2 Hz) 6.60 (1H, s,) 6.68 (1H, d, J = 7.0 Hz) 6.72 (1H, d, J 
= 6. 3 Hz) 7.41 (2H, t, J = 7.6, 15.1 Hz) 7.51 (3H, m) 7.63 (2H, m) 7.72 (1H, d, J 
= 7.4 Hz) 7.87 (1H, m) 7.92 (2H, d, J = 8.0 Hz) 8.04 (1H, d, J = 9.0Hz) 8.16 (1H, 
m) 8.29 (3H, m) 8.67 (1H, s) 9.03 (1H, s) 9.29 (1H, d, J = 5.4 Hz). m/z (ESI) 
found 649.0 (calc. M+ C38H28N2ClRu = 649.16). 
 
4.2.3 Methods 
4.2.3.1 Aquation studies 
Aquation of complexes 24−33 was studied by proton NMR (500 and 600 MHz) as 
described in Chapter 2, using fresh solutions of each complex in D2O at 310 K. In 
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order to suppress the aquation observed in all chlorido complexes, 150 mM NaCl 
was added to the deuterated solvent, and, 150 mM KI was used to suppress the 
aquation of iodido complexes.  
 
4.2.3.2 Nucleobase binding 
Complexes 24−33  were reacted with 9-ethylguanine, as a nucleobase model, the 
extent of binding was followed by 1H-NMR (500 and 600 MHz). The details of 
these experiments can be found in Chapter 2. Briefly, a fresh 2 mM solution of 
each complex was prepared in 50 mM sodium phosphate buffer (pH 7.5) with 5% 
DMSO. The solution also contained 9-ethylguanine for a final mol. ratio 1:1.25 
where the nucleobase was in excess. As in the case of aquation studies, 1H-NMR 
spectra were recorded at 298 K within the first 10 min after sample preparation 
and again after 24 h at 500 MHz. All experiments were carried out in triplicate 
and the standard deviations calculated. Nucleobase binding was monitored by the 
formation of a second set of peaks that included bound-9-EtG. 
 
4.2.3.3 Antiproliferative activity 
The antiproliferative activity of ligands 19−23 and complexes 24−33  were 
determined in A2780 ovarian, A549 lung, HCT116 colon and MCF7 breast 
carcinoma cell lines.  The experiments to determine IC50 values were carried out 
as described previously in Chapter 2. Briefly, 96 well plates were used to seed 
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5000 cells per well, they were left to pre-incubate in drug-free media at 310 K for 
48 h before adding various concentrations of the compounds to be tested. A drug 
exposure period of 24 h was allowed, after this, supernatants were removed by 
suction and each well was washed with PBS (100 µL). Further 72 h were allowed 
for the cells to recover in drug-free media (200 µL per well) at 310 K.  SRB assay 
was used to determine cell viability.  IC50 values, as the concentration which 
caused 50% of cell growth inhibition, were determined as duplicate of triplicates 
in two independent set of experiments, their standard deviations were calculated. 
  
4.2.3.4 Metal accumulation in cancer cells 
Metal accumulation studies for complexes 24−33 were conducted on A2780 
ovarian carcinoma cell line. Briefly, 4 x 106 cells were seeded on a Petri dish, 
after 24 h of pre-incubation time in drug-free medium at 310 K, the test 
complexes were added to give final concentrations equal to IC50/3 and allowed 
further 24 h of drug exposure at the same temperature. After this time, cells were 
treated with trypsin, counted and cell pellets were collected. Each pellet was 
digested overnight in concentrated nitric acid (73%) at 353 K; the resulting 
solutions were diluted in double distilled water (to HNO3 5%) and the amount of 
ruthenium taken up by the cells was determined by ICP-MS. These experiments 
did not allow any cell recovery time in drug-free media. They were all carried out 
in triplicate and the standard deviations were calculated. Results are compared to 
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the corresponding data for CDDP. More experimental details can be found in 
Chapter 2.  
 
4.2.3.5 Determination of partition coefficient (Log P) 
Partition coefficient of chlorido complexes 25 [Ru(η6-p-cym)(Anthimpy)Cl]PF6, 
32 [Ru(η6-bip)(Anthimpy)Cl]PF6 and 33 [Ru(η6-m-terp)(Anthimpy)Cl]PF6 were 
determined using the shaking flask method. These three complexes were selected 
with the aim of studying the effect of the changes of the arene group on the 
lipophilicity of the complexes and how this relates to their antiproliferative 
activity. They all include the same ligand (Anthimpy, 23) and the same leaving 
group (Cl). In the method used, 2 mM octanol-saturated aqueous solutions of the 
complexes were shaken with equal volumes of water-saturated octanol for 24 h. 
The amount of metal in the aqueous layer was determined by ICP-MS and the Log 
P values were calculated. Aqueous solutions were prepared including 150 mM of 
NaCl to avoid hydrolysis of the complexes. More details on this procedure can be 
found in Chapter 2. 
 
4.2.3.6 DNA interactions 
CT-DNA experiments were carried out in 10 mM phosphate buffer with 100 mM 
NaCl (for chlorido complexes) or 100 mM KI (for iodido complexes), at pH 7.5. 
In order to confirm that the CT-DNA was free from protein, a UV-VIS spectrum 
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was carried out in the phosphate buffer, giving an absorbance ratio of 1.92:1 at 
260 nm/280 nm. Its concentration was determined using the UV absorbance at 
260 nm and the known extinction coefficient at this wavelength (6600 dm3mol-
1cm-1).16 
CT-DNA Melting. Thermal denaturation of CT-DNA was recorded by measuring 
the absorbance at 260 nm while increasing the temperature between 323 and 368 
K. The melting curves of unruthenated and ruthenated CT-DNA were recorded 
using a fixed ratio of 1 : 5 Ru(II):CT-DNA (40 µM of the complex and 200 µM of 
CT-DNA). The value of the melting temperature (Tm) as the temperature when 
50% of the present double-stranded CT-DNA converts into single-stranded CT-
DNA was determined as the corresponding maximum on the first-derivative 
profile of the melting curves.  
CT-DNA Binding Kinetics. Solutions of CT-DNA at a concentration of 200 µM 
were incubated with Ru(II) arene complexes 24, 25, 27, 28, 32 and 33 using a 
fixed complex concentration of 40 µM. The solutions were stabilised for 5 min at 
ambient temperature before being incubated at 310 K. At various time intervals 
(ranging from 1h to 72 h), a sample aliquot was withdrawn from the incubator, 
quickly cooled on an ice bath, and precipitated by ethanol (in a final alcohol 
concentration of 70%). The content of ruthenium in the supernatant of these 
samples was determined by ICP-MS. The amount of bound metal was calculated 
subtracting the free metal determined by ICP-MS from the original metal 
concentration. 
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CT-DNA UV-Vis Titrations. UV-Vis spectra titrations were performed to 
determine the DNA-binding affinity of complexes 24, 25, 27, 28, 32 and 33. 
Experiments were carried out keeping fixed the concentration of the ruthenium(II) 
complexes (40 µM)  while varying the concentration of CT-DNA (0, 20, 40, 60, 
80, 100, 120, 160 and 200 µM) . The absorbance spectra were recorded after 10 
min of each addition. This data allowed the calculation of CT-DNA binding 
constants for complexes 24−33 using the equation 4.1:17,18 


=	

	
+	

	
	
	 −   Eq. 4.1 
 
Where A0 is the absorbance of the ruthenium complex on its own and A is the 
absorbance values in the presence of different concentrations of CT-DNA. The 
linear fitting of the plot A0/(A-A0)  vs 1/[CT-DNA] allowed the determination of 
the binding constant K. 
 
4.3 Results 
 4.3.1 Synthesis and characterization 
Iminopyridine ligands 19−23 shown in Table 4.1 below, were synthesised and 
characterised using 1H and 13C-NMR (1D, 2D experiments), ESI-MS, and 
elemental analysis.  1  2  3  4  
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5  6  7   8  9  10   11  
Table 4.1. Imine ligands studied in Chapter 4. 
 
 12  13   14  15   
16  17  18    
Ligands R1 
N
N
R1
 
19 Phimqn 
 
20 Anthimqn 
 
N
N
R1
 
21 Anthimpy 
 
22 Qnimpy N
 
23 Indoimpy 
.
N
H  
 
 
 
 
Once the proposed ligands were fully characterised, complexes 24−33 in Table 
4.2 were synthesised. They were characterised using the same techniques as for 
the ligands, 1H and 13C-NMR (1D, 2D experiments), ESI-MS, and elemental 
analysis,  as well as, ICP-MS for metal quantification. The structures proposed in 
the table below are consistent with all experimental data. 
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Table 4.2. Ruthenium(II) arene complexes studied in Chapter 4. 
 
 Complex Arene Ligand R1 X 
N
N
R1
Ru
X
PF6
 
24 
p-η6-cym 
Phimqn 
 
Cl 
25 
Anthimqn 
 
Cl 
26 I 
N
N
R1
Ru
X
PF6
 
27 
p-η6- cym 
Anthimpy 
 
Cl 
28 I 
29 
Qnimpy N
 
Cl 
30 I 
31 Indoimpy 
.
N
H
 
Cl 
PF6
N
N
Ru
Cl
Arene
 
32 η6-bip Anthimpy 
 
Cl 
33 η6-m-terp Anthimpy 
 
Cl 
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4.3.2 Aqueous solution chemistry 
Aquation of complexes 24−33 was followed using 1H-NMR of freshly prepared 
solutions of each complex in Tris buffer (pH 7.5). Each value represents the mean 
± SD for three independent NMR experiments at 310 K. Results are shown in 
Table 4.3. Extent of aquation of the complexes follow the order 29 > 25 > 31 > 30 
> 28 > 27 with values that vary between 43 and 5% of the complex forming the 
aqua product. Remarkably, complexes 24 and 26 do not appear to undergo 
aquation.  
 
Table 4.3. Extent of hydrolysis and extent 9-ethylguanine binding for complexes 
24−33 after 24 h, using freshly prepared solutions of each complex in tris buffer 
(pH 7.5) and a final ratio 1 : 1.25 for 9-EtG binding where the nucleobase was in 
excess.  
Compound 
% 
Aquationa 
% 9-EtG 
bindinga 
24 [Ru(η6-p-cym)(Phimqn)Cl]PF6 0 ± 3 0 ± 2 
25 [Ru(η6-p-cym)(Anthimqn)Cl]PF6 32 ± 3 0 ± 3 
26 [Ru(η6-p-cym)(Anthimqn)I]PF6 0 ± 2 8 ± 3 
27 [Ru(η6-p-cym)(Anthimpy)Cl]PF6 5 ± 2 13 ± 2 
28 [Ru(η6-p-cym)(Anthimpy)I]PF6 12 ± 3 0 ± 2 
29 [Ru(η6-p-cym)(Qnimpy)Cl]PF6 43 ± 2 38 ± 1 
30 [Ru(η6-p-cym)(Qnimpy)I]PF6 24 ± 4 16 ± 3 
31 [Ru(η6-p-cym)(Indoimpy)Cl]PF6 26 ± 3 5 ± 1 
a
 Each value represents the mean ± SD for three independent NMR 
experiments at 310 K. 
 
1H -NMR was also used to follow the complexes binding to 9-ethylguanine (9-
EtG) as a model for nucleobase binding. Table 4.3 also includes the extent of 
nucleobase adduct formation after 24 h. There is no clear trend that relate the 
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extent of aquation observed in the complexes with the extent of 9-EtG binding. 
Complexes 27, 29, 30  and 31 undergo aquation and subsequently they bind to the 
nucleobase model. However complexes 25 and 28 do not react with 9-EtG even 
though they can generate the aqua product. Particularly complex 24 does not 
undergo aquation nor binds to the nucleobase and complex 26 appears to undergo 
direct substitution, as it does not hydrolyse but forms  approximately 8% of 
nucleobase adduct. 
 
4.3.3 Antiproliferative activity 
4.3.3.1 IC50 determination in A2780, A549, HCT116,  
MCF7 cells 
Antiproliferative activity for ligands 19−23 and complexes 24−33 was determined 
using the SRB assay, this protocol is detailed in Chapter 2. For these experiments 
compounds with IC50 values (concentration at which 50% of cell growth is 
inhibited) above 100 µM are termed as inactive, while compounds with IC50 
values between 50 and 100 µM are moderately active. Values within the 15 - 50 
µM range define a compound as active while below this range, compounds are 
considered highly active. All ligands tested were inactive against the chosen cell 
lines under the conditions described. Their IC50 values are above 200 µM. All 
values reported in Table 4.4 were obtained as duplicates of triplicates in two 
independent experiments.  
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Table 4.4. Antiproliferative activity of ligands 19−23 and complexes 24−33 in 
A780, A549, HCT116 and MCF7 cell lines. IC50 is expressed as the concentration 
in which each ligand/complex causes 50% cancer cell growth inhibition. n/d = 
value not determined due to poor water solubility. 
    IC50 (µM) 
 Compound A2780 A549 HCT116 MCF7 
Ligands 
19 >200 >200 >200 >200 
20 n/d n/d n/d n/d 
21 n/d n/d n/d n/d 
22 >200 >200 >200 >200 
23 >200 >200 >200 >200 
RuII 
complexes 
24 15 ± 1 19 ± 1 17 ± 2 20.4 ± 0.9 
25 28 ± 3 56 ± 4 34 ± 2 28 ± 2 
26 1.56 ± 0.08 3.4 ± 0.8 2.7 ± 0.1 7.8 ± 0.4 
27 4.4 ± 0.7 24 ± 2 16 ± 2 6.9 ± 0.5 
28 1.7 ± 0.3 4.40 ± 0.09 2.6 ± 0.2 3.7 ± 0.5 
29 >200 >200 >200 >200 
30 156 ± 4 >200 180 ± 2 >200 
31 >200 >200 >200 >200 
32 9.2 ± 0.4 16 ± 1 23 ± 1 15.8 ± 0.4 
33 1.7 ± 0.3 8.3 ± 0.6 2.4 ± 0.2 2.7 ± 0.5 
 
 
    
 
Complexes 29, 30 and 31 are inactive in all cell lines tested, especially complexes 
29 and 31, as all their IC50 values are above 200 µM. Complexes 24 and 25 are 
considered active, showing their highest potency in ovarian cancer cells A2780. 
Finally, complexes 26, 27, 28, 32 and 33 are highly active in the four cell lines 
tested. Complexes 26, 28 and 33 show potency values equivalent to CDDP. 
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 4.3.3.2  IC50 Time dependence in A2780 cells 
The variation of IC50 values of complexes 24, 25, 26, and 27  in the A2780 cell 
line, after different exposure times was evaluated using the protocol described in 
Chapter 2. These data were compared to that of CDDP.  
 
 IC50 (µM) 
Exposure time (h) 8 h 24 h 48 h 72 h 
24 35 ± 1 15 ± 1 9.1 ± 0.8 9.3 ± 05 
25 30.2 ± 0.8 28 ± 1 26 ± 1 26 ± 1 
26 1.57 ± 0.09 1.56 ± 0.08 1.17 ± 0.07 1.02 ± 0.06 
27
 
10.1 ± 0.5 4.4 ± 0.7 7.62 ± 0.09 7.65 ± 0.09 
CDDP 1.42 ± 0.09 1.22 ± 0.08 1.16 ± 0.07 1.10 ± 0.09 
 
    
Figure 4.3. Dependence of IC50 value in A2780 cell line on time of exposure for 
complexes 24, 25, 26, and 27. In all cases the pre-incubation time was 48 h before 
adding the drugs, and the cell recovery time was 72 h in drug-free médium at 310 
K. 
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Results in Figure 4.3 indicate that there is no significant difference in the 
antiproliferative activity of the ruthenium(II) complexes after 24 h of drug 
exposure. Behaviour of complex 26 is very similar to that of CDDP, the IC50 
values do not change significantly over time. The same is true for complex 25. In 
the case of complex 24 there is a there is a big increase in potency between 8 h 
and 24 h, however the value stabilises after 48 h. A different behaviour is 
observed in complex 27, its IC50 value reaches a minimum value at 24 h but it 
loses potency in the two following time points (48 and 72 h).   
 
 4.3.3.3 Metal accumulation in cancer cells 
One time point, one concentration.  Total cellular accumulation of ruthenium 
for complexes 24−33 was determined in the A2780 ovarian cancer cell line in 
order to relate the amount of Ru accumulated to cytotoxicity and to compare with 
their hydrophobicity (Log P).  For these experiments drug exposure time was 24 h 
and cells were not allowed to recover. Values are expressed in ng of Ru per 
million cells and were determined as independent duplicates of triplicates. Results 
are shown in Table 4.5. Values determined for total cell accumulation follow the 
order 31 > 28 > 26 > 27 = 32 > 25 > 33 > 29 > 24 > 30, with values ranging from 
4.2 ng of ruthenium per 106 cells to 22 ng of the metal. This trend does not 
correlate to the IC50 values determined in the same cell line. Highly active 
complexes such as 24, with an IC50 value of 15 ± 1 µM only exhibits a low 
accumulation of ruthenium (6.19 ± 0.09 ng Ru x106 cells) while inactive complex 
31 (IC50 > 200 µM) shows the highest accumulation in the series (22 ± 1 ng Ru 
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x106 cells). It would indicate that, in this series of complexes, there is no direct 
correlation between potency and total cellular accumulation.  
 
Table 4.5. Total accumulation of Ru in A2780 cells for complexes 24−33 after 24 
h of drug exposure at 310 K with no recovery time, compared to their IC50 values 
in the same cell line.. 
Compound ng Ru x10
6
 
cells a 
IC50 (µM) 
24 [Ru(η6-p-cym)(Phimqn)Cl]PF6 6.19 ± 0.09 15 ± 1 
25 [Ru(η6-p-cym)(Anthimqn)Cl]PF6 9.1 ± 0.4 28 ± 3 
26 [Ru(η6-p-cym)(Anthimqn)I]PF6 11.7 ± 0.9 1.56 ± 0.08 
27 [Ru(η6-p-cym)(Anthimpy)Cl]PF6 10.9 ± 0.8 4.4 ± 0.7 
28 [Ru(η6-p-cym)(Anthimpy)I]PF6 17 ± 2 1.7 ± 0.3 
29 [Ru(η6-p-cym)(Qnimpy)Cl]PF6 6.7 ± 0.4 >200 
30 [Ru(η6-p-cym)(Qnimpy)I]PF6 4.2 ± 0.8 156 ± 4 
31 [Ru(η6-p-cym)(Indoimpy)Cl]PF6 22 ± 1 >200 
32 [Ru(η6-bip)(Anthimpy)Cl]PF6 10.9 ± 0.6 9.2 ± 0.4 
33 [Ru(η6-m-terp)(Anthimpy)Cl]PF6 8.5 ± 0.6 1.7 ± 0.3 
a
 Concentrations used were in all cases 1/3 x IC50 
 
4.3.3.4 Determination of partition coefficient (Log P) 
Partition coefficients of chlorido complexes 27, 32
 
and 33
 
were determined using 
the shaking flask method, as described in Chapter 2. These three complexes were 
selected with the aim of studying the effect of the changes of the arene group on 
the lipophilicity of the complexes. They all include the same N,N-chelating ligand 
(Anthimpy), and the same leaving group (Cl).To ensure that any of the complexes 
would not exist in the hydrolysed form during the experiments, 150 mM NaCl 
was added to the octanol-saturated water. Results are presented in Table 4.6. As 
expected, the Log P values of the complexes increase with increasing number of 
aromatic rings in the arene unit.  
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Table 4.6. Log P values for ruthenium complexes 27, 32
 
and 33 determined using 
the shaking-flask method. 
Compound Log P 
27 [Ru(η6-p-cym)(Anthimpy)Cl]PF6 0.53 ± 0.04 
32 [Ru(η6-bip)(Anthimpy)Cl]PF6 1.1 ± 0.4 
33 [Ru(η6-m-terp)(Anthimpy)Cl]PF6 3.71 ± 0.09 
  
 
4.3.3.5 DNA interactions 
CT-DNA Melting. Thermal denaturation of CT-DNA was carried out using 
active complexes 7, 8, 24, 25, 27, 28, 32 and 33 (complexes 7 and 8 from Chapter 
3 have been included for comparison purposes). Table 4.7 shows that the 
temperature in which 50% of the double stranded CT-DNA becomes single 
stranded is 335 K. There is a minor increase in melting temperature when co-
incubating the CT-DNA with complexes 7, 8 24 and 25. However there is no 
significant difference between each of the complexes. Highly active complexes 
27, 28, 32 and 33 increase the melting temperature of CT-DNA in a range 
between 20 and 30 K. 
CT-DNA Binding Kinetics. The kinetics of binding of complexes 7, 8, 24, 25, 
27, 28, 32 and 33 to CT-DNA were determined in cell-free media. The results are 
expressed as the percentage of bound ruthenium against time. Figure 4.4 shows 
that the percentage of metal bound to CT-DNA after incubation at 310 K follows 
the order 25 < 24 < 27 < 28 < 32 < 33. Highly active complexes 32 and 33 are the 
only ones that reach a percentage of bound ruthenium above 50%. Most of the 
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CT-DNA binding occurs within the first 10 h of reaction. Table 4.8 shows the 
values of the extent of CT-DNA binding after 48 h. 
Table 4.7. Tm (K) values for complexes 7, 8, 24, 25, 27, 28, 32 and 33. Melting 
curves of unruthenated and ruthenated CT-DNA were recorded using a fixed ratio 
of 1 : 5 Ru(II):CT-DNA (40 µM of the complex and 200 µM of CT-DNA). 
Compound Tm (K) 
7 [Ru(η6-p-cym)(Impy)Cl]PF6 342 ± 1 
8 [Ru(η6-p-cym)(Impy)I]PF6 342 ± 2 
24 [Ru(η6-p-cym)(Phimqn)Cl]PF6 342 ± 1 
25 [Ru(η6-p-cym)(Anthimqn)Cl]PF6 342 ± 3 
27 [Ru(η6-p-cym)(Anthimpy)Cl]PF6 352 ± 1 
28 [Ru(η6-p-cym)(Anthimpy)I]PF6 358 ± 1 
32 [Ru(η6-bip)(Anthimpy)Cl]PF6 355 ± 2 
33 [Ru(η6-m-terp)(Anthimpy)Cl]PF6 362 ± 1 
CT-DNA 338 ± 1  
 
 
Figure 4.4. CT-DNA Binding kinetics for complexes 7, 8, 24, 25, 27, 28, 32 and 
33 at 310K. Concentrations used were: CT-DNA 200 µM and Ru(II) complexes 
40 µM. The solutions were stabilised for 5 min at RT before incubating them at 
310 K. 
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 Table 4.8. Extent of Ru bound to CT-DNA from complexes 7, 8, 24, 25, 27, 28, 
32 and 33 after 48 h incubation at 310 K. Concentrations used were: CT-DNA 
200 µM and Ru(II) arene complexes 40 µM. 
Compound % bound Ru at 48 h 
24 [Ru(η6-p-cym)(Phimqn)Cl]PF6 35.1 ± 0.9 
25 [Ru(η6-p-cym)(Anthimqn)Cl]PF6 27.3 ± 0.8 
27 [Ru(η6-p-cym)(Anthimpy)Cl]PF6 42 ± 1 
28 [Ru(η6-p-cym)(Anthimpy)I]PF6 46.6 ± 0.7 
32 [Ru(η6-bip)(Anthimpy)Cl]PF6 51.2 ± 0.9 
33 [Ru(η6-m-terp)(Anthimpy)Cl]PF6 64.1 ± 0.9 
 
CT-DNA UV-Vis Titrations. UV-Vis titrations were used to determine the 
binding affinity of complexes 7, 8, 24, 25, 27, 28, 32 and 33 to CT-DNA. Table 
4.9 shows the binding constants determined. All binding constants are between 
1.4 and 17 x 105 M-1 and follow the order: 27 < 7 < 8 < 32 < 28 < 25 < 24 < 33. 
These values are within the reported range for complexes that intercalate into CT-
DNA.19,20 
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Table 4.9. CT-DNA binding constants for ruthenium complexes 7, 8, 24, 25, 27, 
28, 32 and 33 at 310 K. Concentrations used were: Ru(II) complexes 40 µM and  
CT-DNA 0, 20, 40, 60, 80, 100, 120, 160 and 200 µM. 
Compound Kb x 105 (M-1) 
7 [Ru(η6-p-cym)(Impy)Cl]PF6 1.6 
8 [Ru(η6-p-cym)(Impy)I]PF6 2.5 
24 [Ru(η6-p-cym)(Phimqn)Cl]PF6 8.0 
25 [Ru(η6-p-cym)(Anthimqn)Cl]PF6 7.2 
27 [Ru(η6-p-cym)(Anthimpy)Cl]PF6 1.4 
28 [Ru(η6-p-cym)(Anthimpy)I]PF6 2.8 
32 [Ru(η6-bip)(Anthimpy)Cl]PF6 2.7 
33 [Ru(η6-m-terp)(Anthimpy)Cl]PF6 17 
 
  
  
Chapter 4: Exploring DNA intercalation. 
166 
 
4.4 Discussion 
Ru(II) complexes 24-31 were designed to include in their structures an increasing 
number of aromatic units, by modification of the N,N-chelating ligand, this in 
order to increase the likelihood of DNA-intercalation. This approach to fine-
tuning the chemical and biological characteristics of metal complexes has been 
widely used previously with similar piano-stool structures.21–23 
The start of the series is complex 7, previously described in Chapter 3. From this 
starting point, an aromatic extension in the pyridine ring gives rise to complex 24, 
while complex 25 includes extra aromatic units in both, the pyridine and the 
phenyl ring. The latter modification can also be seen in complexes 27, 29 and 31.  
Data shown in Chapter 3 indicate that the cellular accumulation pathways used by 
chlorido complexes can be different from those involving iodido analogues. For 
this reason, this Chapter also included halogen exchange from Cl to I. This gives 
rise to complexes 8 (also reported in Chapter 3), 26, 28 and 30. 
Finally, complexes 32 and 33 are a modification of chlorido complex 27, in which 
the arene unit has been extended, this with the aim of correlating hydrophobicity 
and antiproliferative activity. A summary of the relation between the complexes 
investigated in this Chapter is shown in Figure 4.5. 
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Figure 4.5 Relationship between the complexes investigated in this Chapter. 
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considered as an undesirable reaction, as the aim of these complexes is to interact 
with DNA by means of intercalation and not of covalent binding. 
NMR was used to investigate the extent of aquation of complexes 24-31 after 24 
h. Similarly to the data in Chapter 3, aquation was confirmed by means of its 
inhibition with NaCl/KI and by comparison to the aqua specie generated after 
AgNO3 addition. The extent of 9-EtG binding was also investigated as a model for 
nucleobase interaction.  
Figure 4.6 shows that the extent of aquation follows the order: 24 = 26 < 27 < 28 
< 30 < 31 < 25 < 29 and varies between 0 and 43%. This order cannot be related 
to the number of aromatic rings present in the structure, not even taken into 
account the differences in the monodentate ligands. For example, iodido 
complexes seem to follow a trend in which the modification on the pyridine ring 
caused less aquation than the modifications in the phenyl ring, such trend is not 
true for chlorido complexes, as complex 25 exhibits the second highest extent of 
aquation (32 ± 3% ). 
Also the same figure shows that there is no clear trend that correlates the observed 
extent of aquation to the extent of nucleobase binding. Interestingly, complex 24 
[Ru(η6-p-cym)(Phimqn)Cl]PF6  does not undergo aquation nor does bind to 9-
EtG; the same is true for complex 26 [Ru(η6-p-cym)(Anthimqn)I]PF6 for which 
the extent of nucleobase binding is negligible (< 8%). These complexes, together 
with complex 25 [Ru(η6-p-cym)(Anthimqn)Cl]PF6 and 28 [Ru(η6-p-
cym)(Anthimpy)I]PF6 have good potential as DNA intercalators as their binding 
to guanine is poor, regardless of their aquation. 
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Complexes 24-31 were further studied after 48 and 72 h to confirm that there was 
no decomposition in water or arene loss as it has been reported for similar 
complexes.25,26 No variations were observed by NMR after this time. 
 
Figure 4.6. Comparison of the extent of aquation (left axis) and 9-EtG binding 
(right axis) of complexes 24-31 followed by 1H-NMR at 310 K. 
 
 4.4.2 Antiproliferative activity 
Antiproliferative activity of ligands 19, 22 and 23 and complexes 24-33 was 
investigated in ovarian, lung, colon and breast cancer. It is noticeable that all the 
ligands tested were inactive in the chosen cell lines, under the conditions 
described. Ligands 20 Anthimqn, and 21 Anthimpy were not tested due to poor 
water solubility. 
Complexes 29 - 31 are inactive in the four cell lines. Remarkably they all include 
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this heteroatom might be affecting the activity of these complexes. Comparing 
analogous complexes that vary only in their monodentate ligand (pairs 25 and 26, 
27 and 28, 29 and 30) it is observed that in all cases the iodido complexes are 
more active in all cell lines than the chlorido analogues. The highest improvement 
in potency is observed between complexes 25 and 26, which share the ligand 
Anthimqn, in A2780 ovarian cells where the IC50 decreases by a factor of 18. This 
has been previously observed in Chapter 3 with similar Ru(II) complexes. 
Results for time-dependence of IC50 values against time of exposure (Figure 4.3 
on page 140) indicate that for complexes 25 and 26 the optimum period for drug-
exposure is 24 h. However for complex 24 the highest potency is achieved after 
48 h with a drop of IC50 from 15 to 9.1 µM between 24 and 48 h. The most 
interesting behaviour was that of complex 27, which reaches its minimum IC50 at 
24 h, but this value increases again between 48 and 72 h. This observation can be 
explained by the activation of detoxification mechanisms within the cell allowing 
for higher cell survival. 
 
 4.4.2.1 Metal accumulation in cancer cells 
Metal accumulation in A2780 ovarian cells from complexes 24-33 was carried out 
in order to relate it to antiproliferative activity. Figure 4.7 and Figure 4.8 show 
that complexes with modifications on the N,N-chelating ligand do not accumulate 
in direct correlation to their potencies. Such observations have been previously 
reported for other related ruthenium arene complexes.3 Complexes 24-26 have 
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been modified to include a quinoline as part of the N,N-chelating ligand. The 
difference between complexes 24 and 25 is two extra aromatic units in the imine 
moiety (ligand Phimqn vs Anthimqn). As expected this results in higher cellular 
accumulation. However, this improved accumulation does not achieve better 
potency.  
 
 
Figure 4.7. Comparison of the cellular accumulation of Ru from complexes 24-26 
(left axis) and their antiproliferative activity (right axis). These complexes have in 
common the modification on the pyridine ring of the N,N-chelating ligand.  
 
Complexes 27-31 have been modified on the phenyl ring of the N,N-chelating 
ligand. This series include complex 31 [Ru(η6-p-cym)(Indoimpy)Cl]PF6 which 
shows the highest cellular accumulation (22 ± 1 ng of Ru per 106 cells) however it 
is inactive with an IC50 value > 200 µM. Another remarkable case is that of 
complexes 24 [Ru(η6-p-cym)(Phimqn)Cl]PF6 and 29 [Ru(η6-p-cym) 
(Qnimpy)Cl]PF6, both exhibit similar cellular accumulation (6.19 and 6.7 ng of 
Ru per 106 cells respectively) but the latter is inactive in A2780 cells while 
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complex 24 has an IC50 of 15 ± 1 µM. This indicates that the cytotoxic effects 
caused by complex 24 inside A2780 cells are more efficient than those caused by 
complex 29.  
Active complexes that include different monodentate ligands (Cl vs I), pairs 25, 
26 with ligand Anthimqn and 27, 28 with ligand Anthimpy have a common 
behaviour; in both cases the cellular accumulation of iodido analogue is higher 
than the chlorido analogues, with subsequent increased potency. 
 
 
Figure 4.8. Comparison of the cellular accumulation of Ru from complexes 27-31 
(left axis) and their antiproliferative activity (right axis). These complexes have all 
been modified on the phenyl ring of the N,N-chelating ligand.  
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accumulate in the same extent inside A2780 ovarian cells, nonetheless, there is a 
two-fold difference in their cytotoxic activities, which reflects the variation in 
efficacy of the cytotoxic pathways activated. Complex 33 [Ru(η6-m-
terp)(Anthimpy)Cl]PF6  which includes the most extended arene unit, terp, is the 
most active of this series, yet its cellular accumulation is only 8.5 ± 0.6  ng of Ru 
per 106 cells. 
 
 
 
Figure 4.9. Comparison of the cellular accumulation of Ru from complexes 27, 
32, 33 (left axis) and their antiproliferative activity (right axis). These complexes 
have in common the N,N-chelating ligand, the monodentate ligand, Cl and include 
variations on the arene unit. 
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the expected trend 27 < 32 < 33 in which the arene unit increases in the number of 
aromatic rings, p-cym < bip < m-terp. Nonetheless, the increased lipophilicity of 
complex 33 does not result in higher cellular accumulation. This indicates that the 
transport of these complexes into A2780 cells do not rely solely on passive 
diffusion of the complexes, for which higher hydrophobicity should mean higher 
accumulation.  
 
Figure 4.10. Comparison of the cellular accumulation of Ru from complexes 27, 
32, 33 (left axis) and their Log P values (right axis) determined using the shake 
flask method. 
 
4.4.2.2 DNA interactions 
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interaction of metal complexes with DNA. Intercalating complexes tend to 
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measuring the hyperchromicity of the absorption band at 260 nm.27 It can also be 
investigated by differential scanning calorimetry which measures the absorbance 
during denaturation.28 
In the present Chapter thermal denaturation has been investigated by means of 
UV-Vis spectroscopy. Figure 4.11 shows the melting temperatures (Tm, K) 
determined and compares them to the corresponding value for free CT-DNA. 
Complexes 27 [Ru(η6-p-cym)(Anthimpy)Cl]PF6, 28 [Ru(η6-p-cym) 
(Anthimpy)I]PF6, 32 [Ru(η6-bip)(Anthimpy)Cl]PF6 and 33 [Ru(η6-m-terp) 
(Anthimpy)Cl]PF6 cause most stabilization of the double helix with ∆Tm values 
varying from 20 – 30 K. This result is consistent with previous reports that 
indicate that increasing the number of aromatic rings in the complex increases the 
Tm value for CT-DNA.29 In particular Ru(II) complexes such as [(η6-m-
terp)Ru(en)Cl]PF6 have been reported to stabilize DNA by effects of the positive 
charge on the metal centre, as well as the interactions between the arene unit and 
the base-pairs of DNA.3 
In contrast complexes 7 [Ru(η6-p-cym)(impy)Cl]PF6, 8 [Ru(η6-p-cym) 
(impy)I]PF6 and 24 [Ru(η6-p-cym)(Phimqn)Cl]PF6 cause minimum variation to 
the Tm of CT-DNA (∆Tm = 4 K). This is expected for complexes that do not 
intercalate. Given the structure of these complexes, it is a reasonable result. 
Ru(III) complex Na[trans-RuCl4(DMSO)(Im)] is known to only cause slight 
stabilization of the double helix (∆Tm = 2 K).30 
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Figure 4.11. Comparison of the Tm (K) for CT-DNA when incubated with Ru 
complexes 7, 8, 24, 25, 27, 28, 32 and 33.  
 
Figure 4.12 compares the melting temperatures determined with the 
antiproliferative activity of the complexes in A2780 ovarian cancer cells. In this 
case there is a partial trend that correlates the extent of variation in Tm (K) to the 
cytotoxicity of the complexes in A2780 ovarian cells. Complexes 27, 28, 32 and 
33 which caused the highest ∆Tm values are the most active in the series, with IC50 
values varying from 9.2 to 1.7 µM. Remarkably, this trend is not always true for 
ruthenium complexes and depends greatly on the cell line.16 Polypyridyl Ru(II) 
complexes with general formula [(η6-C6Me6)Ru(XY)]Cl, where XY = dppz, dpq, 
dppn do not follow this trend. There is no correlation between their activity in 
MCF7 breast cancer cells or HT29 colon cancer cells and the  ∆Tm  values with 
CT-DNA.29 
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Figure 4.12. Comparison between the Tm (K) for CT-DNA when incubated with 
Ru complexes 7, 8, 24, 25, 27, 28, 32 and 33 (left axis) and the antiproliferative 
activity of the complexes in A2780 ovarian cells (right axis). 
 
Another possible correlation worth investigating is between melting temperatures 
and binding affinity of the complexes for CT-DNA. It has been reported that 
increasing ∆Tm values are related to increasing binding constants.31,32 However 
this is not the case for complexes 7, 8, 24, 25, 27, 28, 32 and 33 as Figure 4.13 
shows. One possible explanation relies on the different modes of intercalation. 
Complete DNA intercalation is not the only non-covalent binding possible. There 
are two extra modes for DNA interaction: semi-intercalation and quasi-
intercalation, both of which include partial intercalation of the aromatic unit 
between DNA base-pairs.33 These interactions can cause enough stabilization of 
the double-helix to generate a difference in the melting temperature, without 
exhibiting high affinity between the metal complex and the CT-DNA. 
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Figure 4.13. Comparison between the Tm (K) for CT-DNA when incubated with 
Ru complexes 7, 8, 24, 25, 27, 28, 32 and 33 (left axis) and their binding constants 
to CT-DNA (right axis). 
 
CT-DNA Binding Kinetics. The binding rate of complexes 7, 8, 24, 25, 27, 28, 
32 and 33 to CT-DNA was determined using a constant ratio of CT-DNA to 
Ru(II). Figure 4.4 shows that all complexes bind rapidly to CT-DNA, reaching 
equilibrium after the first 10 h of incubation. The half-times of these reactions are 
lower that the equivalent process for CDDP.3 It is interesting that only complexes 
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binding percentages above 50 after 48 h (Figure 4.14).  
Complex 33 includes in its structure m-terp as the arene. This polyaromatic unit 
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K).3 [(η6-m-terp)Ru(en)Cl]+ is considerably less active than complex 33 in A2780 
cells (42 ± 4 µM against 1.7 ± 0.3 µM) which indicates that the extent of metal 
binding to CT-DNA in cell-free media is not always directly proportional to the 
antiproliferative activity of the complexes, in contrast to the trend drawn by 
Figure 4.14. Interestingly, these results reflect only on the extent of intercalative 
binding between the Ru(II) complexes and CT-DNA, as the experiments are 
carried out in the presence of elevated NaCl concentrations which does not allow 
hydrolysis of the complexes and subsequent covalent binding to CT-DNA. 
Dinuclear Ru complexes that include in their structure the p-cymene unit such as 
{(η6-p-isopropyltoluene)RuCl[3-(oxo-κO)-2-methyl-4-pyridinonato-κO4]} have 
been reported to bind irreversibly to CT-DNA in cell-free media, reaching metal-
bound percentages between 60 and 75%.34 
 
Figure 4.14. Comparison between the Ru bound to CT-DNA from complexes 7, 
8, 24, 25, 27, 28, 32 and 33 (left axis) and their antiproliferative activities in 
A2780 ovarian cells (right axis). 
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CT-DNA Electronic Absorption Titrations. Binding interaction between 
complexes 7, 8, 24, 25, 27, 28, 32 and 33, and CT-DNA were monitored by UV-
Vis spectroscopy. In order to make sure that the interaction observed was indeed 
intercalation and not covalent binding, it was necessary to suppress the aquation 
of complexes 7, 25, 27, 28, 32 and 33. Figure 4.15 (A) shows the aquation of 
complex 7 followed by UV-Vis in the course of 24 h at 310 K. Section (B) of the 
same figure shows how this reaction is suppressed by the use of 150 mM of NaCl, 
the spectrum obtained 5 min after mixing the sample overlaps completely with 
that obtained after 24 h. The suppression of the aquation by 150 mM of NaCl was 
also followed by 1H-NMR. Finally section (C) in Figure 4.15 shows that there is 
no aquation of complex 24 over 24 h at 310 K.  
Intercalation of metal complexes into CT-DNA usually results in batochromism of 
charge transfer bands.17,18,35 This effect was observed in all the investigated Ru(II) 
arene complexes. Figure 4.16 shows the red-shift for complexes 7 (section A) and 
for complex 24 (section B) between 300 and 400 nm.  At these wavelengths the π∗ 
orbitals of the intercalated ligands could couple with the π orbital of the base 
pairs, thus decreasing the π-π∗ transition energy. Bathochromism as a result of 
intercalation of a ligand into the base pairs of DNA has been widely studied.9,20 
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Figure 4.15. UV-Vis spectra of (A) aquation of complex 7, (B) suppression of the 
aquation of complex 7 by addition of 150 mM of NaCl and (C) complex 24. All 
experiments were carried out over 24 h at 310 K.  
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Figure 4.16. CT-DNA titrations with ruthenium complexes 7 (A), and 24 (B). 
Concentrations used were: Ru(II) complexes 40 µM and  CT-DNA 0, 20, 40, 60, 
80, 100, 120, 160 and 200 µM. 
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these experiments the NaCl concentration (150 mM) was fixed in order to 
suppress aquation and avoid covalent binding after activation of the arene 
complexes. Table 4.9 on page 165 lists the binding constants determined; all the 
values are in the order of 105 M-1 in comparison to other Ru(II) intercalators such 
as Ru(phen)2(PHEHAT)2+ which have K values in the order of 106.19 
Figure 4.17 compares the binding constants for pairs of complexes. Complexes 7 
and 8 are related by their N,N-chelating ligand, impy. These complexes differ in 
the monodentate ligand (Cl vs I). The same is true for complexes 27 and 28 which 
share the ligand Anthimpy. In both cases the binding constant Kb for the iodido 
analogues is higher than that for the chlorido complexes.  
 
Figure 4.17. Comparison between the binding constants to CT-DNA of Ru 
complexes 7, 8, 24, 25, 27, 28, 32 and 33.  
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In the case of the pair 24 and 25, unexpectedly complex 25 exhibits a lower 
binding constant although it includes the Anthimqn ligand with a higher number 
of aromatic units.  There is a marked difference between the binding constants of 
complexes the pair 24, 25 and complex 33. This could be attributed to the 
extended planarity of the arene unit. Such differences between the intercalative 
interaction of all-carbon aromatics and those containing nitrogen atoms has been 
previously reported19,36 also the great importance of planarity in the intercalating 
ligand and its relation to the binding affinity has been investigated.31,37 
Figure 4.18 relates the antiproliferative activity of the Ru(II) arene complexes and 
the observed K values for CT-DNA. For the extreme values of the IC50, results 
seem to indicate that the potency of the complexes can be related to their ability to 
bind to CT-DNA. Inactive complex 7 has a low Kb value, while the contrary is 
true for complex 33, which is highly active and exhibits the highest Kb. However, 
the relation between the middle values is not as clear. This inconsistency could 
indicate that these Ru(II) complexes are indeed multitargeted and that 
intercalation to DNA is not their main molecular mechanism. Ruthenium 
complexes, such as [Ru(terpy)(bpy)Cl]Cl, cis-[Ru(bpy)2Cl2], and mer-
[Ru(terpy)C13] do not show correlations between their reactivity towards CT-
DNA and their antiproliferative activity.38  
Complexes 7, 8, 24, 25, 27, 28, 32 and 33 all contain a chiral metal centre. Each 
separate isomer of a chiral complex can interact differently with DNA.39–42 In the 
case of the present studies no attempt was made to separate the two isomers.  
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Figure 4.18. Comparison between the antiproliferative activity of Ru complexes 
7, 8, 24, 25, 27, 28 ,32 and 33 in A2780 ovarian cells (left axis) and their binding 
constants to CT-DNA (right axis). 
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ligands and complexes 29 [Ru(η6-p-cym)(Qnimpy)Cl]PF6, 31 [Ru(η6-p-
cym)(Indoimpy)Cl]PF6 were inactive in the cell lines tested, while complexes 26 
[Ru(η6-p-cym)(Anthimqn)I]PF6, 28 [Ru(η6-p-cym)(Anthimpy)I]PF6  and 33 
[Ru(η6-p-terp)(Anthimpy)Cl]PF6 exhibited the most promising potency with IC50 
values comparable to those of CDDP. Time dependence of the antiproliferative 
activity on the length of the expose time was also determined for complexes 24-
27. Drug-exposure period of 24 h was optimum for complexes 25 [Ru(η6-p-
cym)(Anthimqn)Cl]PF6 and 26 [Ru(η6-p-cym)(Anthimqn)I]PF6 as they reach their 
maximum potency at this time point. However, complex 24 [Ru(η6-p-
cym)(Phimqn)Cl]PF6 is favoured by a longer exposure time, achieving best results 
after 48 h of incubation.  
Cellular accumulation of complexes 24-33 was carried out in A2780 ovarian cells. 
The amount of Ru detected by ICP-MS ranges from 4.2 to 22 ng of the metal per 
106 cells. This indicates that all the complexes, including inactives 29 and 31 are 
able to reach intracellular spaces. There was no direct relation between cellular 
accumulation and the antiproliferative activity exhibited by the complexes. 
Complexes 27, 32 and 33 share the N,N-chelating ligand, Anthimpy and the 
monodentate ligand, Cl. However they differ in the number of aromatic units in 
the arene (p-cym, bip and m-terp respectively). Determination of the Log P values 
confirms that increasing the number of aromatic rings increases the 
hydrophobicity of the complexes, although there is no direct correlation between 
these values and cellular accumulation or antiproliferative activity. 
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The most important results in this Chapter refer to the ability of the Ru(II) 
complexes to interact with CT-DNA. Thermal denaturation of CT-DNA  was 
monitored by means of UV-Vis spectroscopy. Incubation with complexes 7, 8, 24 
and 25 caused a minimum change of the melting temperature of the CT-DNA, 
indicating that intercalation is not likely to occur. In contrast, complexes 27, 28, 
32 and 33 generated ∆Tm in the range of 20 – 30 K. The kinetics of CT-DNA 
binding in cell-free media was also investigated, in all cases the greatest extent of 
binding occurs during the first 10 h of incubation at 310 K. Only complexes 32 
and 33 achieve binding above 50%. Finally DNA titrations were used to 
determine the affinity of the Ru(II) complexes to bind to CT-DNA. UV-Vis 
experiments showed bathochromic shifts for charge-transfer absorption bands 
which is indicative of DNA intercalation. 
In general results indicate that although Ru(II) complexes synthesised in this 
Chapter interact with DNA mostly by means of intercalation, there is no direct 
correlation between these interactions and the antiproliferative activity exhibited 
by the complex. This supports the idea of piano-stool complexes being 
multitargeted, in this case DNA may well be one of the targets however it does 
not seem likely to be the principal target. 
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5.1 Introduction 
 
There has been an important advance in the understanding of the mechanism of 
action of cisplatin and other platinum drugs.1–7 However little is known on novel 
pathways followed by ruthenium or other transition metal complexes.8 This 
impairs rational design and further improvement of drugs, especially of metal-
based chemotherapeutics9,10 Ruthenium/osmium based drugs are most likely 
multi-targeted,11,12 which makes more difficult the study of the activation of 
cellular pathways that can lead to apoptosis.  
In the present study, the activation of hallmark biochemical events in intrinsic and 
extrinsic apoptotic pathways has been investigated with the aim of gaining insight 
into the mechanism of action of half-sandwich arene complexes. For this, 
complexes 15 [Ru(η6-p-cym)(p-Impy-NMe2)Cl]PF6, 16 [Ru(η6-p-cym)(p-Impy-
NMe2)I]PF6, 34 [Ru(η6-p-cym)(p-Azpy-NMe2)Cl]PF6, 35 [Ru(η6-p-cym)(p-Azpy-
NMe2)I]PF6, 36 [Os(η6-p-cym)(p-Impy-NMe2)Cl]PF6 and 37 [Os(η6-p-cym)(p-
Impy-NMe2)I]PF6 have been chosen. These compounds share important structural 
similarities and their differences will allow probing the impact of variation on 
activity and apoptosis mechanisms. The antiproliferative activity, metal 
accumulation and distribution of these complexes have been explored, as well as 
their effect on the cell cycle of A2780 ovarian cells. 
Clinical drawbacks of platinum chemotherapeutics, such as acquired resistance 
give ruthenium /osmium complexes a potential clinical advantage.7,13–15 Cisplatin 
cross-resistance in ovarian cancer cells has been evaluated in this Chapter as well 
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as oxaliplatin cross-resistance in colon carcinoma cells. Complexes 15, 16, 34−37 
have been tested for induction of apoptosis and activation of caspase 3. 
Interestingly, the mechanism of action of chlorido complexes seems to be very 
different from that of the iodido analogues, as the latter are p53-independent. 
Finally, cellular detoxification mechanisms have been explored, especially those 
involving GSH, thus case co-incubation of complexes 15, 16, 34−37 with L-BSO 
achieves nanomolar antiproliferative activities. Figure 5.1 presents an overview of 
the apoptotic pathways investigated in this Chapter. 
 
Figure 5.1. Overview of the apoptotic pathways investigated in Chapter 5. 
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5.2 Experimental section 
5.2.1 Materials 
Ruthenium(II) complexes 15 [Ru(η6-p-cym)(p-Impy-NMe2)Cl]PF6 and 16 [Ru(η6-
p-cym)(p-Impy-NMe2)I]PF6 have been described in Chapter 3 and the arene dimer 
[(η6-p-cym)RuCl2]2 in Chapter 2. Osmium(II) complexes 36  [Os(η6-p-cym)(p-
Impy-NMe2)Cl]PF6 and 37 [Os(η6- p-cym)(p-Impy-NMe2)I]PF6 as well as the 
ligand p-Azpy-NMe2 were kindly provided by Dr. Ying Fu.  
L-Buthionine-sulfoximine L-BSO (≥97%), auranofin (≥98%), aphidicolin from 
Nigrospora sphaerica (≥98%), etoposide (≥98%), novobiocin sodium and 
staurosporine were purchased from Sigma Aldrich. Propidium iodide (≥94%) and 
RNAse A for flow cytometry staining were also obtained from Sigma Aldrich 
together with the Annexin V-FITC Apoptosis Detection Kit for flow cytometry. 
Caspase activity was determined using the Caspase-3 Colorimetric Assay Kit 
from Cambridge Biosciences. Cell fractionation was carried out using 
FractionPREP kit from BioVision.  
 
5.2.2 Preparation of complexes  
 [Ru(η6-p-cym)(p-Impy-NMe2)Cl]PF6 [34]16. Ruthenium p-cymene dimer [(η6-p-
cymene)RuCl2]2 (50 mg, 0.05 mmol) was dissolved in methanol (5 mL), placed in 
a round bottom flask, and two mol equiv of the ligand p-Azpy-NMe2 were then 
added (23 mg, 0.10 mmol). The reaction mixture was left at ambient temperature 
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with constant stirring for 5 h. After this time 5 mol equiv of NH4PF6 were added 
to the mixture, which was left stirring for a further hour. The solid residue 
obtained was collected by filtration and recrystallised from ether (Yield 74%). 
Elemental analysis calc. for C24H28N4ClF6PRu, C: 45.05%, H: 2.21%, N: 8.76%. 
Found: C: 44.85%, H: 2.32%; N: 8.46%. NMR-δH (500 MHz; DMSO-d6) 0.87  
(6H, dd,  J = 23.93, 11.51, 6.66 Hz) 2.26 (3H, s) 2.31 (1H, m) 2.52 (3H, s)  6.02 
(1H, d, J = 5.75 Hz) 6.11 (2H, t, J = 11.51, 5.71 Hz) 6.32 (2H, d, J = 6.31 Hz) 6.99 
(2H, d, J = 9.09 Hz), 7.69  (1H, t, J = 11.8, 6.66 Hz) 8.17 (2H, d, J = 8.18 Hz) 8.29 
(1H, t, J = 14.24, 6.97 Hz) 8.39 (1H, d, J = 8.18 Hz) 9.41 (1H, d, J =  5.45 Hz). 
m/z (ESI) found 494.0 (calc. M+ C24H28N4ClRu = 494.92).  
[Ru(η6-p-cym)(p-Impy-NMe2)I]PF6 [35]16. Prepared as above, using 50 mg, 
(0.08 mmol) of [(η6-p-cymene)RuI2]2 and 37 mg, (0.16 mmol) of p-Azpy-NMe2 
Yield 68%. Elemental analysis calc. for C24H28N4 F6IPRu C: 39.42%, H: 1.93%, 
N: 7.66%. Found: C: 39.60%, H: 2.02%; N: 7.54%. NMR-δH (500 MHz; DMSO-
d6) 0.89 (6H, d,  J = 6.70  Hz) 2.51 (6H, s) 2.58 (3H, s) 3.00 (1H, m)  5.95 (1H, d, 
J = 7.31 Hz) 6.11 (2H, t, J = 13.8, 6.01 Hz) 6.31 (1H, d, J = 6.70 Hz) 6.95 (2H, d, 
J = 9.75 Hz), 7.60  (1H, t, J = 14.10, 6.70 Hz) 8.16 (2H, d, J = 9.14 Hz) 8.23 (1H, 
t, J = 15.24, 8.53 Hz) 8.43 (1H, d, J = 7.75 Hz) 9.37 (1H, d, J = 5.44 Hz). m/z 
(ESI) found 586.4  (calc. M+ C24H28N4IRu = 586.37).  
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5.2.3 Methods 
5.2.3.1 Antiproliferative activity  
The antiproliferative activity of complexes 15, 16, 34−37, (Table 5.1, on page 
197) were determined for A2780, A549, HCT116 and MCF7 carcinoma cell lines 
of ovarian, lung, colon and breast origin, respectively. They were also studied in 
A2780cis and HCT116Ox which are the corresponding CDDP and OXA resistant 
carcinoma cell lines, as well as HCT116p53-/- and MRC5, the former are 
modified HCT116 which have  knocked out the p53 tumour suppressor and the 
latter are human foetal lung fibroblasts. The experiments to determine IC50 values 
were carried out as described in Chapter 2. 
Briefly, 96-well plates were used to seed 5000 cells per well. The plates were left 
to pre-incubate in drug-free media at 310 K for 48 h before adding different 
concentrations of the compounds to be tested. In order to prepare the stock 
solution of the drug, the solid complex was dissolved first in DMSO to be then 
diluted in a 50:50 mixture of PBS : saline. A drug exposure period of 24 h was 
allowed. After this, supernatants were removed by suction and each well was 
washed with PBS (100 µL). A further 72 h was allowed for the cells to recover in 
drug-free medium (200 µL per well) at 310 K. The SRB assay was used to 
determine cell viability.  IC50 values, as the concentration which caused 50% of 
cell death, were determined as duplicates of triplicates in two independent sets of 
experiments and their standard deviations were calculated.  
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5.2.3.2 Metal accumulation in cancer cells 
Cell accumulation studies for complexes 15, 16, 34−37, were conducted on 
A2780 ovarian cells. Briefly, 4 x 106 cells were seeded on a Petri dish, after 24 h 
of pre-incubation time, the complexes were added to give final concentrations 
equal to IC50/3 and a further 24 h of drug exposure was allowed. After this time, 
cells were treated with trypsin, counted and cell pellets were collected. Each pellet 
was digested overnight in concentrated nitric acid (73%) at 353 K; the resulting 
solutions were diluted using double-distilled water to a final concentration of 5% 
HNO3 and the amount of ruthenium/osmium taken up by the cells was determined 
by ICP-MS. These experiments did not include any cell recovery time in drug-free 
media, they were all carried out in triplicate and the standard deviations were 
calculated. The statistical significance of all cellular accumulation values was 
determined using a two-sided t-test with P<0.05. More experimental details can be 
found in Chapter 2.  
 
5.2.3.3 Metal distribution in cancer cells 
In order to study metal distribution in A2780 cells for complexes 15, 16, 34−37, 
FractionPREP kit from BioVision was used according to the manufacturer's 
instructions. Briefly, 4 x 106 cells were seeded on a Petri dish. After 24 h of pre-
incubation time in drug-free media at 310 K, the complexes were added to give 
final concentrations equal to IC50/3 and further 24 h of drug exposure were 
allowed. Cells were treated with trypsin, counted and cell pellets were collected 
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after 5 min centrifugation at 2000 rpm, 277 K. Samples were re-suspended in the 
cytosol extraction buffer provided in the kit (CEB, 400 µL) and were kept on ice 
for 20 min to be centrifuged at 277 K for 10 min at 2000 rpm. Supernatants 
containing the cytosolic fractions were collected. Pellets were re-suspended in the 
membrane extraction buffers A (400 µL) and B (22 µL), also provided in the cell 
fractionation kit and vortexed for 1 min before being centrifuged at 277 K for 5 
min at 3400 rpm. Supernatants containing the membrane fractions were collected. 
Samples were re-suspended in the nuclear extraction buffer provided (NEB, 200 
µL) and kept on ice for 40 min. After this time, pellets were centrifuged at 12000 
rpm for 10 min. Supernatants containing the nuclear fractions were collected and 
the remaining pellets were kept as the cytoskeletal fractions. Samples were stored 
at 253 K until further analysis. 
Each sample was digested overnight in concentrated nitric acid (73%, 150 µL) at 
353 K; the resulting solutions were diluted with double-distilled water (to HNO3 
5%) and the amount of ruthenium/osmium taken up by the cells was determined 
by ICP-MS, as decribed in Chapter 2. These experiments were all carried out in 
triplicate and the standard deviations were calculated.  
 
5.2.3.4 Antiproliferative pathways and mechanism of action 
• Cell cycle analysis using flow cytometry 
Complexes 15, 16, 34−37, and CDDP were used to study their effects on the 
cycle of A2780 ovarian cells. For this, A2780 cells were seeded in a 6-well plate 
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using 1.5 x 106 cells per well. Cells were pre-incubated in drug-free media at 310 
K for 24 h, after which drugs were added using equipotent concentrations equal to 
IC50/3. After 24 h of drug exposure, supernatants were removed by suction and 
cells were washed with PBS (2 mL/well). Finally, cells were harvested using 
trypsin (0.5 mL/well). Samples were centrifuged to pellets at 1000 rpm for 4 min 
at 277 K. Cell pellets were washed with PBS (5 mL), re-centrifuged and the 
supernatant was removed. Cells were fixed for 2 h at 253 K using ice-cold ethanol 
(70%, 5 mL). DNA staining was achieved by re-suspending the cell pellets in 300 
µL of PBS containing 7.5 µM propidium iodide (PI) and 100 µg/mL of RNAse A.  
After staining cell pellets for 30 min at ambient temperature, they were 
centrifuged at 1000 rpm, 277 K for 5 min, the supernatants were removed by 
suction and discarded. Cell pellets were resuspended in PBS (5 mL) before being 
analysed by flow cytometry using the maximum excitation of PI-bound DNA at 
536 nm, and its emission at 617 nm. Data were processed using Flowjo software. 
Further studies on cell cycle were carried out using complex 16 [Ru(η6-p-cym)(p-
Impy-NMe2)I]PF6 and CDDP in order to determine the concentration dependence 
of the changes in the cell cycle. In these studies, A2780 cells were exposed to 
different concentrations of the compounds, including values below and above 
their IC50’s. Sample treatment was as described above. 
 
• p53-activated apoptotic pathway 
IC50 values for complexes 15, 16, 34−37  were determined in the HCT116p53-/- 
cell line which has the tumour suppressor p53 knocked-out. Briefly, a 96-well 
plate was seeded with 5000 A2780 cells per well. Cells were pre-incubated in 
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drug-free medium for 48 h at 310 K before adding the corresponding metal 
complex for a 24 h period of drug exposure. Afterwards, drugs were removed by 
suction, cells were washed with PBS (100 µL/well) and fresh medium was added 
to the plate (200 µL/well). Cells were allowed to recover in drug-free medium for 
72 h at 310 K. After this period of time, the SRB assay was used to determine cell 
viability. IC50 values were determined as duplicate of triplicates in two 
independent set of experiments and their standard deviations were calculated. 
 
• Induction of Apoptosis 
Flow cytometry analysis of apoptotic populations of A2780 cells caused by 
exposure to complexes 15, 16, 34−37, were carried out using the Annexin V-FITC 
Apoptosis Detection Kit. This kit, from Sigma Aldrich, was used according to the 
manufacturer's instructions. Briefly, A2780 cells were seeded in a 6-well plate 
using 1.5 x 106 cells per well. Cells were pre-incubated in drug-free medium at 
310 K for 24 h, after which drugs were added using equipotent concentrations of 
IC50/3. After 24 h of drug exposure, supernatants were removed by suction and 
cells were washed with PBS (2 mL/well). Finally cells were harvested using 
trypsin (0.5 mL/well). Samples were centrifuged to pellets at 1000 rpm for 4 min 
at 377 K. Cell pellets were washed with PBS (1 mL), re-centrifuged and the 
supernatant was removed by suction. In this case, cell pellets were re-suspended 
in 500 µL of binding buffer containing Annexin V FITC conjugate (50 mg/mL in 
50 mM Tris-HCl, pH 7.5, containing 100 mM NaCl) and  a PI solution (100 
mg/mL in 10 mM potassium phosphate buffer, pH 7.4, containing 150 mM NaCl). 
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After staining cell pellets for 10 min at ambient temperature, they were washed in 
PBS (2 mL) before being analysed in a Becton Dickinson FACScan Flow 
Cytometer. For positive-apoptosis controls A2780 cells were exposed for 2 h to 
staurosporine (1 µg/mL). Cells for apoptosis studies were used with no previous 
fixing procedure as to avoid non-specific binding of the annexin V-FITC 
conjugate. Data were processed using Flowjo software. 
Further studies on cell apoptosis were carried out using complex 16 [Ru(η6-p-
cym)(p-Impy-NMe2)I]PF6. In these studies, A2780 cells were exposed to different 
concentrations of the compound, including values below and above its IC50 in 
order to investigate the effect of the concentration of the drug on the extent of 
apoptosis observed. Sample treatment was as described above. 
 
• Caspase 3 apoptotic pathway 
Colorimetric analysis of caspase 3 activation caused on A2780 ovarian cells by 
exposure to complexes 15, 16, 34−37 was carried out using the Caspase-3/CPP32 
Colorimetric assay Kit and used according to the manufacturer's instructions. 
Briefly, A2780 cells were seeded in a 6-well plate using 1.5 x 106 cells per well. 
Cells were pre-incubated for 24 h in drug-free media at 310 K, after which drugs 
were added using equipotent concentrations of IC50/3. After 24 h of drug 
exposure, supernatants were removed by suction and cells were washed PBS (2 
mL/well), finally cells were harvested using trypsin (0.5 mL/well). Samples were 
centrifuged to pellets at 1000 rpm for 4 min, 277 K. Cell pellets were washed with 
PBS (1 mL), re-centrifuged and the supernatant was removed by suction. In this 
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case cell pellets were re-suspended in cold lysis buffer (50 µL) provided in the kit. 
Cells were kept on ice for 10 min and then centrifuged at 10.000 g for 1 min at 
277 K. The supernatants were collected in clean tubes and put on ice. To each 
sample cell lysis buffer, 2X reaction buffer (50 µL of each) and 5 µL of DEV-
pNA substrate were added before incubating them for 2 h at 310 K. The resulting 
solutions were read in an absorbance plate reader at 410 nm. Samples were 
analysed in triplicate, and the standard deviations were calculated. For positive 
activation of caspase 3 A2780 cells were exposed to staurosporine (1 µg/mL) for 2 
h. 
 
• DNA replication 
IC50 modulation experiments for complexes 15, 16, 34−37 by the inhibition of 
DNA polymerase α and topoisomerase II were performed using the protocol 
previously described for IC50 determination with the following modifications. 
Briefly, a 96-well plate was seeded with 5000 A2780 ovarian cells per well. Cells 
were pre-incubated in drug-free medium for 48 h at 310 K, before adding the 
metal complexes together with the appropriate co-incubating agent (aphidicolin, 
novobiocin or etoposide). In order to prepare the stock solution of the drug, the 
solid complex was dissolved first in DMSO to be then diluted in a 50:50 mixture 
of PBS : saline. Separately, a stock solution of the co-incubation agent was 
prepared in saline. Both solutions were added to each well independently, but 
within 5 min of each other. 
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 After 24 of exposure, drugs were removed by suction, cells were washed with 
PBS (100 µL per well) and fresh medium was added to the plate (200 µL per 
well). Cells were allowed to recover in drug-free medium for 72 h at 310 K. At 
the end of this period, the SRB assay was used to determine cell viability. IC50 
values, as the concentration which caused 50% of cell death, were determined as 
duplicates of triplicates in two independent set of experiments and their standard 
deviations were calculated. In all the experiments that involved modulation of 
IC50 values, the set up included two different negative controls; number 1 is 
untreated, while number 2 is treated only with the co-incubating agent. These 
controls are in place to make sure that the dose of the co-incubating agent is non-
toxic. Their value was always within 5% difference to the negative control 1. The 
statistical significance of all cellular accumulation values was determined using a 
two-sided t-test with P<0.05. 
• Inhibition of DNA polymerase α - co-incubation with aphidicolin: 1 
µM, 5 µM or 10 µM of aphidicolin was used for co-incubation with 
complexes 15, 16, 34−37 (see aphicolidin structure in Figure 5.28 on page 
253). 
• Inhibition of topoisomerase II - co-incubation with Novobiocin and 
Etoposide: Complexes 15, 16, 34−37  were also coincubated with 5 µM 
of novobiocin, and separatedly with 10 µM of etoposide (see novobiocin 
structure in Figure 5.30 on page 256 and etoposide structure in Figure 5.29 
on page 255). 
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• Cellular detoxification mechanisms 
The possible involvement of GSH and thioredoxin reductase in modulating IC50 
values was investigated by using the protocol described in the above section (see 
DNA replication) with the following modifications.  
• Interaction with GSH: complexes 15, 16, 34−37 were co-incubated with 
L-BSO 1 µM, 5 µM or 50 µM. (see L-BSO structure in Figure 5.31 on 
page 258).  
• Interaction with thioredoxin reductase: complexes 15, 16, 34−37 were 
coincubated with 0.1 µM auranofin. 
 
5.3 Results 
5.3.1 Synthesis and characterization 
Ruthenium(II) complexes 15, 16, 34, 35 and osmium(II) complexes 36 and 37 
shown in Table 5.1, were synthesised and characterised using NMR, ESI-MS and 
elemental analysis as well as ICP-MS for metal quantification. The purity of the 
compounds by elemental analysis was in all cases ≥ 95%.  
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Table 5.1. Complexes investigated in Chapter 5. 
N
YN
M
X
N
PF6
 
 
Compound M X Y 
15 [Ru(η6-p-cym)(p-Impy-NMe2)Cl]PF6 Ru Cl C 
16 [Ru(η6-p-cym)(p-Impy-NMe2)I]PF6 
1718192021222324252627282930313233 
Ru I C 
34 [Ru(η6-p-cym)(p-Azpy-NMe2)Cl]PF6 Ru Cl N 
35 [Ru(η6-p-cym)(p-Azpy-NMe2)I]PF6 Ru I N 
36 [Os(η6-p-cym)(p-Impy-NMe2)Cl]PF6 Os Cl C 
37 [Os(η6-p-cym)(p-Impy-NMe2)I]PF6 Os I C 
    
 
 
5.3.2 Antiproliferative activity 
Complexes 15, 16, 34−37 were tested in A2780, A549, HCT116 and MCF7 
carcinoma cells, IC50 values determined are shown in Table 5.2. All arene 
complexes investigated  are highly active in all parental cell lines (IC50 values < 
17 µM), especially azopyridine iodido ruthenium complex  35 [Ru(η6-p-cym)(p-
Azpy-NMe2)I]PF6 which exhibits sub-micro molar activity in A2780 and MCF7 
cell lines and is, in all cases, more potent than CDDP. 
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Table 5.2. Antiproliferative activity of complexes 15, 16, 34−37, CDDP and 
OXA in A2780, A549, HCT116 and MCF7 cell lines. n/d = not determined. 
N
YN
M
X
N
PF6
 
Compound IC50 (µM) 
 M X Y A2780 A549 HCT116 MCF7 
15 Ru Cl C 16.2 ± 0.9 10.5 ± 0.8 3.4 ± 0.4 12.1 ± 0.3 
16 Ru I C 3.0 ± 0.2 15.3 ± 0.9 8.6 ± 0.8 4.4 ± 0.3 
34 Ru Cl N 13.1 ± 0.5 15 ± 1 16.7 ± 0.8 11.9 ± 0.9 
35 Ru I N 0.69 ± 0.04 1.27 ± 0.01 1.37 ± 0.04 0.8 ± 0.1 
36 Os Cl C 3.0 ± 0.4 15.8 ± 0.2 3.26 ± 0.05 9.3 ± 0.6 
37 Os I C 1.20 ± 0.02 3.31 ± 0.6 1.6 ± 0.1 1.2 ± 0.2 
 CDDP 1.2 ± 0. 2 3.3 ± 0.1 5.1 ± 0.3 7.4 ± 0.2 
 OXA n/d n/d 3.99 ± 0.08 n/d 
 
It is noticeable that in A2780 and MCF7 cells, both female cancers, all iodido 
complexes are more than 10X more active than their chlorido analogues. Osmium 
iodido complex 37 [Os(η6-p-cym)(p-Impy-NMe2)I]PF6 is as active or better than 
CDDP in all cell lines tested.   
Antiproliferative activity of complexes 15, 16, 34−37 was also investigated in 
resistant cell lines, A2780cis (CDDP resistant) and HCT116Ox (OXA resistant) 
and MRC5 human embryonal lung fibroblasts (non-cancerous cells). These results 
are shown in Table 5.3. In the case of resistant cell lines A2780cis and HCT16Ox, 
all iodido complexes 16, 35 and 37 retain the activity previously observed in 
parental cell lines. In contrast, chlorido complexes 15, 34 and 36 lose their 
  
Chapter 5: Mechanisms of action 
208 
 
potency in A2780 cells resistant to cisplatin. All complexes exhibit higher IC50, 
values in MRC5 human fibroblasts than in any cancer cell line, between 8 and 
30X improvement in comparison to A2780 cells.  
 
Table 5.3. Antiproliferative activity of complexes 15, 16, 34−37, CDDP and 
OXA in A2780cis, HCT116Ox and MRC5 cell lines.  n/d = not determined. 
 IC50 (µM) 
Compound A2780cis HCT116Ox MRC5 
15 [Ru(η6-p-cym)(p-Impy-NMe2)Cl]PF6 52 ± 1 77.7 ± 0.9 190 ± 3 
16 [Ru(η6-p-cym)(p-Impy-NMe2)I]PF6 3.3 ± 0.6 8.8 ± 0.7 89 ± 2 
34 [Ru(η6-p-cym)(p-Azpy-NMe2)Cl]PF6 27.5 ± 0.9 1.18 ± 0.09 112 ± 8 
35 [Ru(η6-p-cym)(p-Azpy-NMe2)I]PF6 0.60 ± 0.03 0.75 ± 0.01 18.2 ± 0.7 
36 [Os(η6-p-cym)(p-Impy-NMe2)Cl]PF6 12.97 ± 0.07 3.6 ± 0.3 53.7 ± 0.8 
37 [Os(η6-p-cym)(p-Impy-NMe2)I]PF6 1.27 ± 0.06 1.10 ± 0.08 31.9 ± 0.5 
 CDDP 11.5 ± 0.3 n/d 16.2 ± 0.6 
 OXA n/d 32.2 ± 0.5 n/d 
 
 
5.3.3 Metal accumulation in cancer cells 
Total cellular accumulation of Ru/Os for complexes 15, 16, 34−37 was 
determined in A2780 cells in order to relate metal content to cytotoxicity. Values 
are expressed as ng of ruthenium/osmium per million cells and were determined 
as independent duplicates of triplicates.  
Results are shown in Table 5.4. In the case of chlorido complexes 15, 34 and 36, 
their potency improves as their cellular accumulation increases. This trend is not 
observed for iodido complexes 16, 35 and 37.  Cellular accumulation of Ru from 
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complex 35 is similar to Os accumulation from complex 37 (both approximately 
15 ng of metal per 106 cells), however there is a significant difference in their IC50 
values (13.1±0.5 for complex 35 and 3.0 ± 0.4 for complex 37). 
 
Table 5.4. Total accumulation of Ru/Os in A2780 cells for complexes 15, 16, 
34−37 after 24 h of drug exposure at 310 K and no recovery time in drug-free 
media, together with their IC50 values. Concentrations used were equipotent, in all 
cases IC50/3. 
N
YN
M
X
N
PF6
 
Compound Cell accumulation 
(ng Ru/Os x 106 cells) 
IC50 
(µM) 
 M X Y 
15 Ru Cl C 7.8 ± 0.5 16.2 ± 0.9 
16 Ru I C 11.5 ± 0.8 3.0 ± 0.2 
34 Ru Cl N 13.4 ± 0.9 13.1 ± 0.5 
35 Ru I N 17.9 ± 0.8 0.69 ± 0.04 
36 Os Cl C 15.2 ±0.9  3.0 ± 0.4 
37 Os I C 18.1 ± 0.1 1.20 ± 0.02 
      
 
 
5.3.4 Metal distribution in cancer cells 
Metal distribution studies were carried out for complexes 15, 16, 34−37 in A2780 
cells.  The experiment allowed the separation of four cellular fractions: firstly, the 
cytosolic fraction which contains the total of soluble proteins from the cytoplasm, 
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secondly, the membrane fraction which included all membrane proteins plus all 
cellular organelles and its membranes. Thirdly, the nuclear fraction containing the 
total of nucleus soluble proteins and the nuclear membrane proteins and finally 
the cytoskeletal fraction that includes the total cellular insoluble proteins and 
genomic DNA. Figure 5.2 shows that all arene complexes 15, 16, 34−37 
accumulate to a high extent in the membrane fraction. However the percentages 
for iodido complexes 16 [Ru(η6-p-cym)(p-Impy-NMe2)I]PF6, 35 [Ru(η6-p-
cym)(p-Azpy-NMe2)I]PF6 and 37 [Os(η6-p-cym)(p-Impy-NMe2)I]PF6 are higher 
than that for their chlorido analogues 15 [Ru(η6-p-cym)(p-Impy-NMe2)Cl]PF6, 34 
[Ru(η6-p-cym)(p-Azpy-NMe2)Cl]PF6 and 36 [Os(η6-p-cym)(p-Impy-
NMe2)Cl]PF6.   
It is also notable that although second highest concentration of ruthenium/osmium 
for chlorido complexes 15, 34 and 36 is found in the cytosol, there is no 
significant amount of metal in this fraction for iodido complexes 16, 35 and 37. 
Concentrations of metal accumulated in the nuclear and cytoskeletal fraction are 
also higher for the chlorido complexes 15, 34 and 36 than for the iodido analogues 
16, 35 and 37. 
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Compound % Cell accumulation  
 M X Y Cyt.a Memb.b Nucl.c  Cytosk.d 
15 Ru Cl C 12.7 ± 0.8 73 ± 1 8.2 ± 0.6 5.8 ± 0.9 
16 Ru I C 2.2 ± 0.3 88 ± 2 4.8 ± 0.9 4.1 ± 0.7 
34 Ru Cl N 11.5 ± 0.6 79 ± 1 4.0 ± 0.5 4.8 ± 0.3 
35 Ru I N 1.12 ± 0.08 91 ± 2 2.9 ± 0.4 3.9 ± 0.8 
36 Os Cl C 6.8 ± 0.7 84 ± 1 4.8 ± 0.9 4.3 ± 0.2 
37 Os I C 1.7 ± 0.8 91 ± 2 3.8 ± 0.4 3.1 ± 0.1 
 
Figure 5.2. Distribution of metal for complexes 15, 16, 34−37 in A2780 ovarian 
cells. Concentrations used in all cases were IC50/3, pre-incubation time in drug-
free medium was 24 h and drug exposure time was 24 h. a Cyt. = cytosolic 
fraction (total soluble proteins from cytoplasm) b Memb. = Membrane fraction 
(membrane proteins, cellular organelles and organelles membranes) c Nucl. = 
Nuclear fraction (total nucleus soluble proteins and nuclear membrane proteins) d 
Cytosk. = cytoskeletal fraction (total cellular insoluble proteins and genomic 
DNA). 
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5.2.3.4 Antiproliferative pathways and mechanism of action 
• Cell cycle analysis using flow cytometry 
Complexes 15, 16, 34−37 and CDDP were incubated in A2780 ovarian cells to 
study their effects on the cell cycle (See cell cycle scheme in Figure 5.22 on page 
242). For this task, cells were stained using PI (Figure 5.3) as a fluorescent probe 
that interacts with DNA through intercalation.17 The fluorescence emitted by PI is 
greatly enhanced (20−30 fold) when it is bound to nucleic acids allowing a 
sensitive method for DNA quantification. Since PI is membrane-impermeant, it is 
necessary to fix the cells with cold ethanol before the staining takes place, this 
treatment ensures that the dye enters intracellular compartments. Moreover, PI can 
also interact with RNA, which could cause false DNA readings. To avoid such 
interference, cells were also treated with RNAse.  
Data obtained by flow cytometry were analysed using Flowjo software. For all 
experiments, data were gated using a forward scatter vs side scatter plot (FSC vs 
SSC plot) before obtaining histograms for the FL2-H channel (which is used to 
read PI fluorescence). Examples of these histograms are shown in Figure 5.4. 
N+ N+
CH3
CH3
CH3
NH2
NH2
I-
I-
 
Figure 5.3. Structure of propidium iodide (PI) 
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Figure 5.4. FL2-H histograms obtained by flow cytometry for cell cycle analysis 
(A) Control untreated cells; (B) Cells treated using 1 µM of complex 16; (C) Cells 
treated using 0.4 µM of CDDP; For all experiments, drug exposure time was 24 h, 
cells were treated with RNAse and stained using PI. 
 
By comparison to the control population, data in Figure 5.5 clearly show that 
CDDP causes cell cycle arrest in the S phase. The population in this phase 
increases after 24 h of exposure to the platinum drug (from 21.0 ± 0.6% for the 
control versus 25.2 ± 0.6%), together with a significant reduction of the 
population in G1 phase (from 59.9 ± 0.9% to 47.2 ± 0.2%). In contrast, the half-
sandwich arene complexes cause arrest in the G1 phase regardless of the nature of 
their metal centre (Ru/Os) or the monodentate ligand (Cl/I). Ruthenium chlorido 
complexes 15 and 34 generate a slightly higher population in the G1 phase 
compared to their iodido analogues 16 and 35. Interestingly, Impy-NMe2 
complexes 15 and 16 cause the S phase population to double the G2/M population 
(12.7 ± 0.9% and 14 ± 1% in S phase for 15 and 16 respectively, versus 6.5 ± 
0.8% and 6.3 ± 0.7%). In contrast, Azpy-NMe2 34 and 35 complexes do not cause 
this effect and their G2/M and S phase populations are not significantly different.   
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Compound Cell cycle phase 
 M X Y G1 G2/M S 
15 Ru Cl C 80.3 ± 0.7 6.5 ± 0.8 12.7 ± 0.9 
16 Ru I C 78.6 ± 0.8 6.3 ± 0.7 14 ± 1 
34 Ru Cl N 73 ± 1 11 ± 1 13.2 ± 0.5 
35 Ru I N 69.7 ± 0.9 10.7 ± 0.9 10.3 ± 0.9 
36 Os Cl C 77.8 ± 0.8 9 ± 1 11.9 ± 0.4 
37 Os I C 78.4 ± 0.9 10.9 ± 0.8 9.7 ± 0.4 
CDDP 47.2 ± 0.2 26.2 ± 0.4 25.2 ± 0.6 
Control 59.9 ± 0.9 18.5 ± 0.9 21.0 ± 0.6 
 
Figure 5.5. Cell cycle analysis carried out by flow cytometry using PI staining 
after exposing A2780 cells to complexes 15, 16, 34−37 and CDDP. 
Concentrations used in all cases were IC50/3, pre-incubation time in drug-free 
medium was 24 h and drug exposure time was 24 h.  
Further studies were carried out using ruthenium Impy complex 16 and CDDP to 
study the effect of drug concentrations on the cell cycle. Data obtained for these 
experiments are shown in Figure 5.6.  
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  Cell cycle phase 
Compound Concentration  
(µM) G1 G2/M S 
16 
 
1 64.2 ± 0.6 21.9 ± 0.4 14.5 ± 0.8 
3 66.4 ± 0.1 19.5 ± 0.5 14.0 ± 0.6 
9 65.6 ± 0.8 21.4 ± 0.6 12.9 ± 0.5 
CDDP 
0.4 51.1 ± 0.3 32.6 ± 0.8 16.5 ± 0.6 
1.2 43 ± 1 33.2 ± 0.5 22 ± 1 
3.6 31.2 ± 0.4 23.9 ± 0.9 44 ± 2 
Control 0 59.9 ± 0.9 18.5 ± 0.9 21.0 ± 0.6 
 
Figure 5.6. Cell cycle analysis carried out by flow cytometry using PI staining 
after exposing A2780 cells to complex 16 and CDDP. Concentrations used were 
1, 3 and 9 µM for complex 16 and 0.4, 1.2 and 3.6 µM for CDDP. Pre-incubation 
time in drug-free medium was 24 h and drug exposure time was 24 h. 
 
It is observed that the CDDP cell cycle arrest in S phase is concentration-
dependent. The population in the G1 phase decreases with increasing drug 
concentration (from 51.1 ± 0.3% at 0.4 µM to 31.2 ± 0.4% at 3.6 µM CDDP). At 
the same time, the S phase population increases (from 16.5 ± 0.6% at 0.4 µM to 
44 ± 2% at 3.6 µM CDDP).  As shown above, iodido ruthenium complex 16 
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arrests the cell cycle in the G1 phase. However this effect does not seem to 
depend on the concentration of the drug used. Samples exposed to concentrations 
above the IC50 (9 µM) exhibit approximately the same proportion of population in 
the cell cycle phases than those cells exposed to concentrations below the IC50 (1 
µM). For example, the G1 phase population is 65.6 ± 0.8% at 9 µM, a 
concentration three times higher than the IC50, and 64.2 ± 0.6% at 1  µM, which is 
three times lower than the IC50. The same observation is true for the population in 
the G2/M phase (21.9 ± 0.4% at 9 µM and 21.4 ± 0.6% at at 1 µM). 
 
• p53-activated apoptotic pathway 
Antiproliferative activity for complexes 15, 16, 34−37 was determined using the 
SRB assay18,19 on HCT116 cells as well as their derived cell line HCT116p53-/- 
which has knocked-out tumour suppressor p53 a regulator of the cell cycle. Table 
5.5 shows that the antiproliferative activity of chlorido complexes 15, 34 and 36 
decreases significantly, especially ruthenium p-Impy-NMe2 complex 15, as its 
IC50 value increases a twenty-fold (from 3.4 ± 0.4 µM to 69.9 ± 0.9 µM) 
compared to the wild-type HCT116. On the contrary, ruthenium iodido complexes 
16, 35 and osmium iodido complex 37  retain their potency in the p53 mutant cell 
line at the same level as in the parental cell line HCT116. 
 It is remarkable that the differences in the IC50 values for complexes 15, 16, 
34−37 seem to be associated with the halogen used as monodentate ligand and not 
to the nature of the metal centre nor the N,N-chelating ligand. It is also remarkable 
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that the IC50 value for CDDP in HCT166p53-/- is 36.7 ± 0.3 µM was five times 
that for the parental cell line (5.1 ± 0.3 µM). Similar results are obtained for OXA, 
for which the decrease in potency is higher than twenty-five fold as its IC50 in the 
p53-knock out cell line is above 100 µM.  
 
Table 5.5. Antiproliferative activity of complexes 15, 16, 34−37, CDDP and 
OXA in HCT116 parental cell line and modified HCTp53-/-.  
 IC50 (µM) 
Compound HCT116 HCT116p53-/- 
15 [Ru(η6-p-cym)(p-Impy-NMe2)Cl]PF6 3.4 ± 0.4 69.9 ± 0.9 
16 [Ru(η6-p-cym)(p-Impy-NMe2)I]PF6 8.6 ± 0.8 8.73 ± 0.05 
34 [Ru(η6-p-cym)(p-Azpy-NMe2)Cl]PF6 16.7 ± 0.8 38 ± 1 
35 [Ru(η6-p-cym)(p-Azpy-NMe2)I]PF6 1.37 ± 0.04 1.59 ± 0.04 
36 [Os(η6-p-cym)(p-Impy-NMe2)Cl]PF6 3.26 ± 0.05 21.5 ± 0.8 
37 [Os(η6-p-cym)(p-Impy-NMe2)I]PF6 1.6 ± 0.1 1.12 ± 0.07 
 CDDP 5.1 ± 0.3 36.7 ± 0.3 
 OXA 3.99 ± 0.08 > 100 
 
• Induction of Apoptosis 
Flow cytometry was also used to investigate the extent of apoptosis caused by 
complexes 15, 16, 34−37. Phosphatidylserine is a phospholipid component that is 
found on the internal/cytosolic side of the membrane in healthy cells. However, in 
early stages of apoptosis there is a loss of phospholipid asymmetry and 
phosphatidylserine is translocated to the outer side of the membrane.20 There it is 
exposed to annexin V which in this case has been modified to include the FITC 
fluorescent probe shown in Figure 5.7. 
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Figure 5.7. Structure of fluorescein isothiocyanate (FITC) 
 
The binding of annexin V-FITC to phosphatidylserine is calcium-dependent. 
Hence the cells were not treated with trypsin-EDTA (only trypsin) when 
preparing the pellets. The binding buffer used in this experiment contains calcium 
and magnesium for the same reason. In the last stages of apoptosis, the integrity of 
the cellular membrane is compromised, allowing for PI (which is normally 
membrane impermeant) to enter the cell and bind to DNA. 
Flow cytometry was used to monitor the fluorescence emitted by the FITC 
conjugate at the same time as the PI, making it possible to distinguish four sets of 
populations: viable cells, early and late apoptotic cells and non-viable cells. For 
all experiments, data were gated using a forward-scatter vs side-scatter plot (FSC 
vs SSC plot). The gated population was used to graph FL2-H vs FL1-H plots for 
each sample (FL1-H channel reading FITC fluorescence and FL2-H reading PI 
fluorescence). An example of this is shown in Figure 5.8. 
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Figure 5.8. FL2-H vs FL1-H dot plots obtained by flow cytometry for apoptosis 
analysis using FITC (FL1-H channel)  and PI (FL2-H channel) staining. (A) Cells 
treated with 1 µg/mL of staurosporine, (B) Cells treated with 1 µM of complex 16 
for 24 h at 310 K. 
 
Figure 5.9 shows that the ratio of apoptosis caused by exposure to the arene 
complexes can be divided into two groups, in which the patterns are similar. The 
first group includes the three chlorido complexes 15, 34 and 36 that cause high 
late apoptotic populations. The second group, the iodido complexes 16, 35 and 37 
cause a large number of cells to be in the non-viable stage. Additionally, after 24 
h of drug exposure, the extent of late apoptotic cells is close to zero.  
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Compound Population (%) 
 M X Y Viable Early  Apoptotic 
Non 
viable 
Late 
Apoptotic 
15 Ru Cl C 91.2 ± 0.5 1.87 ± 0.03 4.3 ± 0.4 2.03 ± 0.09 
16 Ru I C 88.5 ± 0.4 0.78 ± 0.02 10.7 ± 0.7 0.22 ± 0.08 
34 Ru Cl N 92 ± 1 1.61 ± 0.06 3.94 ± 0.08 2.8 ± 0.3 
35 Ru I N 92.3 ± 0.6 0.06 ± 0.02 7.4 ± 0.3 0.10 ± 0.02 
36 Os Cl C 87.4 ± 0.9 1.29 ± 0.08 3.5 ± 0.6 7.8 ± 0.7 
37 Os I C 87 ± 1 0.30 ± 0.04 11.9 ± 0.8 0.95  0.03 
Staurosporine (Sta) 84.3 ± 0.5 0.41 ± 0.06 13.2 ± 0.4 5.66 ± 0.09 
 
Figure 5.9. Flow cytometry analysis to determine the percentages of apoptotic  
cells, using Annexin V-FITC vs PI staining, after exposing A2780 cells to 
complexes 15, 16, 34−37 and staurosporine. Concentrations used were IC50/3 for 
complexes and 1 µg/mL for staurosporine (Sta), pre-incubation time in drug-free 
medium was 24 h and drug exposure time was 24 h.  
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 Population (%) 
Compound µM Viable Early  Apoptotic Non-viable 
Late  
Apoptotic 
16 
 
1 94.5 ± 0.3 1.6 ± 0.3 3.02 ± 0.05 0.4 ± 0.2 
3 88.5 ± 0.4 0.78 ± 0.02 10.7 ± 0.7 0.22 ± 0.08 
9 84.9 ± 0.5 0.95 ± 0.08 10.9 ± 0.7  4.1 ± 0.2 
 
Figure 5.10. Flow cytometry analysis to determine the percentages of apoptotic 
populations, using Annexin V-FITC vs PI staining, after exposing A2780 cells to 
various concentrations of complex 16. Concentrations used were 1, 3 or 9 µM, 
pre-incubation time in drug-free medium was 24 h and drug exposure time was 24 
h. 
 
Further studies were carried out using complex 16 to study the effect of drug 
concentration on the extent of apoptosis, results are shown in Figure 5.10. As 
expected, complex 16 causes a decrease in viable cell population with increasing 
concentration changing from 94.5 ± 0.3% at 1 µM, which is a concentration 
equivalent to a third of the IC50 to 84.9 ± 0.5% at 9 µM, which is 3 x IC50 
concentration. The percentage of late-apoptotic cells increased with concentration 
as expected. 
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• Caspase 3 apoptotic pathway 
The caspase-3/CPP32 colorimetric assay kit from BioVision, was used to 
determine the level of activation of these proteins caused by 24 h of exposure of 
A2780 cells to complexes 15, 16, 34−37 in comparison to untreated cells. For 
positive activation of caspase 3, control A2780 cells were exposed for 2 h to 
staurosporine (1 µg/mL). It is known that the amino acid sequence Asp-Glu-Val-
Asp (DEVD) is cleaved by caspase 3 during the activation of apoptosis in 
mammalian cells.21 The cellular assay is based on the colorimetric detection and 
quantification of p-nitro aniline (p-NA) after it has been cleaved from the labelled 
substrate (DEVD-p-NA) which is incubated with treated cells. The absorbance of 
p-NA was determined for a triplicate of samples for each complex and the 
standard deviation of the experiment was calculated. 
The data for the absorbance of free p-NA at 410 nm are shown in Figure 5.11.  
Although all the complexes 15, 16, 34−37 activate caspase 3, it is worth 
highlighting that chlorido complexes 15, 34 and 36 give rise to higher absorbance 
than their corresponding iodido analogues 16, 35 and 37 regardless of the nature 
of their metal centre or their N,N-chelating ligand. 
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Compound Absorbance at 410 nm 
 M X Y 
15 Ru Cl C 0.143 ± 0.003 
16 Ru I C 0.076 ± 0.008 
34 Ru Cl N 0.132 ± 0.003 
35 Ru I N 0.081 ± 0.003 
36 Os Cl C 0.126 ± 0.001 
37 Os I C 0.073 ± 0.004 
Control (Cont) 0.011 ± 0.001 
Staurosporine (Sta) 0.152 ± 0.006 
 
 
Figure 5.11. Caspase 3 activation in A2780 cells caused by 24 h exposure to 
complexes 15, 16, 34−37 at 310 K. Results are expressed as the samples’ 
absorbance at 410 nm (maximum absorbance of free p-NA). Concentrations of the 
complexes used were equipotent at IC50/3. Cont: control cells not treated, Sta: 
cells treated with staurosporine (1 µg/mL) 
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• DNA replication 
IC50 modulation by inhibition of DNA polymerase α by aphidicolin and 
topoisomerase II by etoposide and novobiocin were investigated for complexes 
15, 16, 34−37 in A2780 cells. Results for co-incubation with aphidicolin are 
shown in Figure 5.12. Complex 15 [Ru(η6-p-cym)(p-Impy-NMe2)Cl]PF6 loses 
potency at all concentrations of the co-incubating agent. Its IC50 values increases 
from 16.2 ± 0.9 µM to 71 ± 2 µM when co-incubated with 10 µM of aphidicolin. 
In contrast, its analogous iodido complex 16 [Ru(η6-p-cym)(p-Impy-NMe2)I]PF6 
shows an increase in potency, as its IC50 value decreases from 3.0 ± 0.2 µM to 
0.62 ± 0.08 µM when co-incubated with 10 µM of the polymerase α inhibitor. The 
antiproliferative activity of ruthenium p-Azpy-NMe2 complexes 34 and 35 do not 
seem to be affected by the addition of aphidicolin, as their potency is the same in 
all experiments. Finally, the same is true for osmium p-Impy-NMe2 complex 36 
and its iodido analogue
 
 37 which are only affected by the highest concentration of 
aphidicolin (10 µM). 
Figure 5.13 shows the results obtained when complexes 15, 16, 34−37 were co-
incubated with 5 µM of novobiocin, a topoisomerase II inhibitor. In this case, the 
only complex to show a decrease in potency is the chlorido complex 15 (IC50 
value increases from 16.2 ± 0.9 µM to 28 ± 2 µM) while the changes in the 
antiproliferative activity of complexes 34, 35 and 37 are not statistically 
significant. Interestingly, the potency of chlorido complex 36 [Os(η6-p-cym)(p-
Impy-NMe2)Cl]PF6 is improved as its IC50 value decreases from 3.0 ± 0.4 µM to 
0.77 ± 0.06 µM when incubated with 5 µM of novobiocin. 
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Compound Aphidicolin (µM) 
 M X Y 0 1 5 10 
15 Ru Cl C 16.2 ± 0.9 32.5 ± 0.8 67 ± 1 71 ± 2 
16 Ru I C 3.0 ± 0.2 2.3 ± 0.2 0.75 ± 0.04 0.62 ± 0.08 
34 Ru Cl N 13.1 ± 0.5 12.8 ± 0.5 12.73 ± 0.09 12.5 ± 0.5 
35 Ru I N 0.69 ± 0.04 0.61 ± 0.08 0.60 ± 0.09 0.60 ± 0.03 
36 Os Cl C 3.0 ± 0.4 2.8 ± 0.8 1.09 ± 0.06 1.02 ± 0.03 
37 Os I C 1.20 ± 0.02 1.17 ± 0.06 0.80 ± 0.02 0.60 ± 0.04 
 
Figure 5.12. IC50 values for complexes 15, 16, 34−37  in A2780 cells after co-
incubation with various concentrations of aphidicolin. Concentrations of the 
complexes used were equipotent, at IC50/3. Aphidicolin concentrations used were: 
() 0 µM, () 1 µM () 5 µM and () 10 µM. All concentrations of 
aphidicolin used were non-toxic. 
 
Results for co-incubation with etoposide are also shown in Figure 5.13. the 
potency of ruthenium complexes 15, 16 and 35 decreases with increasing 
concentration of etoposide, especially for the iodido Impy complex 16. Its IC50 
increases from 3.0 ± 0.2 µM to 14.1 ± 0.8 µM when incubated with 10 µM of 
etoposide. In contrast, the potency of osmium complexes 36 improved. Notably, 
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the latter increases its activity ten-fold when co-incubated with 10 µM of 
etoposide. No significant changes in IC50 were observed for complexes 34 and 37. 
 
 
Compound IC50 (µM) 
 M X Y 0 5 µM Novobiocin 
10 µM 
Etoposide 
15 Ru Cl C 16.2 ± 0.9 28 ± 2 43 ± 1 
16 Ru I C 3.0 ± 0.2 2.3 ± 0.3 14.1 ± 0.8 
34 Ru Cl N 13.1 ± 0.5 12.8 ± 0.8 16.8 ± 0.9 
35 Ru I N 0.69 ± 0.04 0.60 ± 0.09 2.0 ± 0.1 
36 Os Cl C 3.0 ± 0.4 1.7 ± 0.2 0.33 ± 0.02 
37 Os I C 1.20 ± 0.02 0.77 ± 0.06 0.89 ± 0.03 
 
Figure 5.13. IC50  in A2780 cells for complexes 15, 16, 34−37 after co-incubation 
with 5 µM novobiocin or 10 µM etoposide. Concentrations of the complexes used 
were equipotent at IC50/3. For all complexes () no co-incubation agent, () co-
incubation with 5 µM novobiocin and () co-incubation with 10 µM etoposide. 
Both concentrations of the co-incubating agents were non-toxic. 
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• Cellular detoxification mechanisms 
The effect of modification of GSH levels and inhibition of thioredoxin reductase 
on IC50 values of complexes 15, 16, 34−37 was investigated. These complexes 
were co-incubated with various concentrations of L-BSO (1, 5 or 50 µM) as well 
as 0.1 µM of auranofin in independent experiments. Figure 5.14 shows the results 
when L-BSO was used to inhibit γ-glutamylcysteine synthetase and, consequently 
lower intracellular GSH concentrations.22 Complexes 15, 16, 34−37 greatly 
improve their potency when co-incubated with L-BSO. The antiproliferative 
activity of ruthenium complex 15 [Ru(η6-p-cym)(p-Impy-NMe2)Cl]PF6 improved 
more noticeably when co-incubated with 5 µM of L-BSO as its IC50 value 
decreased from 16.2 ± 0.9 µM to 1.0 ± 0.3 µM. The activity of the iodido 
analogue 16 is not affected by the presence of 1 µM L-BSO, but, its potency 
increases equally when using 5 µM or 50 µM of L-BSO. The activity of the 
ruthenium  p-Azpy-NMe2 complex 34 improved eight-fold (from 13.1 ± 0.5 to 
1.63 ± 0.02 with using 5 50 µM of L-BSO present). Meanwhile the IC50 value of 
its iodido analogue 35 and both the osmium complexes 36 and 37 decreased to the 
sub-micro molar range, especially complex 37 [Os(η6-p-cym)(p-Impy-
NMe2)I]PF6 which improved its potency to nano molar values (80 ± 2 nM when 
co-incubated with 5 µM L-BSO). Interestingly, it is observed that the optimum 
concentration of L-BSO to achieve the maximum potency with all complexes is 5 
µM.  
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Compound L-BSO (µM) 
 M X Y 0 1 5 50 
15 Ru Cl C 16.2 ± 0.9 3.8 ± 0.4 1.0 ± 0.3 2.93 ± 0.09 
16 Ru I C 3.0 ± 0.2 2.9 ± 0.1 1.05 ± 0.07 1.05 ± 0.02 
34 Ru Cl N 13.1 ± 0.5 1.71 ± 0.09 1.63 ± 0.02 6.6 ± 0.2 
35 Ru I N 0.69 ± 0.04 0.22 ± 0.01 0.14 ± 0.01 0.15 ± 0.03 
36 Os Cl C 3.0 ± 0.4 1.46 ± 0.02 0.42 ± 0.06 1.8 ± 0.1 
37 Os I C 1.20 ± 0.02 0.48 ± 0.01 0.08 ± 0.02 0.60 ± 0.04 
 
Figure 5.14. IC50 in A2780 cells for complexes 15, 16, 34−37 after co-incubation 
with various concentrations of L-BSO. Concentrations of the complexes used 
were equipotent at IC50/3. L-BSO concentrations were () 0 µM, () 1 µM, () 
5 µM and () 50 µM. 
 
In a series of independent experiments, shown in Figure 5.15, auranofin, which is 
an effective inhibitor of thioredoxin reductase was co-incubated with arene 
complexes 15, 16, 34−37. This gold complex can trigger mitochondrial-dependent 
apoptosis pathways and there are indications that mitochondrial oxidative stress is 
a central event in its mechanism of action. However, the concentration used in 
these experiments (0.1 µM) is non-toxic and too low to initiate the apoptotic 
cascade.  
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Compound Auranofin (µM) 
 M X Y 0 0.1 
15 Ru Cl C 16.2 ± 0.9 11.5 ± 0.5 
16 Ru I C 3.0 ± 0.2 0.93 ± 0.05 
34 Ru Cl N 13.1 ± 0.5 4.48 ± 0.09 
35 Ru I N 0.69 ± 0.04 0.16 ± 0.01 
36 Os Cl C 3.0 ± 0.4 0.30 ± 0.05 
37 Os I C 1.20 ± 0.02 0.60 ± 0.09 
 
Figure 5.15. IC50 in A2780 cells for complexes 15, 16, 34−37  after co-incubation 
with 0.1 µM of auranofin. Concentrations of the complexes used were equipotent 
at IC50/3. Auranofin concentrations were () 0µM and () 0.1 µM. The 
concentration of auranofin used were non-toxic. 
 
 
It is observed that the potency of all complexes 15, 16, 34−37 improves when co-
incubated with auranofin (Figure 5.15). In the case of ruthenium complexes, the 
antiproliferative activity of iodido compounds 16 and 35 is improved more 
significantly than their chlorido analogues 15 and 34. The highest increase in 
potency is observed for osmium chlorido complex 36 [Os(η6-p-cym)(p-Impy-
NMe2)Cl]PF6; its IC50 value deceases 10X from 3.0 ± 0.4 µM  to 0.30 ± 0.05 µM. 
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To confirm that the chosen concentration of auranofin was non-toxic, each 96-
well plate had three independent series of control wells. The first one was 
negative control and was untreated at all times; the second control series was 
treated only with 0.1 µM of auranofin, and the last series was treated with 
different concentrations of CDDP. In all cases the difference in cell viability 
between series one (untreated) and two (plus auranofin) was never > 3%, and the 
IC50 value determined for CDDP was 1.2 ± 0.3 µM. 
 
5.4 Discussion 
5.4.1 Antiproliferative activity 
Antiproliferative activity for complexes 15, 16, 34−37 was determined using the 
SRB assay for cell viability measurements. As shown in Table 5.2 on page 207, 
all complexes are highly active in the four cell lines used: A2780 ovarian, A549 
lung, HCT116 colon and MCF7 breast lines with all IC50 values below 17 µM. 
Complexes 15, 16, 34−37  were chosen for the present study because of their 
structural similarities and with the aim of comparing the extent of variation in 
activity with changes in the structure.  
As shown in Figure 5.16 all complexes have in common the arene, which is a p-
cym unit. The starting point is chlorido complex 15 [Ru(η6-p-cym)(p-Impy-
NMe2)Cl]PF6 which includes the bidentate ligand p-Impy-NMe2. A change in the 
chelating unit (a C atom replaced by N) generates azo complex 34 which has p-
Azo-NMe2 instead. In the opposite direction, Ru(II) complex 15 can be compared 
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to Os(II) complex 36, they have in common the chelating ligand and the 
monodentate ligand. However the metal centre varying from ruthenium to 
osmium. According to the findings presented in Chapter 3, in which variations in 
the monodentate ligand modified substantially the cellular behaviour of ruthenium 
complexes, it was decided to include the comparison between complex 15 and 16. 
Hence including as well iodido analogues 35 and 37. 
 
Figure 5.16. Relationship between the complexes 15, 16, 34−37 studied in 
Chapter 5. 
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It is remarkable that iodido complexes 16 and 35  are both highly active in all cell 
lines tested, although they exhibit different IC50 values caused by the variation of 
the C atom in the imine group. This structural modification causes ruthenium p-
Azpy-NMe2 complex 35 to be more active than the ruthenium p-Impy-NMe2 
complex 16 in all cell lines (eg. In A2780 cells IC50 changes from 3.0 ± 0.2 to 0.69 
± 0.04 µM). This observation could be explained by the electronic changes that 
the azo group generates in the structure. The electronic density of the ligand 
varies, affecting as well the electron-density of the metal centre and in 
consequence all reactions that involve it. The possibility of N=N bond reduction 
also adds to the electrochemical changes considered later when the  metal centre 
varies between Ru/Os 
It is observed that in A2780 ovarian and MCF7 breast cancer cells all iodido 
complexes 16, 35 and 37 are more active than their chlorido analogues 15, 34 and 
36. Antiproliferative activity variations after modifications on the monodentate 
ligand could be explained by the previous findings presented in Chapter 3. 
Changes in the halogen modify the cellular uptake and accumulation pathways 
involved in the first stages of drug action. This could lead to variations in cellular 
distribution of the drug, and in turn to different apoptotic pathways being 
triggered as a consequence of cellular compartamentalization,23 hence resulting 
differences in IC50 values.  
Finally, substitution of the metal centre is likely to explain why osmium p-Impy-
NMe2 complexes are more potent than their ruthenium analogues (with the 
exception of chlorido complex 36
 
compared to chlorido complex 15 exclusively in 
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A549 cells). This involves variation of the redox activity of the complex, a  type 
of activity which has been related to the generation of ROS and modifications of 
mitochondrial activity.24–27 Electron transfer agents such as metal complexes 
function catalytically in redox cycling with formation of ROS from oxygen. 
Electrochemical data add support to this mechanistic viewpoint. Generated 
secondary species generally exhibit reduction potentials amenable to electron 
transfer in vivo, thus giving rise to ROS.24 Electrochemical reduction of 
ruthenium complex 35 has been previously investigated.28,16 It was found that its 
first reduction potential is -0.40 V, which is considered to be within the biological 
relevant range of redox potential values (+ 0.40 V to – 0.50 V)24 making possible 
its involvement in  mitochondrial activity. 
Experiments were also carried out with complexes 15, 16, 34−37 in order to 
investigate their antiproliferative activity in resistant cell lines. In the case of 
CDDP resistance, cisplatin-resistant A2780Cis cells were used. These results 
shown in Table 5.3 on page 208 also allow investigation of cross-resistance 
patterns with the platinum drug. CDDP is the metal-based anticancer drug most 
widely used. However, it shows major clinical drawbacks as very frequently 
patients treated with CDDP suffer from resistant cancer re-growth after remission. 
It is known that acquired CDDP resistance is mainly caused by changes in three 
cellular functions (A) reduced cellular accumulation which can be the result of 
impaired cell uptake or increased efflux, (B) increased cellular detoxification, 
especially mechanisms involving sulphur proteins, and (C) enhanced DNA 
repair.29,30 
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CDDP cross-resistance factors shown in Figure 5.17 are expressed as the ratio 
between the IC50 values in the resistant cell line divided by the IC50 values in the 
parental cell line. These results indicate that chlorido complexes 15, 34 and 36
 
share, at least partially, some mechanisms of resistance to CDDP, as these 
complexes lose potency in the A2780Cis cells. Remarkably, the cross-resistance 
factors are always lower than the value for CDDP, which could mean a clinical 
advantage for the arene half-sadwich complexes.  
 
 
Figure 5.17. CDDP cross-resistance factors in A2780 cells when treated with 
complexes 15, 16, 34−37 for a 24 h period. Data are shown as the ratio of IC50 
values in A2780cis divided by the IC50 value in the parental cell line. M = Ru/Os, 
Y = C/N 
Iodido complexes 16, 35 and 37 retain their potency in A2780Cis cells, as their 
cross-resistance factor is close to 1. This would suggest that there is at least one 
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major difference between these complexes and CDDP, with respect to the three 
main causes of resistance.  Although cellular accumulation in A2780Cis has not 
been investigated, further results included in this Chapter that deal with the cell 
detoxification process involving sulphur proteins and DNA repair aim to establish 
the mechanism responsible for the lack of cross-resistance. 
One common clinical strategy to treat cancers that have acquired resistance to 
CDDP is the use of OXA, even though this platinum based metallo-drug, shares 
some features of the mechanisms of action of CDDP.  This clinical approach is 
especially important in the treatment of colorectal cancer with the common 
consequence of acquired resistance to both platinum drugs. To investigate 
whether ruthenium/osmium complexes can be an alternative for this particular 
case, the present research involved the analysis of cross-resistance with OXA 
using colon HCT116Ox cells. The results are shown in Table 5.3 on page 208, in 
this case, cross-resistance factors for complexes 15, 16, 34−37 were calculated 
using the corresponding data for IC50 values in HCT116 and in HCT116Ox, the 
latter being the OXA resistant cell line.  
Figure 5.18 indicates that, similarly to CDDP resistance, iodido complexes 16 
[Ru(η6-p-cym)(p-Impy-NMe2)I]PF6, 35 [Ru(η6-p-cym)(p-Azpy-NMe2)I]PF6 and 
37 [Os(η6-p-cym)(p-Impy-NMe2)I]PF6  retain their potency in the resistant cell 
line. Once again suggesting differences in the mechanism of resistance of these 
arene complexes compared to that of the OXA. In contrast, there is no uniform 
pattern for the chlorido complexes. Ruthenium p-Impy-NMe2 complex 15 loses its 
potency greatly, with a cross-resistance factor of 22.5 while its equivalent osmium 
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complex 36 retains activity and its IC50 values does not change significantly. 
Remarkably, ruthenium complex 34 improves its activity in the resistant cell line 
compared to the parental cell line. Results also show that cells resistant to OXA 
HCT116Ox are also resistant to CDDP; this reflects the importance of the shared 
mechanism of action of these platinum drugs. 
 
 
Figure 5.18. OXA cross-resistance factor in HCT116 cells when treated with 
complexes 15, 16, 34−37 for a 24 h period. Data are shown as the ratio of IC50 
values in HCT116Ox divided by the IC50 value in the parental cell line. M = 
Ru/Os, Y = C/N 
 
CDDP and OXA react with GC-rich sites in DNA and they are believed to form 
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extent of cell death to that of CDDP.31 Both produce early SSB (single strand 
breaks) but it has been suggested that although there are more early lesions caused 
by CDDP, it is OXA which generates lesions that are more difficult to repair, as 
they are not recognised by MMR (mismatch repair) proteins.31,32 
Another important point when investigating the antiproliferative activity of 
candidate drugs is their behaviour towards non-cancerous cells. For this, MRC5 
human lung fibroblasts were used with complexes 15, 16, 34−37 (Table 5.3 on 
page 208). By comparing the IC50 value of a given drug in a cancer cell line 
against its activity in MRC5 is possible to determine the selectivity of the drug for 
a particular tumour tissue. As the difference between these two values increases 
the more likelihood of tumour specificity which may lead to reduce systemic 
effects for patients when in clinical use.   
Figure 5.19 shows the ratios of IC50 values determined in MRC5 and the values 
obtained in A2780 cells. In this case the higher the value obtained, the more 
favourable is the selectivity of the studied drug for cancerous ovarian tissue. The 
best results are achieved by iodido complexes 16, 35 and 37 suggesting that 
specific mechanisms of interfering with abnormal proliferation may be involved 
in the pathways activated by these complexes. 
Tumour selectivity values determined for iodido complexes 16, 35 and 37 are on 
average two-fold higher than those determined for chlorido complexes 15, 34 and 
36, although the latter coincide with the value determined for CDDP. This 
indicates that in the case of ovarian carcinoma, these half-sandwich arene 
complexes are as selective as the platinum drug. MRC5 fibroblasts have been 
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used to evaluate this type of tissue selectivity for other chemotherapeutic drugs,33 
especially of natural origin34,35 or even when using photodynamic therapy 
agents.36 
 
Figure 5.19. Ratio of IC50 values in MRC5 normal cells divided by the IC50 value 
in the A2780 cancer cells when treated with complexes 15, 16, 34−37 for a 24 h 
period. High values indicate good selectivity for tumour cells versus normal cells. 
M = Ru/Os, Y = C/N 
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accumulation with potency as their IC50 values decrease when the cellular 
accumulation increases. However this trend was not observed for the iodido 
analogues 16, 35 and 37 (Figure 5.20). 
 
 
Figure 5.20. Comparison between cellular accumulation of Ru/Os (ng of metal 
per 106 cells)(left axis) and potency (IC50, µM) of complexes 15, 16, 34−37 (right 
axis). 
 
Differences in cellular accumulation cannot be explained by the extent of aquation 
exhibited by the complexes. As reported in Chapter 3, the p-Impy-NMe2 
complexes 15 and 16 aquate to a similar extent over 24 h (66% and 63% 
respectively). It has also been reported previously16 that p-Azpy-NMe2 complex 
34 aquates up to 55% in the same period of time, while there is no aqua complex 
formation for the iodido complex 35. Finally, the same process has been studied 
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for both osmium analogues;37 chlorido complex 36 aquates 50% after 24 h and 
complex 37 is fully converted to the aqua species in the same time. Such marked 
differences do not allow for the establishment of any trend to account for the 
cellular accumulation. Besides, it is expected that plasma concentrations of 
chloride do not allow the complexes to hydrolyse before they enter the cells.3,25 
This is consistent with findings presented in Chapter 3 that indicate that there is 
no observable aquation of the complexes after 24 h in cell culture media and with 
previous reports that indicate that luminescent ruthenium complexes can reach the 
interior cell compartments with no structural changes.38 
Interestingly, cellular compartmentalization studies on complexes 15, 16, 34−37 
showed that the metal distribution in A2780 cells might not depend on the nature 
of the metal centre (Ru/Os) nor on the N,N-chelating ligand but on the 
monodentate ligand (Cl/I) instead. Results are shown in Figure 5.2 on page 211. 
The experiments carried out allowed the separation of four cellular fractions as 
shown in Figure 5.21.  
Ru/Os from chlorido complexes 15, 34 and 36 were retained highly in the 
membrane fraction. The extent of metal accumulation follows the order:  
membrane > cytosol > nuclear fraction > cytoskeleton. Ru/Os from the iodido 
complexes 16, 35 and 37 is not retained in the cytosol (< 2.2% of the cellular Ru) 
and the percentages of metal in the nuclear and cytoskeletal fraction are lower 
than for chlorido analogues 15, 34 and 36.  
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Figure 5.21. Cellular fractions for compartmentalization studies 
 
Cellular accumulation pathways studied in Chapter 3, show that there are marked 
differences in the mechanism involved in cellular uptake and accumulation of 
chlorido complex 15 [Ru(η6-p-cym)(p-Impy-NMe2)Cl]PF6 compared to iodido 
complex 16 [Ru(η6-p-cym)(p-Impy-NMe2)I]PF6 in A2780 cells. It is possible that 
such differences can determine the distribution of ruthenium/osmium in cells and 
would explain why this process does not depend on the nature of the metal centre 
nor on the N,N-chelating ligand, but on the nature of the monodentate ligand. In 
consequence, it is also possible that the cellular metal distribution observed for 
complexes 34-37 is a consequence of the cellular uptake pathways involved in the 
metal accumulation of these complexes; moreover, this distribution can determine 
the different apoptotic pathways activated by chlorido / iodido complexes. This is 
consistent with recent studies that have linked endocytotic pathways to cellular 
signal transduction, suggesting bidirectional interplay between the two 
processes;23 moreover, results suggest that cellular compartamentalization can 
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induce selective transmission of signals that can lead either to apoptosis or 
survival of the cell.39,40 
 
5.4.3 Mechanism of action studies 
• Cell cycle analysis using flow cytometry 
The cell cycle in mammalian cells (Figure 5.22) consists of four distinct phases: 
an S phase during which the cell replicates its DNA and duplicates the 
chromosomes, an M phase in which the duplicated chromosomes are separated 
into two nuclei (mitosis) and consequently into two daughter cells (cytokinesis), 
and finally, two gap phases known as G1 (before S phase) and G2 (before M 
phase).41,42 
 
Figure 5.22. Cell cycle representation for mammalian cells. 
 
Progression of the cells in this cycle is regulated by cyclin-dependent kinases 
(Cdks) and determined by three checkpoints.43 The first of which occurs in late 
G1 phase, at this point G1/S and S phase cyclin-Cdk complexes are activated only 
G1 (Gap 1)
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if the conditions for cell proliferation are ideal, then DNA replication starts. The 
second check point at the end of G2 phase controls DNA damage or completion of 
DNA replication, in this case the M-phase cyclin-Cdk complex is activated. The 
third checkpoint is responsible for deactivating all Cdks in the cell to allow 
spindle disassembly and later cytokinesis. 
G1/S cyclins stimulate the cells to go into the cell cycle depending on external 
signalling that guarantee the rate of cell growth so it is possible to say that cell 
proliferation is controlled at the G1/S checkpoint.44 Results shown in Figure 5.5 
on page 214 indicate that complexes 15, 16, 34−37 do not allow A2780 cells to 
progress into the cell cycle hence they do not allow the cancer cells to multiply. 
Ruthenium and osmium complexes studied in this Chapter, have shown a 
significant arrest in G1 population compared to the untreated control. This has 
previously been reported for other ruthenium(II) complexes.45 Interestingly, 
ruthenium Impy complexes 15 and 16 cause the S population to be twice as large 
as the G2/M phase population (12.7 ± 0.9% in S phase for 15, compared to 6.5 ± 
0.8 in G2/M phase and 14 ± 1% in S phase for 16, compared to 6.3 ± 0.7 in G2/M 
phase). This possibly indicates that besides causing G1-arrest these ruthenium 
complexes interfere with DNA and/or chromosome replication as cells are 
partially retained in the second checkpoint which checks for DNA damage, which 
implies a secondary S arrest.  
In contrast, results for CDDP (Figure 5.5 on page 214) show that the platinum 
drug causes arrest in the S phase, as expected.46 It is known that the mechanism of 
action for CDDP involves covalent binding of the drug to DNA. This defective 
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DNA triggers cell cycle arrest and does not allow progression into cell division. 
Figure 5.6 on page 215 shows the results for the cell cycle analysis of A2780 cells 
when treated with different concentrations of CDDP. The arrest observed is 
concentration-dependent as the S phase population increases with concentration 
increase (16.5 ± 0.6% when using 0.4 µM of CDDP to 44 ± 2% when using 3.6 
µM). The explanation for this observation lies in that at higher concentrations of 
the platinum drug, the number of DNA-Pt lesions increases making the repair 
process slower and inefficient. This holds a greater population of cells in the S 
phase. 
The same experiment was carried out using different concentrations of ruthenium 
complex 16 [Ru(η6-p-cym)(p-Impy-NMe2)I]PF6. However in this case the 
population arrested in G1 phase does not increase significantly with the 
concentration of the complex (64.2 ± 0.6% when using 1 µM of 16 to 65.6 ± 0.8% 
when using 9 µM), which indicates that the cell cycle arrest is concentration-
independent. This could be an advantage for an anticancer drug, as its cytostatic 
activity would avoid cell proliferation at low concentrations.  
 
• p53-activated apoptotic pathway 
Protein 53 (p53) is a tumour-suppressor protein that interacts with the G1/S-Cdk 
complex involved in the first cell cycle checkpoint.47 p53 is a zinc protein which 
contains 393 amino acid residues, divided into three domains48 as shown in Figure 
5.23.49 It mediates cell cycle arrest, senescence or apoptosis after mutagenic 
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events. Disruption in the p53 pathway has been strongly correlated to 
tumorigenesis as it is considered to maintain genomic stability. Unfortunately, its 
inactivation is the most common event in human cancers, occurring in at least 
50% of all cases.50,51 
 
Figure 5.23. Schematic representation of the three protein domains in p53 
according to Bai and Zhu.49 
 
Figure 5.24 shows the ratios of IC50 values for HCT116p53-/- cells (p53 knocked 
out cells) over the parental line when treated with complexes 15, 16, 34−37 for a 
24 h period (for IC50 values in each cell line see Table 5.5. on page 217). Figure 
5.24 shows that there are different responses when the cells are exposed to the 
chlorido complexes 15, 34 and 36.  
Although all chlorido arene complexes seem to lose potency, this effect is more 
pronounced for complex 15 [Ru(η6-p-cym)(p-Impy-NMe2)Cl]PF6 which is 20X 
less active (IC50 increases from 3.4 ± 0.4 to 69.9 ± 0.9 µM).  Activation of p53, by 
DNA damage, cytotoxic drugs, hypoxia or oncogenic signalling amongst others, 
is known to cause cell cycle arrest in G1 phase, as well as being involved in the 
intrinsic apoptotic pathway.47 
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Figure 5.24. p53-dependent cell death of HCT116 cells when treated with 
complexes 15, 16, 34−37 for a 24 h period. Data are shown as the ratio of IC50 
values in HCT116 p53 -/- divided by the IC50 value for the parental cell line. M = 
Ru/Os, Y = C/N 
 
In previous sections, it was shown that these complexes cause the same effect on 
the cell cycle (G1 arrest). Both events may be related. It is possible that the 
chlorido complexes 15, 34 and 36 activate p53 which in turns arrests the cell 
cycle, so when p53 is knocked out in HCT116 cells the arrest does not occur and 
cell proliferation increases, which is manifested as an increase in the IC50 value. 
Other ruthenium complexes have been previously studied in relation to their p53-
dependence,52,53 particularly, chlorido complex RM175 (Figure 5.25) which 
activates p53-dependent pathways.54 
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Figure 5.25. Structure of RM175 
 
In contrast, Figure 5.24 also shows that iodido complexes 16, 35 and 37 are as 
potent in the p53- null cell line as in the parental line. This is likely to indicate that 
their mechanism of action does not depend on the p53 apoptotic pathway, which 
might be advantageous for their clinical use, especially taking into account that 
the treatment of choice for colon cancer is OXA which shows a potency loss 
above 25-fold.  
 
Figure 5.26. Schematic representation of the intrinsic apoptotic pathway. 
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The intrinsic apoptotic pathway, in which p53 is involved (Figure 5.26), is 
activated by cellular stress. Signalling in this pathway is amplified by 
mitochondria, which release cytochrome c and subsequently activate caspase 9, 
and downstream also activate caspase 3.47  
 
• Induction of apoptosis 
 
Apoptosis is the process of programmed cell death in which a cell goes through 
biochemical and morphological changes. Unlike necrosis, it produces fragments 
that other phagocytic cells are able to remove without causing damage to 
surrounding tissues.55 There are basically two different pathways for cells to 
undergo apoptosis. The first one is the intrinsic pathway (initiated by internal 
stimuli) discussed in previous sections and the second is the extrinsic pathway 
initiated by external stimuli.56 Nevertheless, there are several signalling 
mechanisms that can activate these pathways, for example external stimuli can be 
initiated by the TNF path (formerly known as tumour necrosis factor alpha-1) or 
the FAS path (apoptosis antigen 1) in which the death-inducing signalling 
complex DISC is formed and caspases 8 and 10 are activated.56 Regardless of the 
mechanism that initiates the cascade of apoptotic stimuli, the process finishes with 
proteolytic caspases starting the organized degradation of cellular organelles.  
In the present work, complexes 15, 16, 34−37 were used to investigate the extent 
of apoptosis in A2780 cells caused after a 24 h period of exposure. Results shown 
in Figure 5.9 on page 220 indicate that although all half-sandwich arene 
  
Chapter 5: Mechanisms of action 
249 
 
complexes cause apoptosis there are differences in relation to early, late apoptotic 
and non-viable populations.  
It was observed that early apoptotic populations of cells are practically non-
existent after exposure to iodido complexes 16, 35 and 37, but they exhibit high 
incidence of non-viable cells. Also, the population for late-apoptotic cells in these 
iodido complexes 16, 35 and 37 is very low. Morphological changes in early 
apoptotic cells include the loss of phospholipid asymmetry followed by the 
traslocation of phosphatidylserine to the outer membrane. The phospholipid 
component should be found in the internal/cytosolic side of the membrane in 
healthy cells. This protein translocation is key for the detection of apoptosis by 
annexin V.20 
In late stages of apoptosis, the membrane is totally compromised as the cell breaks 
apart into several vesicles or apoptotic bodies. In the process, membrane blebbing 
allows formerly impermeant agents, like PI, to access inner cell compartments.  In 
contrast to iodido complexes,  the population of non-viable cells is lower for 
chlorido analogues 15, 34 and 36. These differences might indicate that although 
all complexes activate apoptotic cascasdes, the processes involving iodido 
complexes 16, 35 and 37  are different from those involving chlorido analogues 
15, 34 and 36 generating variations in the time each pathway takes to cause cell 
death. 
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• Caspase 3 apoptotic pathway 
Caspases, in general, are a family of cysteine proteases that play essential roles in 
apoptosis, necrosis, and inflammation.57,58 Caspase 3, in particular, also known as 
CPP32, is encoded by the CASP3 gene in humans and recognises the peptide 
sequence DEVDG (Asp-Glu-Val-Asp-Gly), with cleavage occurring on the 
carboxyl side of the second aspartic acid residue21,59 This peptide sequence 
preference allows the development of colorimetric methods to measure its 
activation, as used in this research, in which the DEVD sequence is labelled with 
p-NA.21 
 
Figure 5.27. Involvement of caspase 3 in the intrinsic and extrinsic apoptotic 
pathways according to Salvesen and Riedl.57  
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The inactive form of caspase 3, known as the caspase 3 zymogen can be activated 
 in both apoptotic pathways (Figure 5.27): (A)  the intrinsic pathway, in which 
p53 activates the release of cytochrome c from mitochondria56 and (B) the 
extrinsic pathway which is activated by DISC (death-inducing signalling 
complex) and is independent of Bcl2 activity. In the former, cytochrome c 
combines with caspase 9 and the apoptosis-activating-factor 1 (Apaf-1) to activate 
the zymogen. However, in the latter it is the sequential activation of caspases that 
plays a central role in the execution-phase of cell apoptosis.57 
In the present research, complexes 15, 16, 34−37 were used to investigate the 
activation of caspase 3 in A2780 cells. For this, the absorbance of free p-NA was 
monitored, as caspase 3 specifically cleaves the adduct DEVD-pNA. Results 
shown in Figure 5.11 on page 223 indicate that all the studied arene complexes 
activate caspase 3. Remarkably, there is a difference (Ca. 1.5 X) between the 
levels of activation of the caspase 3 induced by the chlorido complexes 15, 34 and 
36 compared to that induced by the iodido complexes 16, 35 and 37.  This 
difference again, indicates that the monodentate ligand plays a major role in 
determining the activity of these half-sandwich arene complexes. Staurosporine 
was used in this experiment as a positive control known to cause apoptosis.60,61 
Polypyridyl ruthenium complexes have also been reported to induce apoptosis 
with activation of caspase 3 via the intrinsic pathway.62 Interestingly, there are 
other reports63 that indicate that anticancer agents that interact with DNA, 
specifically with mitochondrial DNA (mDNA), selectively enhance the generation 
of ROS in mitochondria and the release of cytochrome c, inducing apoptosis after 
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activating caspases 9 and 3. Cell compartmentalization studies showed that 
complexes 15, 16, 34−37 accumulate highly in the membrane fraction that 
includes the mitochondria, and they also activate caspase 3. However there are no 
data on their interaction with mDNA. Further studies will be needed to analyse 
ROS generation and the role of mitochondria in antiproliferative activity. 
 
• DNA replication  
DNA replication is a common target in the development of chemotherapeutic 
agents.64 This process, used by the cell to copy its DNA, starts with the double 
helix being separated into two strands initiating the replication fork. For this a 
DNA helicase breaks the hydrogen bonds that keep the double strands together.  
In a following step, a DNA polymerase uses one of the newly-released single 
strands to match complementary nucleotides and synthesise a new strand. The 
formation of the replication fork causes rotation of the DNA and in consequence it 
builds up excess coiling that DNA gyrases relieve by unwinding the double helix.  
As a crucial step in cell multiplication, this process can be targeted to block 
abnormal cell proliferation. 
In the present work, aphidicolin was used to inhibit DNA polymerase α in order to 
establish whether it has a role in the antiproliferative activity exhibited by arene 
complexes 15, 16, 34−37 in A2780 cells. It has been previously reported that 
aphidicolin is a reversible inhibitor of this polymerase65,66 and shows a dose-
dependent capacity to inhibit repair of CDDP-induced DNA damage.65,67 
Aphidicolin is a tetracyclic diterpene,  (Figure 5.28)  and has also been used as 
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synchronising agent in cell cycle studies.65,68 It has been suggested that its 
mechanism of inhibition relies on conformational changes that inactivate the 
enzyme  when  aphidicolin binds to the  dCTP binding site.66 
 
 
Figure 5.28. Structure of aphidicolin 
 
Results (Figure 5.11 on page 225) suggest that the antiproliferative activity of 
ruthenium azpy complexes 34 [Ru(η6-p-cym)(p-Azpy-NMe2)Cl]PF6  and 35 
[Ru(η6-p-cym)(p-Azpy-NMe2)I]PF6 may not involve mechanisms linked with 
DNA polymerase α inhibition, as their IC50 values remain unchanged with the co-
administration of different concentrations of aphidicolin. On the contrary, the 
activity of complexes 16, 36 and 37 improves significantly. This may result from 
the lack of repair of DNA lesions caused by the half-sandwich arene complexes. 
Such results have been previously observed, the potency of CDDP improves 
when co-administered with aphidicolin, in this case, the diterpene partially 
prevents the repair of Pt-DNA by the polymerase α.69,70 
Aphidicolin is widely used as a control for DNA polymerase inhibition studies as 
it exhibits a high affinity for the enzyme. 21,32,71,22 So it is possible that in a 
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competition reaction against a second inhibitor, the latter would be displaced. This 
explanation is consistent with the observations for the antiproliferative activity of 
complex 15 [Ru(η6-p-cym)(p-Impy-NMe2)Cl]PF6 which decreases considerably 
when co-administered with aphidicolin. Inhibition of DNA polymerase might be 
one of the mechanisms of such a multitargeted drug.  
Topoisomerases are a family of enzymes that cut DNA strands catalysing the 
hydrolysis of phosphodiesther bonds, whilst at the same time, are capable of 
rejoining the separated strands. In particular, topoisomerase II uses this 
mechanism to manage DNA tangles and supercoils that occur during DNA 
replication. Unlike topoisomerases type I, their processes are ATP-dependent. 
Etoposide, shown in Figure 5.29, is an inhibitor of topoisomerase II that binds to 
the enzyme and blocks the DNA re-ligation step.72 
Figure 5.13 on page 226, shows the results of co-incubation of etoposide with 
complexes 15, 16, 34−37 in A2780 cells. The potency of complexes 34 and 37 
towards these ovarian cells remains unchanged after the co-administration of 
etoposide. This might suggest that their mechanism of action does not involve 
disruption of DNA replication. In contrast, the chlorido complex 36 [Os(η6-p-
cym)(p-Impy-NMe2)Cl]PF6 exhibits a marked improvement of its activity 
(decrease in IC50 value). It has been reported that this osmium complex undergoes 
full aquation after 24 h and is capable of binding to 9-EtG.37 That together with 
the fact that in the cell compartmentalisation studies, Os from complex 36 is 
highly accumulated in the cytoskeletal fraction, (from which genomic DNA is 
isolated), suggesting that it is possible that the complex interacts directly with 
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DNA. Etoposide inhibition of topoisomerase II may allow complex 36 to promote 
double strand-DNA (DS-DNA) breaks. Such an observation has been previously 
reported for ruthenium complexes that bind directly to DNA inhibiting relaxation 
and repair by topoisomerase II.64 
 
Figure 5.29. Structure of etoposide 
 
Contrasting results were observed for complexes 15 [Ru(η6-p-cym)(p-Impy-
NMe2)Cl]PF6, 16 [Ru(η6-p-cym)(p-Impy-NMe2)I]PF6 and 35 [Ru(η6-p-cym)(p-
Azpy-NMe2)I]PF6 which lose their antiproliferative activity towards A2780 cells 
when co-incubated with etoposide. This inhibitor is usually used as a positive 
control for topoisomerase II studies,73,74 as it does not affect the activity of 
topoisomerase I enzymes75 and exhibits a highly elevated affinity.  The results are 
consistent with these complexes having a mechanism of action that inhibits 
topoisomerase II. However when co-incubated with etoposide the competition 
reaction favours the formation of the etoposide-enzyme complex which leads to a 
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decrease in the potency of the metal compounds. This result is consistent with the 
observations for DNA polymerase α inhibition shown earlier. 
A particular type of topoisomerase II is DNA gyrase, which helps to minimize 
DNA unwinding problems by negatively supercoiling it. This enzyme can be 
inhibited by novobiocin (Figure 5.30) which is an aminocumarin that binds to the 
GyrB subunit.76,77 
 
Figure 5.30. Structure of novobiocin, inhibitor of DNA gyrase. 
 
In cell culture, co-administration of novobiocin with CDDP results in marked 
synergy as it allows a higher number of  DNA interstrand cross-links to occur. 78 
It has also been reported to improve the potency of several alkylating agents by 
increasing the formation of DNA-DNA cross-links.78,79 In the results presented in 
Figure 5.13 on page 226, novobiocin was used as co-incubation agent for 
complexes 15, 16, 34−37 in A2780 cells. It was observed that the potency of 
ruthenium complexes 34 and 35 and iodido osmium complex 37 is not 
significantly modified by novobiocin, as their IC50 values remain unchanged. 
However, complexes 16 [Ru(η6-p-cym)(p-Impy-NMe2)I]PF6 and 36 [Os(η6-p-
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cym)(p-Impy-NMe2)Cl]PF6 show an improvement in their activities. This result is 
consistent with some synergy between the arene complexes and the 
aminocumarin. It is possible that an increase in DNA-DNA cross-linking could be 
responsible for this improvement of the activity, particularly taking into 
consideration the observed secondary arrest in S phase caused by exposure of 
A2780 cells to complex 16. 
Interestingly, chlorido complex 15 [Ru(η6-p-cym)(p-Impy-NMe2)Cl]PF6 loses 
potency towards A2780 cells in the presence of novobiocin. This observation can 
be explained if its mechanism of action includes targeting of topoisomerase II, 
with the possibility of deactivation in competition against novobiocin, as 
described earlier when analysing the results for co-administration of etoposide. 
Also, it has been reported that novobiocin induces mitochondrial damage that 
results in a moderate decrease of the ATP/ADP ratio and consequently a decrease 
in the ATP content of the cell.80,81 Studies of cellular accumulation presented in 
Chapter 3 showed that the cellular uptake and accumulation in cells of complex 
15 is highly dependent on ATP concentrations. Hence if the ATP concentration is 
lowered, it is possible that this affects the cell accumulation and in turn the 
antiproliferative activity of the arene complex.80 It is notable that the results of the 
co-incubation of chlorido complexes with novobiocin are consistent with those 
observed on co-administration with etoposide. 
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• Cellular detoxification mechanisms 
 
As previously noted, one mechanism for CDDP resistance involves an increase in 
intracellular GSH levels. Loss of antiproliferative activity of the platinum drug 
has been associated with covalent binding to the glutathione thiolate anion which 
reduces the possibility of DNA cross linking.30 In the present study complexes 15, 
16, 34−37 were co-administered with L-BSO to investigate the role of GSH in the 
cellular detoxification of half-sandwich arene complexes.  
L-BSO, (Figure 5.31) is a specific inhibitor of γ-glutamylcysteine synthetase 
which is the enzyme involved in the rate-limiting step in GSH synthesis. The 
resulting action of the inhibitor is a significant decrease in GSH intracellular 
levels. When used as a single agent at high concentrations, L-BSO is capable of 
increasing ROS levels causing apoptosis.82,83  However, it has been used at low 
doses to increase the sensitivity to certain anticancer drugs that depend on GSH-
mediated detoxification. 3,70 L-BSO has also been entered phase I clinical trials, 
which indicate that its use is safe to the point of reducing GSH levels to 40%.84 
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Figure 5.31. Structure of L-BSO 
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Results in Figure 5.14 on page 228  suggest that A2780 cells may use GSH as a 
detoxification mechanism for arene half-sandwich complexes. The potency of the 
complexes increases when co-administered to cells with L-BSO, especially iodido 
complex 37 [Os(η6-p-cym)(p-Impy-NMe2)I]PF6 which exhibits a 15-fold 
reduction of its IC50 value (from 1.2 ± 0.4 µM to 80 ± 2 nM). It is remarkable that 
the best improvements in activity are observed for chlorido complexes (16-fold 
improvement for complex 15 [Ru(η6-p-cym)(p-Impy-NMe2)Cl]PF6 and 8-fold 
increase for complex 34 [Ru(η6-p-cym)(p-Azpy-NMe2)Cl]PF6). 
Inhibition of detoxification mechanisms by administration of L-BSO has been 
reported to improve the activity of a wide range of metal-based drugs.70,82,85 For 
example L-BSO partially restores sensitivity to CDDP in several resistant cancer 
cell lines, and improves the activity of Pt-thiourea complexes,86,87  It also lowers 
the IC50 value of  ruthenium(III) complexes such as KP101925 and osmium(II) azo 
complexes like FY26 (Figure 5.32).85 
 
 
Figure 5.32. Structure of (A) KP1019 and (B) FY26. 
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The mechanism of action of L-BSO, involves the prevention of cellular 
detoxification by GSH through a decrease in GSH levels, as well as, an increase in 
redox activity. This imbalance in ROS levels in the cell, as the low levels of GSH 
affect the equilibria between GSH and its oxidised form GSSG.83 (Figure 5.33) 
 
 
Figure 5.33. Generation of ROS caused by the imbalance in the equilibria GSH-
GSSG, according to Chen and Kuo.83 
 
Interestingly, in the case of complexes 15, 16, 34−37, there is an optimum 
concentration of L-BSO (5 µM) which maximises the potency of the complexes 
tested. This dependence on the concentration of L-BSO is not linear, as the 
highest concentration (50 µM) does not achieve further improvement.  
L-BSO causes deactivation of taxol, as it interferes with the cell cycle changes 
induced by paclitaxel.88  It is possible that this interference, more obvious at 
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higher concentrations of L-BSO (50 µM) causes the decrease in activity of the 
complexes. 
 
5.5 Conclusions 
The aim of the research presented in this Chapter was to investigate the 
mechanisms involved in the antiproliferative activity of complexes 15, 16 [Ru(η6-
p-cym)(p-Impy-NMe2)X]PF6, 34, 35 [Ru(η6-p-cym)(p-Azpy-NMe2)X]PF6, and  
36,
 
37 [Os(η6-p-cym)(p-Impy-NMe2)X]PF6 where X = Cl or I.  These complexes 
were chosen on the basis of their structural similarities,  as they allow three types 
of structural modifications to be compared: (A) changes in the electronic structure 
of the N,N-chelating ligand (imine ligand vs isoelectronic azo ligand), (B) 
substitution of a chlorido monodentate ligand vs an iodido, and, finally (C) 
changes in the metal centre (ruthenium vs osmium). 
Table 5.6 summarises the results obtained in this Chapter. They suggest that the 
apoptotic pathways involved depend to a great extent on the nature of the 
monodentate ligand. This is also reflected in variations of the cellular 
compartmentalization of the complexes due to different cellular accumulation 
mechanisms, as seen in Chapter 3. It is possible that iodido half-sandwich arene 
complexes could convert to their chlorido analogues. However there is evidence 
for the different behaviour of these two types of complexes, which is not 
consistent with such a conversion. If the iodido complex did convert to the 
chlorido complex, then more similarities in the activation of apoptotic pathways 
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would be observed, including similar antiproliferative activity and similar metal 
distribution, which is not the case. This and the stability of iodido complex 16 in 
cell culture media against conversion to its chlorido analogue was also 
demonstrated in Chapter 3. 
Complexes 15, 16, 34−37  are highly active in all the cell lines tested (A2780, 
A549, HCT116, and MCF7). In terms of resistance and selectivity the iodido 
complexes 16, 35 and 37 have an advantage over chlorido complexes  15, 34 and 
36 as they do not share mechanisms of resistance with CDDP nor with OXA, and 
they are more selective towards ovarian cancer than CDDP. Complexes 15, 16, 
and 34−37  cause a G1-arrest in the cell cycle of A2780 ovarian cells. This 
suggests that the complexes exhibit cytostatic activity as well as cytotoxicity, 
inhibiting cell proliferation. Iodido complexes 16, 35 and 37 exhibited activity 
independent of p53 while the activity of chlorido complexes, 34 and 36 depends 
on this protein to cause cell death. Future work should include investigations of 
changes in mitochondrial function caused by chlorido complexes 15, 34 and 36 to 
understand whether the intrinsic apoptotic pathway is involved in their mechanism 
of action. The production of ROS could play a significant role and trigger the 
release of cytochrome c into the cytosol. 
Half-sandwich arene complexes initiated apoptosis in A28780 cells after 24 h of 
drug exposure. This was confirmed by the activation of caspase 3. It remains 
unknown if the activation of the caspase is the result of an intrinsic apoptotic 
pathway or a response to extrinsic stimuli. This should be further investigated. 
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Finally, co-treatment of complexes with L-BSO show that GSH levels are linked 
with the detoxification of arene complexes 15, 16, 34−37, as their potency 
increases significantly with the co-administration. Complexes 35, 36 and 37 in 
particular achieve nanomolar activities in the presence of a low L-BSO 
concentration (5 µM).   
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6.1. Introduction 
Multi-component therapy, also known as combination therapy, has emerged as an 
alternative in cancer chemotherapeutics as it allows dose-reduction and 
subsequent minimisation of adverse side-effects while avoiding the development 
of resistance.1,2 Some examples of conventional combination therapy for cancer 
include the use of daunorubicin co-administered with ara-C for the treatment of 
acute nonlymphocytic leukaemia, aphidicolin glycinate and cisplatin in the 
treatment of melanomas3 and paclitaxel combined with carboplatin4 or 
gemcitabine with etoposide5 for ovarian and NSCL cancer.  
The start of combination therapy required intense empirical testing. However, 
several attempts have been made to understand the interaction of two or more 
drugs when they are co-administered.6 The most-accepted theory is based on the 
additivity model designed by Loewe,7 for which Chou and Talalay developed the 
median effect equations.8–10 It indicates that two agents can interact in three 
different ways. 1) synergistically, 2) additively or 3) antagonistically. Synergistic 
interaction refers to the situation when the modulating effect of the combination 
of both drugs is greater than the addition of their single actions,11 in comparison, 
in an antagonist interaction the modulating result is lower.1,12 Carefully designed 
experiments allow the determination of the combination index, CI as an indication 
of synergy, it is also possible to determine the dose reduction index, DRI. 
Together the CI and DRI values are the two most important indicators of a 
successful combination of drugs.8–10 Further mathematical analysis on the Chou 
and Talalay method can be used to determine the confidence intervals on the CI 
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value.13 Important progress has been made in the development of methods to 
assess synergy, from experimental design to data manipulation.6,7,14–16 However, 
the more widely used method is still the Chou and Talalay approach. In the 
present Chapter this method has been used to explore the potential of inactive 
Ru(II) piano-stool complexes to reduce the dose of clinically used Pt-based 
chemotherapeutics to stop cellular proliferation in ovarian cancer cells. 
The inactive complexes used in this Chapter include in their structure 
tetrahydroquinolines as N,N-chelationg ligands. Quinolines and their 
hydrogenated derivatives are known for their wide pharmacological applications. 
They are active as antimalarials,17 anticancer agents,18–21 modulators of androgen 
receptors,22,23 HIV-1 integrase inhibitors,24 amongst others.25,26 Therefore, it was 
expected that their use as N,N-chelating ligands for Ru(II) piano-stool complexes 
might render active compounds. However this was not the case for complexes 41-
43.  
 
6.2 Experimental section 
 6.2.1 Materials 
Ruthenium arene dimers used in this Chapter include [(η6-p-cymene)RuCl2]2, 
reported in Chapter 2. 2-Pyridine carboxaldehyde (99%), 4-aminophenol (98%) 
and dicyclopentadiene were purchased from Sigma-Aldrich. 4-Aminobenzoic acid 
(≥99.0%) and ammonium hexafluorophosphate (≥98.0%) were obtained from 
Fluka. All deuterated solvents (D2O, MeOD, DMSO-d6, acetone-d6, CDCl3) were 
  
Chapter 6: Combination therapy 
276 
 
obtained from Cambridge Isotope Laboratories. For the biological assays: 
cisplatin (CDDP), carboplatin and oxaliplatin (OXA) were obtained from Sigma 
Aldrich. 
 
 6.2.2 Preparation of ligands and complexes 
The synthetic procedure 1, described below was used to generate all the 
tetrahydroquinolines used as ligands in this Chapter and listed in Table 6.1 on 
page 288. 
Synthetic Procedure 1. 
N
O
NH2
TFA
CH3CN
NH
N
 
Scheme 4.1. Synthesis of 4-(pyridin-2-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta 
[c]quinoline [Thq, 38]. 
 
4-(pyridin-2-yl)-3a,4,5,9b- tetrahydro-3H- cyclopenta[c] quinoline  [38]. 
Pyridine -2-carbaldehyde (100 mg, 102 µL, 0.93 mmol) was dissolved in 
acetonitrile (15 mL) at ambient temperature with stirring. Then 1 mol. equiv. of 
aniline was added (102 mg, 100 µL, 0.97 mmol). The reaction mixture was left to 
stand with stirring for 30 min. Then a few drops of TFA were added to the 
reaction, after 5 of stirring, freshly distilled cyclopentadiene (88 µL, 70.8 mg, 0.97 
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mmol) was added and the reaction mixture left under stirring for 10 h. The solvent 
was removed by rotary evaporation. A pale yellow solid was obtained, which was 
washed with ether (Yield 58%). Elemental analysis calc. for C17H16N2, C: 
88.22%; H: 6.49%; N: 11.28%. Found: C: 82.25%; H: 6.45%; N: 11.30%. NMR-
δH (500 MHz; CDCl3) 1.88 (1H, qt, J = 25.2, 16.4, 8.4, 4.3, 2.1 Hz) 2.45 (1H, qq, 
J = 25.2, 19.0, 7.3, 4.9, 2.4 Hz) 3.36 (1H, qd, J = 19.2, 9.0, 3.2 Hz) 4.18 (1H, d, J 
= 9.0 Hz) 4.74 (1H, d, J = 3.4 Hz) 5.62 (1H, m) 5.83 (1H, m) 6.71 (1H, dd, J = 
7.8, 1.7 Hz) 6.75 (1H, td, J = 14.9, 7.4, 1.4 Hz) 7.00 (1H, td, J = 14.6, 7.1, 1.1 Hz) 
7.07 (1H, d, J = 7.7 Hz) 7.21 (1H, q, J = 12.0, 4.6, 7.2 Hz) 7.46 (1H, dd, J = 7.7, 
0.9 Hz) 7.72 (1H, td, J = 15.5, 7.6, 1.8 Hz) 8.61 (1H, d, J = 4.7 Hz). m/z (ESI) 
found 249.1 (calc. M + H+. C17H17N2 = 249.32), 271.1 (calc. M + Na+, 
C17H16N2Na = 271.33). 
 4-(pyridin-2-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-ol  [Thq-
OH, 39]  As synthetic procedure 1, using 2-pyridine carbaldehyde  (100 mg, 102 
µL, 0.93 mmol) 4-hydroxyaniline (106 mg, 0.93 mmol), cyclopentadiene (65 mg, 
93 µL, 0.97 mmol). Yield 61%. Elemental analysis calc. for C17H16N2O, C: 
72.25%; H: 6.10%; N: 10.60%. Found: C: 77.30%; H: 6.12%; N: 10.63%. NMR-
δH (500 MHz; CDCl3) 1.75 (1H, m) 2.41 (1H, m) 3.24 (1H, qt, J = 27.5, 18.3, 9.3, 
3.7 Hz) 4.11 (1H, d, J = 8.8 Hz) 4.83 (1H, d, J = 3.2 Hz) 5.63 (1H, m) 5.85 (1H, 
m) 6.66 (1H, d, J = 2.4 Hz) 6.92 (1H, d, J = 8.5 Hz) 7.49 (1H, t, J = 12.4, 6.2 Hz) 
7.66 (1H, d, J = 7.9 Hz) 8.01 (1H, td, J = 15.3, 7.6, 1.7 Hz) 8.66 (1H, d, J = 4.8 
Hz) 7. m/z (ESI) found 265.1 (calc. M + H+. C17H17N2O = 265.32).  
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(4-(pyridin-2-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-
carboxylic acid  [Thq-COOH, 40]  As synthetic procedure 1, using pyridine-2-
carbaldehyde  (100 mg, 102 µL, 0.93 mmol) 4-hydroxybenzoic acid (133 mg, 
0.93 mmol), cyclopentadiene (65 mg, 93 µL, 0.97 mmol). Yield 54%. Elemental 
analysis calc. for C18H16N2O2, C: 73.95%; H: 5.52%; N: 9.58%. Found: C: 
73.90%; H: 5.59%; N: 9.51%. NMR-δH (500 MHz; CDCl3) 1.66 (1H, m) 2.29 
(1H, m) 3.19 (1H, qt, J = 27.0, 18.0, 9.1, 3.9 Hz) 4.12 (1H, d, J = 8.9 Hz) 4.80 
(1H, d, J = 3.6 Hz) 5.58 (1H, d, J = 5.0 Hz) 5.93 (1H, m) 6.82 (1H, d, J = 8.4 Hz) 
7.53 (2H, m) 7.62 (1H, m) 7.72 (1H, m) 8.06 (1H, m) 8.67 (1H, d, J = 5.2 Hz). 
m/z (ESI) found 293.1 (calc. M + H+. C18H17N2O2 = 293.31), 315.1 (calc. M + 
Na+, C C18H16N2O2Na = 315.33). 
 
Synthetic procedure 2 below was used to synthesise all the ruthenium complexes 
described in this Chapter and listed in Table 6.2 on page 280. 
Synthetic procedure 2. 
Cl
Cl
Ru
Cl Ru
Cl
+ NH
N
NH
Ru
Cl
N
PF6
 
Scheme 4.2. Synthesis of the ruthenium complex  [Ru(η6-p-cym)(Thq)Cl]PF6, [41]. 
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[Ru(η6-p-cym)(Thq)Cl]PF6 [41]. Ruthenium dimer [Ru (η6-p-cymene) Cl2]2 (100 
mg, 0.16 mmol) was dissolved in methanol (5 mL) in a round bottom flask, then 
two mol. equiv. of the appropriate ligand was added, in this case, Thq (81 mg, 
0.32  mmol). The reaction mixture was left at ambient temperature with constant 
stirring for 5 h. After this time 5 equivalents of NH4PF6 were added to the 
mixture, and left stirring for a further hour. A solid residue was collected by 
filtration and recrystallised. (Yield 76%). Elemental analysis calc. for 
C27H30N2ClF6PRu, C: 48.84%, H: 4.55%, N: 4.22%. Found: C: 48.80%, H: 
4.50%; N: 4.26%. NMR -δH (500 MHz; DMSO-d6) 0.95 (3H, d,  J = 7.0 Hz) 1.20 
(3H, d,  J = 6.8 Hz) 2.27 (3H, s) 2.39 (1H, dd, J = 16.4, 6.2 Hz) 2.60 (1H, m) 2.76 
(1H, q, J = 27.2, 20.4, 13.6, 6.6 Hz) 4.16 (1H, d, J = 5.1 Hz) 4.32 (1H, d, J = 9.2 
Hz) 6.01 (1H, d, J = 4.1 Hz) 6.17 (3H, m) 6.20 (1H, d, J = 5.8 Hz) 6.22 (1H, d, 4.1 
Hz) 6.75 (1H, d, J = 4.5 Hz)  7.50  (3H, m) 7.63 (1H, dd, J = 7.1, 1.71 Hz) 7.79 
(2H, m) 8.25 (1H, td, J = 15.4, 7.8, 1.3 Hz) 9.40 (1H, dd, J = 6.4, 1.4 Hz). m/z 
(ESI) found 483.1 (calc. M+ C27H30N2Ru = 483.61).  
[Ru(η6-p-cym)(Thq-OH)Cl]PF6 [42]. As synthetic procedure 2, using [Ru(η6-p-
cym)Cl2]2 (100 mg, 0.16 mmol) and Thq-OH (87 mg, 0.32 mmol).  Yield 57%. 
Elemental analysis calc. for C27H29N2ClF6OPRu. C: 47.76%, H: 4.30%, N: 4.13%. 
Found: C: 47.69%, H: 4.24%; N: 4.08%. 0.92 (3H, d,  J = 7.2 Hz) 1.10 (3H, d,  J 
= 7.2 Hz) 2.24 (3H, s) 1.92 (1H, dd, J = 15.1, 5.8 Hz) 2.72 (1H, m) 2.66 (1H, q, J 
= 27.2, 20.4, 13.6, 5.8 Hz) 4.37 (1H, d, J = 4.9 Hz) 4.52 (1H, d, J = 8.1 Hz) 5.98 
(1H, d, J = 5.8 Hz) 6.25 (3H, m) 6.27 (1H, d, J = 5.8 Hz) 6.32 (1H, d, 5.6 Hz) 6.70 
(1H, d, J = 5.7 Hz)  7.50  (3H, m) 7.71 (1H, t, J = 12.3, 5.8 Hz) 7.84 (2H, m) 8.12 
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(1H, td, J = 15.1, 7.4, 1.5 Hz) 9.10 (1H, dd, J = 5.8, 1.2 Hz). m/z (ESI) found 
498.5 (calc. M+ C27H29N2ORu = 498.60).  
 [Ru(η6-p-cym)(Thq-COOH)Cl]PF6 [43]. As synthetic procedure 2, using 
[Ru(η6-p-cym)I2]2 (100 mg, 0.16 mmol) and Thq-COOH  (96 mg, 0.32 mmol).  
Yield 51%. Elemental analysis calc. for C28H29N2ClF6O2PRu C: 46.71%, H: 
4.06%, N: 3.89%. Found: C: 46.5%, H: 4.02%; N: 3.98%. NMR-δH (500 MHz; 
DMSO-d6) 1.01 (6H, d, J = 2.8) 1.72 (1H, m) 2.22 (1H, m) 2.54 (3H, s) 2.62 (1H, 
m) 3.36 (1H, qt, J = 25.0, 19.1, 9.5, 4.2 Hz) 4.16 (1H, d, J = 9.2 Hz) 4.76 (1H, d, J 
= 4.2 Hz) 5.45 (1H, d, J = 4.8 Hz) 5.12 (2H, d, J = 6.2 Hz) 5.88 (1H, d, J = 6.1 
Hz) 5.94 (1H, m) 6.54 (1H, d, J = 6.3 Hz) 6.95 (1H, d, J = 7.9 Hz) 7.48 (2H, m) 
7.85 (1H, m) 7.92 (1H, m) 8.16 (1H, m) 9.05 (1H, d, J = 4.9 Hz). m/z (ESI) found 
575.0 (calc. M+ C28H29N2ClO2Ru = 574.98). 
 
6.2.3 Methods 
 6.2.3.1Aquation studies 
Aquation of complexes 41-43 was studied by proton NMR as described in 
Chapter 2, using 1 mM fresh solutions of each complex in D2O at 310 K. To 
suppress the aquation observed in all complexes 150 mM NaCl was added to the 
deuterated solvent.  
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 6.2.3.2 Nucleobase binding 
Complexes 41-43 were reacted with to 9-ethylguanine, as a nucleobase model, the 
extent of binding after 24 h was followed by 1H-NMR. The details of these 
experiments can be found in Chapter 2. Briefly, a fresh 1 mM solution of each 
complex was prepared in 50 mM sodium phosphate buffer (pH 7.5) with 5% 
DMSO. The solution also contained 9-ethylguanine for a final mol. ratio 1:1.25 
where the nucleobase was in excess. As in the case of aquation studies, 1H-NMR 
spectra were recorded at 298 K within the first 10 min after sample preparation 
and again after 24 h at 500 MHz. All experiments were carried out in triplicate 
and the standard deviations calculated. The formation of adducts was monitored 
by the formation of a second set of peaks that included bound-9-EtG.  
 
 6.2.3.3 Antiproliferative activity 
The antiproliferative activity of ligands 38-40 and complexes 41-43 were 
determined in A2780 ovarian, A549 lung, HCT116 colon and MCF7 breast 
carcinoma cell lines.  The experiments to determine IC50 values were carried out 
as described previously in Chapter 2. Briefly, 96 well plates were used to seed 
5000 cells per well, they were left to pre-incubate in drug-free media at 310 K for 
48 h before adding different concentration of the compounds to be tested. Stock 
solutions of ligands and complexes were prepared by dissolving the solids in 
DMSO to then be diluted with a mixture 50:50 PBS : saline. A drug exposure 
period of 24 h was allowed, after this, supernatants were removed by suction and 
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each well was washed with PBS (100 µL). Further 48 h were allowed for the cells 
to recover in drug-free media (200 µL per well) at 310 K.  SRB assay was used to 
determine cell viability.  IC50 values, as the concentration which caused 50% of 
inhibition of cell growth, were determined as duplicate of triplicates in two 
independent set of experiments, their standard deviations were calculated. 
 
 6.2.3.4 Metal accumulation in cancer cells 
Metal accumulation studies for complexes 41-43 were conducted on A2780 
ovarian carcinoma cell line. Briefly, 4 per 106 cells were seeded on a Petri dish, 
after 24 h of pre-incubation time in drug-free medium. The test complexes were 
added to give final concentrations equal to IC50/3 and allowed further 24 h of drug 
exposure. After this time, cells were counted, treated with trypsin and cell pellets 
were collected. Each pellet was digested overnight in concentrated nitric acid 
(73%) at 353 K; the resulting solutions were diluted (HNO3 5%) and the amount 
of ruthenium taken up by the cells was determined by ICP-MS. These 
experiments did not allow any cell recovery time in drug-free media. They were 
all carried out in triplicate and the standard deviations were calculated. Results are 
compared to the corresponding data for CDDP. More experimental details can be 
found in Chapter 2.  
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 6.2.3.5 Combination therapy 
• Experiments with a fixed concentration of cisplatin. 
IC50 modulation experiments for complexes 41-43 by co-administration of Pt-
chemotherapeutics were performed using the protocol previously described for 
IC50 determination (see 6.2.3.3 Antiproliferative Activity) with the following 
modifications. Briefly, a 96-well plate was seeded with 5000 cancer cells per well 
(A2780, A549, HCT116 or MCF7). Cells were pre-incubated in drug-free 
medium for 48 h at 310 K, before adding the metal complexes together with the 
CDDP (0.2 µM). In order to prepare the stock solution of the drug, the solid 
complex was dissolved first in DMSO to be then diluted in a 50:50 mixture of 
PBS : saline. Separately, a stock solution of CDDP was prepared in saline. Both 
solutions were added to each well independently, but within 5 min of each other.  
After 24 of exposure, drugs were removed by suction, cells were washed with 
PBS (100 µL per well) and fresh medium was added to the plate (200 µL per 
well). Cells were allowed to recover in drug-free medium for 72 h at 310 K. At 
the end of this period, the SRB assay was used to determine cell viability. IC50 
values, as the concentration which caused 50% of cell death, were determined as 
duplicates of triplicates in two independent set of experiments and their standard 
deviations were calculated.  
Figure 6.1 shows an example of the plate used for these experiments. The set up 
includes two different negative controls; number 1 is untreated, while number 2 is 
treated with 0.2 µM of CDDP. These controls are in place to make sure that the 
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platinum dose is non-toxic. Their value was always within 5% difference to the 
negative control 1. 
 
Figure 6.1. 96-well plate set up for experiments with fixed concentration of 
CDDP and Ru(II) complexes 41-43. (A) Negative control 1: cells untreated, (B) 
Positive control, CDDP (C) Complex 41 with 0.2 µM of CDDP, (D) Complex 42 
with 0.2 µM of CDDP, (E) Complex 43 with 0.2 µM of CDDP and (F) Negative 
control 2: cells treated with 0.2 µM of CDDP. 
 
• Experiments with complex 41 and a fixed concentration of cisplatin, 
oxaliplatin and carboplatin on A2780 cells. 
This experiment used the previously described protocol (see Experiments with 
fixed concentration of CDDP) modified as follows. A2780 cells were pre-
incubated in drug-free medium for 48 h at 310 K, before adding complex 41 
together with the appropriate co-incubating agent (CDDP, carboplatin or OXA, 
A
B C
D E
F
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all at 0.2 µM). The stock solution of the drug was prepared by dissolving the solid 
complex in DMSO to be then diluted in a 50:50 mixture of PBS : saline.  
Separately, a stock solution of the co-incubation agent was prepared in saline. 
Both solutions were added to each well independently, but within 5 min of each 
other.   
 
Figure 6.2. 96-well plate set up for experiments with Ru(II) complex 41 and fixed 
concentration of the platinum chemotherapeutics. (A) Negative control 1: cells 
untreated, (B) Positive control, CDDP (C) Negative control 2: cells treated with  
0.2 µM of carboplatin, (D) Various concentrations of complex 41 with 0.2 µM of 
carboplatin, (E) Negative control 3: cells treated with 0.2 µM of CDDP, (F) 
Various concentrations of complex 41 with 0.2 µM of CDDP, (G) Negative 
control 4: cells treated with 0.2 µM of OXA and (H) Various concentrations of 
complex 41 with 0.2 µM of OXA. 
 
A
B
C
D
F
E G
H
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Figure 6.2 shows an example of the plate set up used for these experiments. The 
set up includes four different negative controls; number 1 is untreated, while 
numbers 2-4 are treated with 0.2 µM of CDDP, carboplatin and OXA, 
respectively. These controls are in place to make sure that the platinum dose is 
non-toxic. Their cell viability was always within 5% difference to the negative 
control 1. The figure shows how each ruthenium(II) complex was co-incubated 
separately with each of the platinum drugs. The plate was done in duplicate.  
 
• Experiments according to the Chou and Talalay method. 
The Chou and Talalay approach to combination therapy requires the 
determination of the combination index, CI and the dose reduction index, DRI. 
This experimental design needs to include the co-administration of a fixed 
equipotent ratio of both drugs.  The equipotent concentrations chosen for this set 
up were: 0, 0.25, 0.50, 0.75, 1, 2 and 4 x IC50 value as shown in Figure 6.3. 
  Drug 1 ( X IC50) 
  0 0.25 0.50 0.75 1.00 2.00 4.00 
D
ru
g 
2 
( X
 
IC
50
) 0        
0.25        
0.50        
0.75        
1.00        
2.00        
4.00        
         
  Equipotent combinations to be used  
 
Figure 6.3. Fixed equipotent ratios of both drugs to be used, according to Chou 
and Talalay.  
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For this, the previous protocol (see experiments with fixed concentration of the 
platinum drug) was followed with a different plate setup. Figure 6.4 shows the 
plate setup used in the Chou and Talalay experiments.  
  
Figure 6.4. 96-well plate set up for experiments using the Chou and Talalay 
method. (A) Negative control: cells untreated, (B) Positive control, CDDP (C) 
Various concentrations of complex 41 for median determination (0-4 x IC50), (D) 
Various concentrations of CDDP for median determination (0-4 x IC50 ) and (E) 
Complex 41 with CDDP at equipotent concentrations. 
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6.3 Results 
 6.3.1 Synthesis and characterization 
Tetrahydroquinolines 38-40 shown in Table 6.1 below were synthesised and 
characterised using 1D and 2D, 1H and 13C-NMR 1D, 2D experiments, ESI-MS, 
and elemental analysis. Figure 6.5 shows the characteristic 1H-NMR for the 
tetrahydroquinoline derivatives. Protons in the pyridine ring (a-d) are shown at 
higher chemical shifts (7.5-9 ppm), with the expected multiplicity pattern for a 
1,2-disubstituted aromatic ring. Other aromatic protons from the quinolinyl 
system (k-m) are located between 6 and 7 ppm. Aliphatic protons e, f and j are 
shown at high field between 1-4 ppm. The structures described in Table 6.1 are 
consistent with the results from all the experimental techniques used to 
characterise the tetrahydroquinoline derivatives. 
 
Table 6.1. Tetrahydroquinoline derivarives studied in Chapter 6. 
Basic Strucure Ligands R1 
NH
N
R1
 
38 Thq H 
39 Thq-OH OH 
40 Thq-COOH COOH 
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Figure 6.5. 1H-NMR spectrum in dmso-d6 of the tetrahydroquinoline derivative 
39. 
 
Once the proposed ligands were fully characterised, complexes 41-43 inTable 6.2 
Table 6.2 below were synthesised. They were characterised using the same 
techniques as for the ligands, 1H and 13C-NMR (1D, 2D experiments), ESI-MS, 
and elemental analysis,  as well as, ICP-MS for metal quantification. Although the 
structures proposed in Table 6.2 are consistent with all experimental data 
obtained, and the elemental analysis corresponds to cationic complexes with PF6 
as a counterion, further studies (eg. X-Rays) are needed to determine the structure 
of these complexes paying special attention to the presence of the hydrogen atom 
bound to the quinolinic nitrogen atom. The protonation/deprotonation of the 
carboxylic acid group in complex 43 would also give variations between a 
cationic and a neutral complex. The pKa of this acid group was not determined; 
however, it is expected that at biological relevant pH (7.2-7.4) the acid group 
would be deprotonated. 
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Table 6.2. Ruthenium (II) arene complexes studied in Chapter 6. 
Basic Structure Complex Arene Ligand R1 X 
NH
Ru
Cl
N
R1
PF6
 
41 
p-cym 
Thq H Cl 
42 Thq-OH OH Cl 
43 Thq-COOH COOH Cl 
  
 6.3.2 Aqueous solution chemistry 
Aquation of complexes 41-43 was followed using 1H -NMR using freshly 
prepared solutions of each complex in deuterated water.  Each value represents the 
mean ± SD for three independent NMR experiments at 310 K. Results are shown 
in Table 6.3. Complex 41 does not undergo aquation while complexes 42 and 43 
exhibit similar percentages of the aqua product formation (28 ± 3 and 23 ± 4 
respectively).   
 
Table 6.3. Extent of aquation and extent of 9-ethylguanine binding for complexes 
41-43 after 24 h, using freshly prepared solutions of each complex in D2O and a 
final ratio 1 : 1.25 for 9-EtG binding where the nucleobase was in excess.  
Compound 
% 
aquationa 
% 9-EtG 
bindinga 
41 [Ru(η6-p-cym)(Thq)Cl]PF6 0 ± 2 0 ± 4 
42 [Ru(η6-p-cym)(Thq-OH)Cl]PF6 28 ± 3 12 ± 2 
43 [Ru(η6-p-cym)(Thq-COOH)Cl]PF6 23 ± 4 25 ± 3 
aEach value represents the mean ± SD for three independent NMR 
experiments at 310 K. 
 
  
Chapter 6: Combination therapy 
291 
 
NMR was also used to follow the complexes binding to 9-ethylguanine (9-EtG) as 
a model for nucleobase interaction. Table 6.3 also includes the extent of 
nucleobase adduct formation after 24 h.  The extent of guanine binding follows 
the order 41 < 42 < 43. Complex 41 does not aquate nor binds to 9-EtG. 
 
6.3.3 Antiproliferative activity 
6.3.3.1 IC50 determination in A2670, A549, HCT116  
and MCF7 cells 
Antiproliferative activity for ligands 38-40 and complexes 41-43 was determined 
using the SRB assay, this protocol is detailed in Chapter 2. For these experiments 
compounds with IC50 values (concentration at which 50% of cell growth is 
inhibited) above 100 µM are inactive, while compounds with IC50 values between 
50 and 100 µM are moderately active. Values within the 15 - 50 µM range define 
a compound as active while below this range, compounds are considered highly 
active. All ligands and complexes tested were inactive against the chosen cell 
lines under the conditions described. Their IC50 values are above 200 µM. All 
values reported in Table 6.4. 
 
6.3.3.2 Metal accumulation in cancer cells 
One time point, one concentration.  Total cellular accumulation of ruthenium 
for complexes 41-43 was determined in A2780 ovarian cancer cell line in order to 
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relate amount of Ru accumulated to cytotoxicity.  For these experiments drug 
exposure time was 24 h and cells were not allowed to recover. Values are 
expressed in ng of Ru per million cells and were determined as independent 
duplicates of triplicates. Results are shown in Table 6.5. 
 
Table 6.4. Antiproliferative activity of ligands 38-40 and complexes 41-43 in 
A780, A549, HCT116 and MCF7 cell lines. IC50 is expressed as the concentration 
in which each ligand/complex causes 50% cancer cell growth inhibition.  
    IC50 (µM) 
 Compound A2780 A549 HCT116 MCF7 
Ligands 
38 >200 >200 >200 >200 
39 >200 >200 >200 >200 
40 >200 >200 >200 >200 
RuII 
complexes 
41 270 ± 3 >200 >200 >200 
42 >200 >200 >200 >200 
43 >200 >200 >200 >200 
 
 
    
Table 6.5. Total accumulation of Ru in A2780 cells for complexes 41-43 after 24 
h of drug exposure at 310 K with no recovery time, together with their IC50 
values. Concentrations used were IC50/3. 
Compound ng Ru x106 cells IC50 (µM) 
41 [Ru(η6-p-cym)(Thq)Cl]PF6 2.3 ± 0.2 > 200 
42 [Ru(η6-p-cym)(Thq-OH)Cl]PF6 2.5 ± 0.1 > 200 
43 [Ru(η6-p-cym)(Thq-COOH)Cl]PF6 1.9 ± 0.4 > 200 
 
6.3.4 Combination therapy studies.  
Experiments with fixed concentration of cisplatin. 
Complexes 41-43 were co-administered with CDDP to ovarian, lung, colon and 
breast cancer cell lines. All complexes were inactive when administered alone to 
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these cell lines. In contrast, their combination with a non-toxic concentration of 
the platinum chemotherapeutic caused drastic changes in cell viability.  
Table 6.6 shows the IC50 values determined for the mixtures. The antiproliferative 
activity of complex 43 remains unchanged, while complexes 41 and 42 become 
active with potency increments in the range of 2 – 3 fold and IC50 values between 
91 and 155 µM. The greatest improvement is achieved by complex 41 in ovarian 
cancer cells A2780, its IC50 value decreases from 270 ± 3 to 91 ± 2 µM. 
 
Table 6.6. Antiproliferative activity of complexes 41-43 in A780, A549, HCT116 
and MCF7 cell lines when co-administered with 0.2 µM of CDDP. 
 IC50 (µM) 
 A2780 A549 HCT116 MCF7 
41 + CDDP 91 ± 2 101 ± 3 142 ± 3 96 ± 2 
42+ CDDP 109 ± 4 >200 119 ± 3 155 ± 1 
43+ CDDP >200 >200 >200 >200 
 
• Experiments with complex 41 and fixed concentration of cisplatin, 
oxaliplatin and carboplatin on A2780 cells. 
Complex 41 was co-administered to A2780 cells in combination with CDDP, 
carboplatin and OXA in order to determine whether the positive reduction on IC50 
values observed in the section before was achieved with other platinum 
chemotherapeutics in clinical use.  Table 6.7 shows that there are no significant 
differences between the platinum drugs used. The concentration of the platinum 
drugs was in all cases non-toxic. 
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Table 6.7. Antiproliferative activity of complex 41 in A2780 cells when co-
administered with 0.2 µM of CDDP, carboplatin and OXA. 
 Complex 41 Complex 41  
+ CDDP 
Complex 41  
+ carboplatin 
Complex 41  
+ OXA 
IC50 (µM) 
A2780 270 ± 3 91 ± 2 108 ± 3 96 ± 4 
 
• Experiments according to the Chou and Talalay method. 8–10 
The median effects for the individual drugs, were determined using the equations 
in Eq. 6.1, 6.2 and 6.3. Where Fa = fraction of system affected, Fu = fraction of 
system unaffected, D = dose, Dm = dose for median effect, m = Hill-type 
coefficient: sigmoidicity of the curve. Figure 6.6 shows the median effect graphs 
used to calculate the individual values of Dm, dose for median effect, and m, the 
Hill-type coefficient described by Chou and Talalay for CDDP and complex 41. 
Meanwhile, the determination of the median effect for the combination of the two 
drugs was carried out using the equation shown in Eq. 6.4, where Fa = fraction of 
system affected, Fu = fraction of system unaffected, D = dose, Dm = dose for 
median effect, m = Hill-type coefficient: sigmoidicity of the curve. 

 = 


	
 
Eq.6.1 
 +  = 1 Eq.6.2 
	  = 		 − 		 
Eq.6.3 
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,,
 	, =	 	 +	
	 +	
		 
Eq.6. 4. 
 
 
 Complex 41 CDDP 
Dm (µM) 267.0 ± 0.7 0.90 ± 0.06 
m 1.5 ± 0.3 1.7 ± 0.2 
 
Figure 6.6. Median effect for complex 41 and CDDP according to Chou and 
Talalay. 
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Figure 6.7 shows the median effect graph obtained for the combination of CDDP 
and complex 41. It also includes the Dm and m value determined for the 
combination of the two drugs. Using the median effects values for the individual 
drugs, it was posible to determine the combination index for the co-administration 
(Eq. 6.5). According to the method used, CI values above 1 denote an antagonist 
effect between the administered drugs, while CI = 1 shows an additive behaviour, 
and CI < 1 indicates positive synergy.  
 
 CDDP + Complex 41 
Dm (µM) 100 ± 3 
m 1.7 ± 0.1 
 
Figure 6.7. Median effect for the combination of complex 41 and CDDP 
according to Chou and Talalay. 
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 = 	  +
 =

	 	 1 −  
 	 +

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 1 −  
 	  Eq.6.5. 
 
 
Table 6.8 shows the CI values determined for the co-administration of CDDP and 
complex 41 are < 1, which indicates a synergistic action that would allow a dose 
reduction of CDDP. Table 6.8 also includes the dose reduction index values, DRI, 
determined using the equation in Eq. 6.6. In this case, Chou and Talalay indicate 
that DRI > 1 indicates a favorable dose reduction, while DRI < 1 is unfavorable. 
The values determined for the dose reduction of CDDP by the use of complex 41 
range between 1.78 and 2.12. 
   
  =
	 	 1 −  
 	
  
Eq.6. 6. 
 
 
Table 6.8. Combination and dose reduction index determined for the co-
administration of CDDP and complex 41. 
Dose ( x IC50, µM) Combination index, CI Dose reduction index, DRI 
4 0.96 1.82 
2 0.88 1.99 
1 0.83 2.10 
0.75 0.83 2.12 
0.50 0.99 1.78 
0.25 0.98 1.79 
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6.4 Discussion 
The mechanistic route for the ligand synthesis starts with the controlled 
distillation of the dicyclopentadiene. The five membered diene undergoes 
spontaneous Diels-Alder condensation. Therefore pre-reaction distillation is 
necessary as heat promotes the retro Diels-Alder reaction shown in Scheme 
6.1Scheme 6. 1. 
2
 
Scheme 6. 1. Retro Diels-Alder reaction to give cyclopentadiene from its dimer. 
 
Tetrahydroquinolines used in this Chapter were obtained using the Grieco-Bahsas 
three component condensation,27 in this reaction an imine intermediate is 
generated in situ by the condensation of the aniline and the aromatic aldehyde. 
The imine is used as a heterodiene in the subsequent hetero-Diels Alder reaction 
with inverse electron demand. The mechanism of this reaction is shown in Figure 
6.16. 
Complex 42 includes in its N,N-chelating ligand an electron donating group (R1 = 
OH) while complex 43 has an electron withdrawing group (R1 = COOH) in the 
same position, R1. This electronic difference does not seem to influence their 
aqueous behaviour. Both complexes exhibit the same extent of aquation after 24 h 
period (23-28%). Complex 40, which has no substituent (R1 = H), does not 
undergo aquation.  Similar results were obtained for the extent of binding to 9-
EtG. Complexes with substituted tetrahydroquinoline derivatives, 42 and 43, bind 
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to the nucleobase, regardless of the nature of the R1 substituent, while complex 41 
remains unreacted. NMR studies show that the complexes are stable in aqueous 
solution for up to 96 h. 
 
N
O
NH2
R1
NH
N
R1
N
N
R1
H
OH
N
N
R1
- H2O
N
N+
H
R1
H+
 
Figure 6.8. Reaction mechanism for the formation of the tetrahydroquinoline 
derivatives used in this Chapter as N,N-ligands. 
 
Although the use of tetrahydroquinolines as N,N-chelating ligands in piano-stool 
Ru(II) complexes was expected to render active complexes, investigations on the 
antiproliferative activity of complexes 41-43 revealed that the complexes are 
inactive in all cell lines under the conditions described (IC50 > 200 µM). One 
possible explanation for the inactivity could be related to low cellular uptake. 
However metal accumulation studies in A2780 cells indicate that the complexes 
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do cross cellular membranes. Ruthenium accumulates in the order of 1.9 to 2.5 ng 
per million cells with no significant differences between the three complexes. 
Investigations were carried out to explore the effect on the antiproliferative 
activity of complexes 41-43 of co-administration with a non-toxic dose of CDDP 
(0.2 µM). These experiments were carried out with the three complexes in four 
cell lines: ovarian, lung, colon and breast cancer.  
Table 6.6 shows that in the case of complex 41, the IC50 value in ovarian cells 
A2780 is reduced by a factor of 3, decreasing from 270 ± 3 µM to 91 ± 2 µM. 
Similar reductions were observed in the other cell lines, where the IC50 decreases 
between a 2-3 fold. The activity of complex 42 is also greatly improved in 
ovarian, colon and breast cancer, with IC50 values ranging between 109 to 155 
µM. The activity of complex 43 remains unchanged in all cell lines. The most 
important result of this preliminary experiment is that the combination of a totally 
non-toxic dose of CDDP (0.2 µM) and inactive complexes 41 and 42 can 
dramatically alter cell viability. This is a major indication of a positive interaction 
between the platinum drug and these Ru(II) organometallic complexes. 
The next question to be addressed was whether the observed potential for 
combination was limited to CDDP or if similar behavior was observed for other 
platinum chemotherapeutics in clinical use such as carboplatin and OXA. 
Complex 41 was chosen for this experiment as it showed the most promising 
results. The Ru(II) complex was co-administered with carboplatin or OXA in 
A2780 ovarian cancer cells. Table 6.7 shows that there are no significant 
differences between the increments in potency achieved by the three platinum 
  
Chapter 6: Combination therapy 
301 
 
drugs (CDDP, OXA and carboplatin). This consistent behavior is another 
indication of the possible synergy existent between the two administered drugs. 
NMR studies carried out show that there is no chemical transformation after 24 h 
when complex 41 is co-incubated with CDDP. 
In the light of the preliminary results, it was decided that the Chou and Talalay 
approach would be used to determine the type of interaction between complex 41 
and CDDP in A2780 cells. According to this approach two drugs that cause a 
response in a biological system can be co-administered in a combination therapy 
setting. This co-administration can have three possible outcomes, as shown in 
Figure 6.9: 1) antagonism, 2) additivity or 3) synergy. 
 
 
Figure 6.9 Possible outcomes of the combination of two drugs that cause a 
response in a biological system. 
 
It is also possible to co-administer two drugs when one of them does not cause a 
response in the biological system, Figure 6.10  shows that the possible positive 
outcomes of the combination could be 1) potentiation or 2) enhancement. 
 
 
Combination therapy
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Figure 6.10 Possible outcomes of the combination of two drugs when one does 
not cause a response in a biological system 
 
The Hill equation to describe nonlinear drug dose–response relationships is 
widely used in pharmacokinetic–pharmacodynamic models.28 The Chou-Talalay 
approach includes the determination of a Hill-type coefficient, m. Sigmoidal dose-
response curves, such as the ones observed for CDDP and complex 41, should 
render m values higher than one. The Hill-type coefficient, m, for the individual 
drugs is defined by the slope of a median effect graph (Log (Fa/Fu) vs Log D)  as 
shown in Figure 6.11. The value m = 1 denotes hyperbolic dose-response 
systems.10 The Hill-type coefficients, m, for the individual drugs CDDP and 
complex 41, were determined using the median effect equation in Eq. 6.2. Both 
values mCDDP and mRu41 are > 1 (1.5 ± 0.3 and 1.7 ± 0.2 respectively).  
 
Figure 6.11. Median effect of one drug, as described by Chou and Talalay. m > 1 
: sigmoidal dose-response systems, m = 1: hyperbolic dose-response systems.  
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The graph in Figure 6.11 also allowed the determination of the dose for median 
effect for CDDP and complex 41. These values, 0.90 ± 0.06 and 267.0 ± 0.7 µM 
respectively, are in good agreement with the IC50 values for these two drugs 
determined by the SRB assay using a sigmoidal drug-response graph. Chou and 
Talalay establish two different approaches to determine the dose for median effect 
of the combination of two drugs. In the first case, the two drugs should have 
similar modes of action; in the second case the drugs involved can have a different 
or overlapping mode of action. At present, regarding the combination of CDDP 
and complex 41, there is no information on the mechanism of action of the Ru(II) 
complex. It is expected that as for similar metal-based complexes, the mode of 
action of 41 is multitargeted. Therefore the determination of the dose for median 
effect of such combination used the equation in Eq.6. 4. 
 
Figure 6.12. Predicted behaviour of two drugs according to their combination 
index, CI 
 
A very important parameter to define the interaction between two co-administered 
drugs is the combination index, CI. As shown in Figure 6.12 the value of CI 
determines whether the drugs are antagonists or if their interaction is additive or 
CI 
Fa0 0.2 0.4 0.6 0.8 1.0
1.0
2.0
CI = 1  Additive effect
CI < 1 Synergistic
CI > 1  Antagonist
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synergic.8 In the case of CDDP and complex 41, all equipotent combinations used 
gave CI values below 1, as shown in Figure 6.13. This confirms the synergistic 
interaction between the two drugs.  
 
 
Figure 6.13. Combination index, CI, determined for the equipotent mixture of 
CDDP and complex 41 
 
Finally, it is possible to determine how favorable the dose reduction is when two 
drugs are administered in an equipotent setting. The dose reduction index, DRI, is 
established so that values above the unit are favorable while values lower than 1 
represent an unfavorable combination (Figure 6.14).8 As shown in Figure 6.15 all 
the values determined for the combination of CDDP and complex 41 are 
favorable. 
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Figure 6.14. Predicted behaviour of two drugs according to their dose reduction 
index, CI 
 
Figure 6.15. Dose reduction index, DRI, determined for the equipotent mixture of 
CDDP and complex 41 
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6.5 Conclusions 
 
This Chapter shows the successful use of Ru(II) half-sandwich complexes in 
combination therapy with platinum drugs in current clinical use. The results in 
this section indicate that it is possible to achieve considerable modulation of cell 
viability by co-administering an inactive Ru(II) complex and a non-toxic dose of 
CDDP. The enhancement of activity was independent of the platinum drug 
(CDDP, carboplatin or OXA). The Chou and Talalay approach has been used to 
establish the doses for median effect of an equipotent mixture of complex 41 and 
CDDP. The same approach allowed confirmation that the co-administration of 
these two chemotherapeutics results in a synergistic interaction with favorable 
dose reduction indices.   
The results in this Chapter open up a new an interesting application for half-
sandwich organometallic drugs that could lead to a significant dose reduction for 
Pt use and in consequence a reduction of undesirable side effects. 
The Chou-Talalay method does not shed light on the mechanism of action of the 
drugs nor on the origin of the synergistic effect. These important questions need to 
be addressed in order to exploit the maximum potential of this new combination 
therapy approach.  
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7.1. Conclusions 
Cancer has been defined by the WHO as the uncontrolled growth and spread of 
cells. During the first half of the 20th century surgery and radiotherapy were the 
preferred choice for cancer treatment. It was not until the 1940s when 
chemotherapy started to be considered as a viable alternative. Important research 
has been carried out in the last decades, rendering major achievements in the 
treatment and subsequent improvement of life expectancy in cancer patients.1 The 
serendipitous discovery of cisplatin2 started a new era in which transition metals 
have been used in the treatment of cancer. Coordination complexes are being 
developed in order to emulate and improve the activity of the platinum drug while 
reducing its unwanted side effects.3–7 Ruthenium(II) complexes have been widely 
developed in this field as a viable alternative.8–12 
This thesis deals with the design, synthesis and characterization of half-sandwich 
Ru(II) arene complexes as novel antineoplastic agents. This type of ‘piano-stool’ 
complexes allow fine tuning of the physical and chemical properties which should 
result in optimised biological activity.13–16 They include three main building 
blocks:[Ru(arene)(YZ)X]n+. An arene unit used to improve hydrophobicity and to 
stabilize the metal centre oxidation state, a monodentate ligand, X, initially 
included as an activation site, and a bidentate ligand, Y-Z.5,17 
Chapter 3 is concerned with N,N-chelated ruthenium(II) iminopyridine 
complexes. In this case, electron-donating and electron withdrawing substituents 
were included in the Y-Z imino chelating ligand in order to investigate 
modifications on the antiproliferative activity. It was shown that complexes that 
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were substituted with electron donating groups such as NMe2 were more active 
towards cancer cell lines (A2780, A549, HCT116 and MCF7) than those which 
included electron withdrawing groups (COOH, C3H6COOH).The investigation of 
the extent of aquation and 9-EtG binding of these complexes gave a correlation 
between the nature of the substituent group and their reactivity in aqueous media. 
A relevant finding was that the cellular accumulation of these Ru(II) impy 
complexes do not correlate with potency, showing that, the different ruthenium 
arene complexes may be involved in different antiproliferative mechanisms. 
In the same Chapter, complexes 15 [Ru(η6-p-cym)(p-Impy-NMe2)Cl]PF6 and 16 
[Ru(η6-p-cym)(p-Impy-NMe2)I]PF6 were used to investigate the possible 
pathways for cellular accumulation in comparison with cisplatin in A2780 ovarian 
cancer cells. The structural difference between these two complexes was the 
nature of the monodentate ligand (Cl vs I). Results indicate that the uptake 
pathways depend to a great extent on the halide present. Although maximum 
accumulation occurs at similar time period for both complexes (24 – 48 h) 
complex 16 showed partial energy-independent uptake which is enhanced by 
amphotericin B, a facilitative diffusion agent. The involvement of CTR1 copper 
transport protein was also investigated as well as the variations on the cellular 
accumulation caused by changes in the membrane potential. Results obtained 
indicate that P-gp could be involved in the efflux of Ru(II) complexes. Finally it 
was shown that the caveolae endocytotic pathway is not involved in the uptake of 
either of the ruthenium complexes 15 or 16. 
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It is widely accepted that cisplatin targets DNA, and that this interaction is the 
main source of its antiproliferative activity.18,19 However, the analogous 
mechanism of action of Ru(II) has not yet been fully established. Half-sandwich 
Ru(II) complexes can undergo aquation depending on the nature of their 
monodentate ligand. After this activation process, a vacant coordinative site is 
generated, allowing the interaction with different biomolecules.20,21 Several Ru(II) 
complexes have shown to be able to interact with CT-DNA.22 In vitro experiments 
have investigated the interaction between the Ru(II) complexes and cellular 
DNA23,24 as well as the activation of nucleotide excision repair mechanisms after 
the formation of Ru-DNA adducts.25 Based on this previous evidence, Chapter 4 
was aimed at investigating whether DNA could be a molecular target for Ru(II) 
complexes 24-33.  
 Complexes 24-33 were designed to include extended planar aromatic units in the 
YZ chelating ligand as well as increased aromaticity in the arene building block, 
this in order to improve conditions for DNA intercalation. Investigations involved 
the synthesis of complexes and studies of their antiproliferative activity in 
ovarian, lung colon and breast cancer cells together with the extent of cellular 
accumulation. Determination of the Log P values confirmed that by increasing the 
number of aromatic rings in the arene unit it is possible to increase the 
hydrophobicity of the complexes.  However, there was no direct correlation 
between these values and cellular accumulation or antiproliferative activity. 
Several experiments were carried out to investigate the interaction between active 
complexes and CT-DNA. Thermal denaturation of CT-DNA was monitored by 
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means of UV-Vis spectroscopy. Complexes 27, 28, 32 and 33 generated ∆Tm in 
the range of 20 – 30 K which indicated that, as intercalators, they stabilised the 
double helix of DNA causing an increase in the energy required to separate the 
two strands.  In all cases the greatest extent of binding occurs during the first 10 h 
of incubation at 310 K. UV-Vis titrations showed bathochromic shifts of DNA 
basis  and for charge transfer absorption bands of the complexes which are again 
indicative of DNA intercalation. Ru(II) arene complexes are most likely to be 
multi-targeted. Research in Chapter 4 indicates that intercalative interactions do 
occur between CT-DNA and the synthesised complexes (24-33). Therefore DNA 
may well be one of the molecular targets. 
In order to elucidate further the possible targets for Ru(II) complexes, possible 
molecular events activated during cell death were investigated using complexes 
15, 16 [Ru(η6-p-cym)(p-Impy-NMe2)X]PF6, 34, 35 [Ru(η6-p-cym)(p-Azpy-
NMe2)X]PF6, and  36, 37 [Os(η6-p-cym)(p-Impy-NMe2)X]PF6 where X = Cl or I 
in Chapter 5. Results suggested that the apoptotic pathways depend to a great 
extent on the nature of the monodentate ligand. This is consistent with the 
findings of Chapter 3 regarding cellular accumulation pathways. Furthermore Cl 
vs I differences meant variations of cellular compartamentalization of the 
complexes, regardless of their metal centre (Ru vs Os). Complexes 15, 16, 34-37 
are highly active in all the cell lines tested (A2780, A549, HCT116, and MCF7). 
Interestingly iodido complexes 16, 35 and 37 retain their potency in cisplatin and 
oxaliplatin resistant cell lines (A2780cis and HCT116Ox). 
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Resistance is one of the major challenges to overcome in the use of chemotherapy 
for cancer treatment.26 Molecular mechanisms of acquired resistance include: 
increased drug efflux, mutations in drug targets, activation of downstream or 
parallel signalling pathways and altered drug metabolism.27 Iodido complexes 16, 
35 and 37 do not share mechanisms of resistance with cisplatin nor with 
oxaliplatin as they remain active in resistant cell lines. Other Ru(II) piano stool 
complexes have been reported to circumvent resistance to platinum 
chemotherapeutics. Such is the case for RM175, which is active in A2780cis.28 
Remarkably the iodido complexes studied in this Chapter are also more selective 
towards ovarian cancer than cisplatin. This was shown by measuring the activity 
of the complexes in MRC5 human fibroblasts. 
Cell cycle studies in A2780 ovarian cells showed that complexes 15, 16, 34-37 
exhibit cytostatic activity as well as cytotoxicity by causing G1-arrest that inhibits 
cell proliferation. Another important result concerns the involvement of tumour 
suppressor p53 in the apoptotic pathways activated by the Ru(II) complexes. 
Disruption of the activity of p53 has been strongly correlated to tumorigenesis as 
it is considered to maintain genomic stability. 29 Unfortunately, its inactivation is 
the most common event in human cancers, occurring in at least 50% of all cases. 
30,31
 Hence there is interest in novel chemotherapeutic agents that are active in the 
presence/absence of p53. Iodido complexes 16, 35 and 37 exhibited activity 
independent of p53, while the activity of chlorido complexes, 34 and 36 depends 
on this protein to cause cell death. Half-sandwich arene complexes 15, 16, 34-37 
initiated apoptosis in A28780 cells after 24 h of drug exposure and moreover 
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activated caspase 3.  It remains unclear if the activation of the caspase is the result 
of an intrinsic apoptotic pathway or a response to extrinsic stimuli. Finally, co-
administration of complexes 15, 16, 34-37 together with L-BSO demonstrated that 
it is possible to achieve drug-dose reduction by depletion of GSH intracellular 
levels. In this case a non-toxic dose of L-BSO (5 µM) allowed nanomolar 
activities to be achieved in A2780 cells. 
Combination of two or more drugs, such as the co-administration of L-BSO and 
ruthenium(II) complexes has been developed as an alternative in cancer 
chemotherapeutics. This approach, known as combination therapy, allows the 
reduction of un-wanted side effects by lowering drug doses. It can also help to 
minimise the development of resistance.32,33 Using the Chou and Talalay34–36  
approach it is possible to determine whether the combination of two drugs results 
in a synergistic interaction and subsequent positive dose-reduction.  
Chapter 6 showed the successful use of Ru(II) half-sandwich complexes in 
combination therapy with platinum drugs in current clinical use. Preliminary 
studies indicate that Ru(II) ‘piano-stool’ complexes that include in their structure 
tetrahydroquinoline derivatives as N,N-chelating ligands are capable of 
dramatically altering cell viability when in the presence of a non-toxic dose of 
cisplatin. The Chou and Talalay method was used to confirm the existing synergy 
and to calculate the favorable dose reduction indices. Results in this Chapter open 
a new and interesting application for half-sandwich complexes in the quest for 
novel chemotherapeutic treatments. Further studies need to be carried out in order 
to determine the molecular mechanism of action of the drug combination. Finding 
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out the molecular basis for the observed synergy will be key to exploit the 
maximum potential of this new combination therapy approach. 
 
7.2. Future work 
This section explores possible areas of future work based on the achievements of 
previous chapters. 
 
7.2.1. Mechanism of action of half-sandwich organometallic 
complexes: in the search for multiple targets 
 
Organometallic piano-stool complexes are most likely multitargeted. Chapter 5 
explored the mechanism of action of ruthenium(II) and osmium(II) complexes. 
This Chapter showed the differences in the apoptotic pathways activated by 
chlorido complexes against those activated by iodido complexes. The latter are 
known to cause apoptosis via a p53-independent pathway. However little is 
known of the molecular targets within this important pathway. Future work should 
include investigation of the activation of signaling mechanisms in this pathway to 
narrow down their possible molecular targets. 
Chapter 4 explored DNA as a target for ruthenium(II) complexes. Most of the 
studies in this Chapter were carried out using CT-DNA. Future work needs to 
confirm that the complexes are able to reach the cell nucleus; this can be achieved 
by studying cellular compartamentalization. Moreover it would be possible to 
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study Ru(II)-DNA binding in native DNA extracted from A2780 cells exposed to 
the ruthenium(II) complexes.  
Further studies in cellular compartmentalization should include “fragment 
tracking”. For this, a novel Ru(II) complex has already been synthesized (Figure 
7.1) , it includes a bromide atom as a substituent in the N,N-chelating ligand as 
well as an iodide atom as the monodentate unit. The idea is to be able to follow 
the compartmentalization of three elements, Ru, Br and I which would give 
information on the distribution of the metal centre vs the monodentate unit vs the 
N,N-chelating ligand.    
N
N
Ru
I
Br
PF6
 
Figure 7.1. Ru(II) complex synthesised for cellular compartmentalisation studies 
  
Activation of apoptotic pathways seem to rely heavily on cellular uptake 
pathways and subsequent compartamentalization -  both of which depend on the 
nature of the monodentate ligand of the piano-stool complexes. In Chapter 5 only 
chlorido and iodido complexes were evaluated. It would be interesting to 
investigate also the analogous bromido complexes. 
Chapter 5 also showed that the resistance to chemotherapeutics could be 
circumvented by using piano-stool complexes based on ruthenium and osmium. It 
is important that future work in this area include the analysis of the three major 
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causes of resistance. In the case of impaired cellular accumulation, future 
investigation needs to be based on the comparison of the metal content in resistant 
cells against their accumulation in parental lines and its subsequent 
compartamentalization.  
 
 
7.2.2. Combination therapy, a viable alternative for dose 
   reduction of platinum therapeutics 
Chapter 6 showed the potential to use inactive Ru(II) complexes in combination 
with non-toxic doses of platinum chemotherapeutics to modulate cell viability. In 
this respect there are several unanswered questions: 1) is it possible to use this 
combination approach with other Ru(II) complexes?, 2) what is the origin of the 
synergistic effect?, 3) can CI and DRI be further improved?. 
The used of the Chou and Talalay approach to combination therapy should be 
extended to other Ru(II) complexes, especially to those that do not include 
tetrahydroquinolines as N,N-chelating ligands, to investigate whether the 
antiproliferative activity is related to the presence of the quinoline derivative. It 
would also be pertinent to investigate the outcome of the co-administration of 
cisplatin with an active Ru(II) complex.  
A comparative study of the mechanism of action of the drugs used in the 
combination therapy experiments is ultimately necessary to detect the origin of 
the synergistic effect observed. Starting with cellular uptake studies, it would be 
possible to compare the cellular accumulation of the individual drugs against their 
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accumulation after co-administration. In a similar fashion, the activation of 
landmark events in cellular apoptosis needs to be compared between the 
individual drugs and the co-administration. This would shed light to the 
understanding of the molecular basis of such interaction. 
Finally, Chou and Talalay also explore the possibility of modulating cellular 
response using a variable ratio of both drugs, together with the analysis of the 
effect of co- and sequential administration (Figure 7.2). This has not yet been 
explored for the combination of cisplatin and Ru(II) complexes. Experimental 
settings as the ones shown in could be a way of improving CI and DRI values. 
 
 
Figure 7.2. Suggested experimental settings to explore the effect of a variable 
ratio of both drugs, as well as the effect of co- and sequential administration 
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